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1. Introduction 
This volume contains the research methodology used in the second 
General Population Drug Prevalence Survey in the Republic of Ireland, 
conducted by Ipsos MORI on behalf of the National Advisory Committee on 
Drugs (NACD) in Ireland.    
1
The extent and pattern of 
.1. Background 
drug use in the general population is one of the five key 
indicators produced by the EMCDDA1, the European Monitoring Centre for Drugs and 
Drug Addiction (www.emcdda.org), and adopted by EU Member States.  In order to 
ensure that reliable and comparable data are obtained in this regard, the 
measurement of the extent and pattern of drug use amongst the general population 
in Ireland is one of the priorities set out by the NACD in its current work programme 
and agreed by Government.   
The NACD and DAIRU (Drug and Alcohol Information and Research Unit) 
As with the previous survey in 2002/03, the NACD and the DAIRU worked together in 
 
 to oversee the commissioning process 
 Arthurs, Eddie – NACD/Department of Community Rural and Gaeltacht Affairs 
D 
an, DAIRU 
al Population (2002), P.80 
commissioned a Drug Prevalence Survey to establish population prevalence of drug 
use in Ireland and Northern Ireland in 2002/2003.  In 2006, the NACD decided to 
commission a repeat of this survey in both jurisdictions, and Ipsos MORI was 
commissioned to conduct the fieldwork for the Republic of Ireland.  Ipsos MORI was 
required to follow the relevant guidelines published by the EMCDDA and to achieve 
an approximate population sample of 5,000 in Ireland, using An Post’s GeoDirectory 
as its Sampling Frame.  The sample size of 5,000 was agreed in order that the 
sample size remained consistent with the previous survey and to enable reporting by 
HSE area. 
commissioning this research into the prevalence of drug use in Ireland and Northern 
Ireland respectively.  Their collaboration brings an all island perspective to drug 
prevalence whilst maintaining individual responsibility to provide information to their 
respective Governments. 
 
Planning and commissioning process 
A Research Advisory Group (RAG) was formed
and to support the implementation of the survey to the EMCDDA standard.   The 
membership comprised of the following representatives from DAIRU and the NACD 
(in alphabetical order by surname): 
 
¾
¾ Corrigan, Des – PhD, Chairman, NACD 
¾ Horgan, Justine – PhD, Researcher, NAC
¾ Long, Jean – PhD, NACD/ Health Research Board, Alcohol Drug Research Unit 
¾ Lyons, Mairéad – Director, NACD 
¾ Moore, Kieron – Principal Statistici
___________________________ 
Drug Use Among The Gener1 EMCDDA Handbook for Surveys on 
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The tender was advertised in the Official Journal of the European Commission (OJEC) 
firstly as an Expression of Interest in January 2006 and then as a Request for Tender 
in April 2007.  See details in Appendices A and B. 
 
In July 2006, the NACD formally commissioned Ipsos MORI to conduct the 
2006/2007 national drug prevalence study in the Republic of Ireland.  What followed 
was a detailed project set-up phase, whereby Ipsos MORI and the Research Advisory 
Group worked together from July-October 2006 to plan all aspects of the study in 
order to ensure its success. 
 
During the working period of the project between July 2006 and December 2007, a 
total of 12 RAG meetings were held and six of these meetings were convened 
between the RAG and Ipsos MORI (the Central Survey Unit in Northern Ireland also 
attended).  Members of the RAG also participated in the four briefing sessions to field 
workers conducted by Ipsos MORI. 
 
 
1.2. Research Objectives 
The core objective of the research was to provide up-to-date, robust data regarding 
the prevalence of (licit and illicit) drug use amongst the general population.  The 
tender brief stated that the survey would be based on the guidelines produced by 
the EMCDDA which states its main aims as follows: 
(1) To report prevalence and continuation rates of the most common illicit drugs 
in the general population by gender and age groups; 
(2) To allow cross country assessment of relationships between general patterns 
of use of illicit and licit drugs; 
(3) To allow the assessment of relationships between particular population 
attributes and the use of illicit drugs. 
 
As with the previous study, the survey was also required to; 
¾ be reliable, in that overall results are statistically reliable estimates of the 
prevalence of drug use in each jurisdiction and on the island as a whole 
¾ be comparable with Northern Ireland and as far as possible with similar studies 
being conducted throughout the European Union 
¾ allow analysis of results in terms of a variety of demographic factors. 
 
To meet the objectives of the study, a target of 5,000 interviews was set and a final 
sample size of 4,967 interviews was achieved.   
 
The survey was carried out using the EMCDDA Model Questionnaire with some 
modification and face-to-face interviewing method amongst 15 to 64 year olds.  A 
standardised questionnaire was used to collect the information on drug use, while 
the sample was selected using probability sampling. 
 
Although the questionnaire content remained largely unchanged from the 2002/2003 
study, the major change between this study and the previous one was the transition 
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of data collection methodology from pen-and-paper to Computer Assisted Personal 
Interviewing (CAPI).  CAPI is the preferred method under EMCDDA guidelines.  The 
move to CAPI meant new challenges and called for a comprehensive set-up phase, 
involving close liaison between Ipsos MORI and the Research Advisory Group, from 
reviewing the question wording and coding, through piloting the survey itself and 
testing the CAPI approach, using a detailed sampling process.   
 
Furthermore, the interviewers were taken through a detailed programme of 
engagement, briefing and instruction, to ensure they were fully prepared to conduct 
the interviews. 
 
Ultimately, the transition to CAPI data collection proved successful and eliminated 
many of the challenges associated with pen-and-paper data collection which had 
been encountered previously. 
 
1.3. Inclusion of booster sample in Ballymun 
 
As well as the move to CAPI outlined above, the other key difference in the 2006/07 
study was the decision to run a smaller, booster survey in parallel in the area of 
Ballymun, Dublin 11, which was designed to test the merit of conducting a local 
prevalence study.   
 
The NACD agreed that the questionnaire used in the main survey could be used to 
conduct a booster survey of adults aged 15-64 in Ballymun.  This survey was also 
conducted on CAPI, with a target number of 300 interviews.  The approximate 
sample size of 300 was agreed in order that the survey would provide robust and 
reliable data at a total sample level only and would keep the cost low. 
 
Range of error (+/-) for 95% CI   -  for range of percentages by survey size 
(assumes simple random sample)       
            
  5% or 95% 10% or 90% 20% or 80% 30% or 70% 50% 
Base           
100 4.3 5.9 7.8 9.0 9.8 
200 3.0 4.2 5.5 6.4 6.9 
300 2.5 3.4 4.5 5.2 5.7 
500 1.9 2.6 3.5 4.0 4.4 
 
This smaller study was conducted on behalf of the Ballymun Local Drugs Task Force.  
There was ongoing liaison with Marie Lawless, Policy and Research Officer, Ballymun 
Local Drugs Task Force and she also attended Research Advisory Group meetings 
between Ipsos MORI and NACD.   
 
Further detail on the Ballymun survey is provided in Appendix P. 
 
Running a national and local survey in parallel proved to be a challenging experience.  
The biggest difficulty with such an approach is one of interviewer capacity, whereby 
interviewers may be required to work on both surveys.  As the local survey was 
taking place in Dublin, which in the national survey proved to be one of the more 
challenging parts of the country to secure interviews in, this meant that progress of 
both surveys was slower than had been anticipated. 
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The main advantage of running both surveys in parallel, meanwhile, was that lessons 
from one could quickly be adapted to the other.  As the fieldwork for the main study 
was underway by the time the Ballymun survey commenced, many early difficulties 
or issues that had been encountered could be anticipated.  Furthermore, guidance on 
the likely respondent reactions and frequently asked questions were identified in the 
main study, and hence could be anticipated in the local survey. 
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2. Survey Design 
2.1.  Target Population 
 
The universe for the survey was defined as a survey of all adults, aged between 15 
and 64, living in private households in the Republic of Ireland and Northern Ireland, 
as per EMCDDA guidelines.  This report focuses on the Republic of Ireland 
survey only.   
 
As the EMCDDA Handbook observes, surveys of this nature are typically conducted in 
the respondent’s home for methodological and practical reasons1.  In addition to 
this, the length of the questionnaire, i.e. approximately 20 minutes interviewing time, 
dictated that the interview needed to be conducted in the respondent’s home and 
not on the street; moreover the sensitive nature of the subject matter lent itself 
better to the more confidential surroundings of the person’s home.   
Language 
 
It is worth noting at this stage that the survey did not make a specific provision for 
interviews to be conducted in languages other than English.  Households could 
participate in the study, regardless of their language needs, and NACD was willing to 
provide translation if required.  However, from a practical point of view, it was 
agreed at the outset that this issue would be closely monitored on an ongoing basis 
and, if a significant number of respondents requiring translation of the questionnaire 
or an interpreter was encountered, that this would immediately be brought to the 
attention of the Research Advisory Group to allow it to monitor additional costs.   
In fact, although approximately 10 households requested the original letter to be 
translated into Polish to help them better understand the survey and make a decision 
about participation, ultimately no interviews were conducted in any language other 
than English and no respondents requested the service of an interpreter.   
(A copy of the Polish translation of the letter is provided in Appendix J). 
                                                          
1 EMCDDA Handbook for Surveys on Drug Use Among The General Population (2002) p.80 
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Age 
 
Adults aged 15-64 years were included in the study in line with EMCDDA guidelines 
and as before, there were two sections of the population which were deliberately 
excluded in terms of age.  The first of these were the under 15s, who were excluded 
in line with EMCDDA guidelines.  Under Market Research Society guidelines, it is only 
permissible to interview 15 year olds and under with the written consent of their 
parents or guardian.  Therefore, in order to include 15 year olds in this study, the 
written consent of their parents or guardians was obtained. It should be noted that 
the parent/guardian also had the right to sit in on the interview, if they so wished.   
 
The table below outlines the numbers of 15-year-old respondents, who conducted 
the interview in the presence of a parent/guardian. 
 
 Total 
Parent present 26 
Parent not present 31 
Total 57 
 
The second age group which was excluded were people aged 65 and over.  This 
group was excluded because, as the EMCDDA points out, responses from 
respondents in this group may be less reliable (due to effects of memory), and in any 
case the prevalence of (lifetime) drug use amongst this group is not expected to be 
very high2. 
 
Audiences outside the scope of this study 
 
Similar to the last study, it was decided not to set out to deliberately achieve 
interviews with specific groupings such as the homeless, members of the Traveller 
community or other minority and ethnic groups, nor with those in institutions, such 
as prisons.   
 
2.2.  Mode of Interviewing 
 
Selecting the most appropriate mode of data collection was critical to the success of 
this survey.  The mode selected had to deliver a highly-accurate dataset while 
remaining cost-effective.  It had to be acceptable and viable to both interviewers and 
respondents, while allowing for stringent project management and monitoring of 
fieldwork. 
 
The research brief specified the use of Computer Assisted Personal 
Interviewing (CAPI) as the preferred mode of interviewing in the 2006/07 
study.   A pen and paper method was used in the 2002/03 study.  Some of the 
particular benefits of using CAPI over a pen and paper questionnaire included: 
 
                                                          
2 EMCDDA Handbook for Surveys on Drug Use Among The General Population (2002) p.79 
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¾ Interviewer routing error was avoided, as the programme automatically 
guided interviewers to the correct question. This also saved time;  
 
¾ Complex routing was made possible, which was extremely difficult to 
administer on a traditional paper questionnaire. In an attempt to overcome the 
complex routing in the last Drug Prevalence study, the questionnaire was 
designed with indicators and sections (i.e. questionnaire ‘flaps’) – the need for 
this was now negated through the use of CAPI; 
 
¾ Automatic CAPI checks and edits reduced interviewer error and prompted 
respondents to consider their answers where they answered questions 
inconsistently; 
 
¾ The need for data punching, a traditional source of error in market research 
surveys, was eliminated; 
 
¾ Completed interviews were automatically downloaded via modem, 
allowed immediate access to the data and allowed much faster data processing 
than a paper based questionnaire. Data could be almost immediately linked to 
SPSS, the data processing tool. 
 
 
2.3.  CAPI Set-Up and Validation 
 
SPSS MR’s Quancept software was used for Computer Assisted Personal Interviewing 
(CAPI). Quancept is an integrated suite of software tools for designing surveys and 
conducting CAPI. It has a Microsoft Windows-based graphical user interface making 
it extremely easy to use. Interviewers required minimal training and supervisors 
could efficiently manage complex projects with numerous field interviewers.  
 
We put in place the following procedures to ensure that the data were suitably 
validated, further enhancing the quality of the data.   
 
1) Range Checks: 
Range checks were built into the CAPI script so that, for example, if the range of 
possible answers to a particular question was between 1 and 5, the interviewer could 
not input the number 50 by mistake and continue.  
 
2) Rigorous checking of routing (skips): 
All routing was rigorously checked by members of the CAPI set-up team and also by 
several members of the Executive team.  
 
3) Consistency checks: 
Consistency checks were built into the script and also rigorously checked as part of 
the checking of routing (skips). 
 
Members of the Research Advisory Group took part in the script approval 
process, by viewing the CAPI script on a laptop after it had been scripted.   
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2.4. Sampling 
 
Population surveys on drug use, in common with most other surveys, are usually 
conducted among a sample of the entire target population because it is not practical, 
nor cost or time-efficient to interview every single individual in the population.   
A survey is only as good as its sample.  This is especially true of a population survey 
such as this, where the key objective was to provide for reliable national estimates of 
the prevalence of drug use in Ireland to feed into public policy making.  
Random Sampling 
 
The EMCDDA Handbook suggests that “in prevalence studies, as in social studies in 
general, it is usually not possible to make assumptions (about the distribution of 
survey variables in the population) and, as a consequence probability sampling 
should almost be considered mandatory”3.  Given that collecting accurate, up-to-date 
profile data was a key aim of the survey, and this sampling method was used in 
2002/2003, the RAG and project team felt that a similar approach should be used in 
2006/2007.   
 
2.5. Sample Frame 
 
As a randomly drawn sample, this survey was one in which every member of the 
defined population (in this case, those aged 15-64) had a calculable chance of being 
included in the sample.  Therefore, the first step in drawing a random sample is to 
define the sampling frame, i.e. a list of all the members of the population.  However, 
such a list is not available in Ireland.   
The survey used the An Post/Ordnance Survey Ireland GeoDirectory as the 
primary sampling frame.  This file is comprehensive, regularly updated, and has a 
high degree of accuracy.  Additionally, this sampling frame was used in the 
2002/2003 study and was the RAG’s preferred sampling frame for the 2006/07 
study.  In particular, the GeoDirectory address lists were chosen because: 
¾ It contained every address point in Ireland and is designed for use for market 
research and by all kinds of businesses; 
¾ It is updated on a quarterly basis; 
¾ It avoids double counting as buildings, which have alternative names (e.g. No.15, 
Any Street and Rose Cottage, Any Street), would be counted only once; 
¾ GeoDirectory provides separate lists for businesses and residential addresses. 
¾ It links every address to its electoral division, allowing for the separation of data 
from both large (e.g. HSE areas, Regional Drug Task Forces) and small 
geographic areas (e.g. Electoral Divisions (EDs) alike; 
¾ Demographic data from the CSO can be easily obtained at an ED level and 
incorporated into databases provided by GeoDirectory; 
3 EMCDDA Handbook for Surveys on Drug Use Among The General Population, (2002), p.97 
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¾ The address lists provided by GeoDirectory would also include those who may 
not be on the electoral register for one reason or another. 
 
Despite these obvious advantages, using the GeoDirectory list still had the same 
potential for limitations (extra dwellings, combined dwellings and addresses without 
dwellings).  Again, interviewers’ contact sheets were used to gather information on 
the addresses that were excluded. 
 
2.6. Selection of Sample 
A three-stage process was used to construct the sample for this survey: 
Selection of Primary Sampling Units (PSUs) 
 
Stratification techniques were used to select Primary Sampling Units (PSUs).  In this 
case, Electoral Divisions (EDs) were defined as Primary Sampling Units (PSUs) in the 
sample stages of the study.   
Since January 2005, the health boards in Ireland have undergone restructuring and 
are merged under one authority – the Health Service Executive (HSE).  However, 
when the last survey was carried out in 2002/3, data were weighted by the now 
former 8 health board areas including the Eastern Regional Health Authority which 
incorporated 3 local area health boards.  All of these health boards corresponded to 
the Regional Drug Task Force (RDTF) structures set up under the National Drug 
Strategy, therefore it was agreed that aggregation of data and application of 
population weights would continue to apply according to the RDTFs.   
In the first stage of stratification, the number of interviews per RDTF area was 
agreed.  The decision on the number of interviews per RDTF area was primarily in 
proportion to the population, with some modifications for the smaller RDTF areas 
such as the Midlands and the North Western regions, where the number of 
interviews was over-sampled to around 400 in each region to enable a more robust 
sample size for these regions, as indicated in the table below.   
The table below provides the latest known population figures at the time of 
commencing fieldwork. As the latest census data had not yet been released by 
detailed age breakdown, population estimates for 2006 for the population aged 15-
64 were used based on data from the 2002 Census.  As detailed in a subsequent 
section, 2006 Census figures were used for the purposes of re-weighting results. 
13
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HSE Region equivalent to RDTFs Total % of 
population 
Sample 
size 
ERHA4 1,064,100 36.60% 1,532 
Midland RDTF (Midlands HB) 167,766 5.77% 401 
Mid Western RDTF (Mid Western HB) 245,399 8.44% 537 
North Eastern RDTF (North EasternHB) 265,873 9.14% 446 
North Western RDTF (North Western HB) 155,033 5.33% 386 
South Eastern RDTF (South Eastern HB) 307,793 10.59% 440 
Southern RDTF (Southern HB) 422,749 14.54% 682 
Western RDTF (Western HB) 278,760 9.59% 543 
    
TOTAL 2,907,473 100.00% 4,967 
 
In the second stage of stratification, a decision was made on the number of Primary 
Sampling Units (PSUs) to be selected (385 in total).  The decision on the number of 
PSUs selected was based on practical considerations (an appropriate compromise 
between allowing sufficient range of coverage and the need to be practical from a 
data collection and field management perspective).  
These PSUs were then ranked by socio-demographic indicators, from census data, 
such as population density, male unemployment and social class, to ensure that a 
representative cross-section of areas was included, and the likelihood of selecting an 
individual PSU would be proportional to the population of that PSU.  In this way, 
PSUs of all sizes and compositions would have an equal chance of selection.  The 
table below shows the breakdown of PSUs to HSE regions. 
HSE Region equivalent to RDTFs Number of Sampling Points 
ERHA 135 
Midland RDTF 31 
Mid Western RDTF 34 
North Eastern RDTF 35 
North Western RDTF 31 
South Eastern RDTF 35 
Southern RDTF 49 
Western RDTF 35 
Total 385 
 
On average, 24 addresses were chosen at each of the sampling points. 
 
No reserve sample points were used in this study. 
 
                                                          
4 ERHA in this instance refers to the combined group of RDTFs: Northern Area RDTF, South Western 
RDTF, East Coast RDTF each equivalent to the former local health board areas prior to 2005. 
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Selection of Addresses 
 
A sample was drawn at random, from each of the randomly selected PSUs, using the 
information provided in An Post/Ordnance Survey’s GeoDirectory.   
 
Additional addresses were only issued for a given assignment point when an 
interviewer had encountered 10 or more ineligible properties.  These were non-
residential, derelict, and demolished properties, and where no one in a particular 
household was eligible to take part in the survey, for example because of age. 
The use of CAPI meant that the interviewer needed to physically access the inside of 
the respondent’s home, which was likely to cause some concern to some 
respondents.  To alleviate this, Ipsos MORI wrote a letter in advance to the 
entire selected sample, outlining that a survey was taking place and that 
an interviewer could call to their door. 
To ensure confidentiality and anonymity, no interviewers conducted the research in 
their immediate locality, thus reducing the likelihood of interviewers having to speak 
to an acquaintance, friend or relative.  
Property and Household Selection 
 
When an interviewer called at an address, their initial task was to establish whether 
the address was residential and occupied.  If it was, they next had to establish the 
number of properties or self-contained dwelling units it comprised (typically defined 
as a self-contained dwelling behind its own front door).   
 
A household is defined as a person, or group of people who normally live at the 
same property, who share a living room or at least one meal a day.  In properties 
with multiple households, one was randomly selected. 
 
Respondent Selection 
 
Individuals (aged 15-64) within each randomly selected household were randomly 
selected to take part in the survey, using a “last birthday rule” – i.e. the person 
answering the door at any given residential address was asked to list the birthdays of 
all residents in the target age group.  The person with the most recent birthday was 
then selected to participate.  This random selection procedure took place during an 
initial screening interview, with an adult member of the household.  If the individual 
selected was not present at that time an appointment was arranged for a later date. 
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3. Questionnaire Design 
3.1. Questionnaire Development 
The questionnaire used on this study followed the EMCDDA model questionnaire with 
modifications appropriate to the Irish context and without prejudice to the purpose 
of the questionnaire. 
 
The questionnaire was designed with the full involvement of the RAG.  The group 
made minor adaptations and refinements to tailor the questionnaire to Ireland, whilst 
ensuring full comparability with other surveys conducted with the model 
questionnaire.   
 
Since the survey was being conducted simultaneously in both jurisdictions, the 
Republic of Ireland and Northern Ireland, careful consultation was required to ensure 
comparisons could be made to both sets of results, while there was also opportunity 
to customise certain questions where appropriate. 
 
3.2. Pilot Study 
Ipsos MORI, in line with EMCDDA guidelines, conducted a comprehensive piloting of 
the questionnaire design.  Although there were minimal changes to the questionnaire 
content from the previous study, the introduction of a CAPI approach meant that the 
pilot phase was necessary to highlight any potential issues.  
 
The purpose of the pilot study was to thoroughly test all aspects of the survey in 
advance of the main fieldwork period.  It was required to assess both interview 
content (question wording, use of showcards, interview flow) and practical 
considerations (measurement of interview length, respondent reactions and 
identification of potential queries etc.).  The experience and results from the 2002/03 
were also used to inform the approach. 
 
Firstly, the questionnaire was subjected to Ipsos MORI’s internal piloting procedures.  
At this stage, members of the fieldwork team and the core project team tested the 
questionnaire.  This process was primarily designed to ensure all questions were 
included with the correct wording and in the correct order, and also to check the 
routing.   
 
Secondly, a series of live pilot interviews was conducted.  The pilot interviewers were 
briefed in Ipsos MORI’s offices by members of the project team, after which a total 
of 50 pilot interviews were conducted with members of the public in September 
2006.  The pilot interviews took place in a range of geographical areas across the 
country to ensure the survey was understood by respondents from a variety of 
backgrounds.   
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Once these pilot interviews were completed, interviewers produced detailed 
comment sheets which the Ipsos MORI project team then reviewed.  In addition, the 
data from the pilot interviews was analysed to ensure the CAPI script and data 
outputs were correct in advance of the main fieldwork period.   
 
In order to identify any actions that were required in advance of the full study, a 
pilot debrief meeting was convened at the Ipsos MORI (Dublin) office, whereby the 
interviewers working on the pilot study met with members of the project team.  This 
meeting took place on 21st September 2006.   
 
Among the key actions taken as a result of the pilot study and subsequent 
discussions were; 
 
¾ Minor word changes and amendments to specific questions. 
¾ The inclusion of a ‘Refused’ option for most questions (which would not be 
offered to the respondent but was required to enable progress through the CAPI 
script). 
¾ The provision (by NACD) of updated ‘street names’ for certain drugs. 
¾ Preamble text added at several points during the script to aid interview flow. 
¾ The inclusion of a ‘Frequently Asked Questions’ sheet which could be provided to 
respondents upon request, explaining issues such as confidentiality and the use 
of a laptop, if results will be shared, etc.  (See Appendix M) 
 
In summary, the pilot study proved a valuable exercise, as evidenced by the issues 
raised and the corrective actions taken. 
 
 
3.3. Questionnaire Approval 
The final version of the questionnaire was formally approved by the RAG on 10th 
October 2006. 
A copy of the Final Questionnaire and Showcards is provided in Appendix E/F. 
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4. Fieldwork 
4.1. Overview 
As noted earlier, there were a variety of possible ways of undertaking this research 
but for this study, fieldwork was conducted by means of face-to-face interviews 
conducted in the respondents’ homes as per EMCDDA guidelines.  There was a 
number of reasons for this decision, as follows:  
¾ The length of the questionnaire dictated that the interview needed to be 
conducted “in-home” and not “on street”; 
¾ The sensitive nature of the subject matter lent itself better to the more 
confidential surroundings of the person’s home; 
¾ Conducting the survey using an “interviewer completion” approach (rather than 
self-completion) was a better means of collecting information from all 
respondents (i.e. including those who had finished education ‘early’ (pre-primary, 
primary), who were illiterate or who had difficulty reading); 
¾ Any potential bias which may have arisen from the way an interviewer asked a 
question was largely removed through the use of a straightforward 
questionnaire, and the high level of interviewer training and supervision; 
¾ Face-to-face interviews also generate higher response rates. 
It is worth noting that face-to-face interviews are known to result in under-reporting 
particularly when sensitive questions are used. 
 
 
4.2. Fieldwork Period 
The fieldwork was conducted in two phases, namely from November 2006 to 
December 2006 and from January 2007 to May 2007, spread across all Regional 
Drug Task Force areas.  This was to allow a spread of interviews before and after 
Christmas 2006.  There were no differences in the questionnaires used or in 
sampling and interviewing techniques used during either period. 
 
 
4.3. Interviewer Briefings & Instructions 
One of the factors most correlated with high response rate is the experience 
interviewers already have with that particular survey and the extent to which they 
feel an attachment to it.  Prior to conducting the fieldwork, it was agreed to conduct 
a series of interviewer briefings, to ensure interviewers were fully prepared to 
conduct the survey and to allow for discussion and dialogue between interviewers, 
the Ipsos MORI team and the Research Advisory Group. 
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The meetings included opportunities for discussion, practice sessions, and role-play 
exercises.  Senior members of the study teams led the briefings, which each and 
every interviewer working on the study attended.  In line with EMCDDA guidelines, 
the briefings were attended by members of the RAG, who were able to give the 
interviewers the benefit of their specialist expertise. 
 
In addition to the verbal briefings, all interviewers received full written instructions 
on all aspects of the survey.  A copy of the full instructions for interviewers is 
outlined in Appendix N. 
 
A total of four interviewer briefings were held in hotel locations with all interviewers 
assigned to the survey; two in Dublin, one each in Limerick and Sligo.  The briefings 
lasted between four and a half and five hours, and provided opportunities for 
discussion and role-play, as well as a thorough run-through on the survey.   
The details and attendance at the briefings was as follows; 
 
Date Location Fieldwork attendees 
26th September 2006 Dublin 14 interviewers, 2 supervisors 
28th September 2006 Sligo 12 interviewers, 1 supervisor 
5th October 2006 Limerick 16 interviewers, 1 supervisor 
10th October 2006 Dublin 17 interviewers, 4 supervisors 
 
The four sessions all followed the same format and were led by Brenda Boyd, Field 
Director of Ipsos MORI in Ireland.  All Field Office staff who will be working on the 
study attended at least one briefing session.   
 
Mairéad Lyons, Director of NACD, attended both the Limerick briefing and the second 
Dublin briefing, while Eddie Arthurs from the Research Advisory Group attended the 
first Dublin briefing.  Also present in Dublin on 10th October were Project Director, 
Tarik Laher and other members of the Ipsos MORI team. 
 
Interviewing Team 
All interviewing was carried out by members of the Ipsos MORI Interviewer Panel 
who have been trained and work to the standards of the Interviewer Quality Control 
Scheme (IQCS).  Interviewers working on the study were both male and female, 
across a range of ages but with a higher proportion in the 50+ age category, which 
is reflective of the profile of market research interviewers nationally.  They are 
recruited on the Ipsos MORI panel via a formal process, involving a written 
application form, a personal interview, a detailed training session and completion of 
test interviewing projects. 
All Ipsos MORI Interviewers and Recruiters carry Identity Cards issued by the Market 
Research Society (MRS), which bear the photograph and signature of the 
interviewer, and are issued only after the signing of a declaration which states that 
the interviewer has read and agrees to abide by the MRS Code of Conduct.  This 
Identity Card was shown to each respondent before an interview takes place, to 
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reassure them that the study was genuine.  Furthermore, respondents were given a 
leaflet at the end of the interview which stresses the confidentiality of the process, 
and provides the telephone number of Ipsos MORI’s Field department to call if they 
had any further queries.   
A minimum of 10% of completed interviews are back-checked on all quantitative 
surveys carried out by Ipsos MORI using a combination of telephone recall or postal 
check card.  This is applied to ensure that the interviewers have conducted the 
interviews professionally and in line with survey specifications.  In general, 
respondents are asked to comment on, among other things, the duration of the 
interview, their recollection of their being asked specific questions, being shown 
interviewer identification and their reaction to both the interview and the interviewer.   
Content of Interviewer Briefings 
All those attending the briefings had copies of all the documentation that will be used 
by interviewers during fieldwork, including interviewer instructions, show cards, and 
examples of contact sheets.  All briefings followed a similar format, the content of 
which is summarised below. 
¾ Introductions and the background to the study, with input from 
representatives of the Research Advisory Group.   
¾ Discussion about the previous study and its results, enabling interviewers to 
appreciate better how the results might be used. 
¾ Full explanation of the study design to be employed on the study, with 
emphasis on the importance of random sampling and the need to obtain a 
high response rate.   
¾ Illustration of the contact sheet.  Advice on averting refusals and how to gain 
cooperation from the initial contact. 
¾ Discussions around the selection for interview of an individual within a 
household.  Use of Kish grids and how to administer the “last birthday rule”.   
¾ Working through the survey itself (with the questionnaire projected on to a 
screen), with interviewers given the opportunity to go through the questionnaire 
following different routes, depending on the answers given.   
¾ Demonstration of progress reporting using e-progress (an electronic form 
onto which interviewers can record information from their contact sheets – 
number and outcome of calls made to addresses on a given day).   
¾ Further opportunity for practice interviews as required. 
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4.4. Field Management 
Following the sample selection, Ipsos MORI’s Fieldwork Management System was 
used to control and monitor progress on the study.  The process involved was as 
follows: 
¾ The sample was loaded into the General Management Survey System (GSMS).   
This was designed specifically to control and manage large scale pre-selected 
studies such as this.   
¾ The allocation of areas was made to interviewers on a rolling basis to ensure an 
even spread of interviews by region by week.  This ensured that any seasonal 
variations in results would be evenly spread out across the country.  
¾ Interviewers called at the selected addresses and where contact was established 
with a member of the household, either the interview was carried out if the 
selected person was available, or an appointment was made to call back and 
interview the selected household member.  Dates and times of all calls made and 
their outcomes, (successful interview taken, appointment made, no contact, 
refusals etc.,) were entered into GSMS by interviewers using e-progress at the 
end of each interviewing shift.  E-progress reports on each contact were 
uploaded to the server at the time of uploading completed interviews.  
¾ Every day, supervisors and field staff were able to check individual interviewers’ 
progress and monitor success rates, numbers of refusals, un-worked contacts 
etc.  
¾ As well as the questionnaires, interviewers also filled in contact sheets for each 
address visited, documenting each attempt to contact or interview the selected 
individual (following the “last birthday rule” methodology as detailed in the 
Sample Design section). They also established some basic details about them 
(i.e. type of house).  The final outcomes of the attempts to interview the selected 
respondent were noted, as were any reasons for not taking part.   
Further information on contact sheets is provided in Section 4.8.   
A copy of the Contact Sheet is provided in Appendix G.   
¾ Contact sheets were kept separate from the questionnaires in order to reassure 
respondents about confidentiality.  However, if needed, it was still possible to link 
each contact sheet to each completed questionnaire via identification numbers.  
Contact sheets from each area were returned on an ongoing basis by 
interviewers in the post.  Upon receipt, these contact sheets were edited and 
validated to ensure that the correct person in the household had been selected 
for interview. After this quality control procedure had taken place, they were 
entered into GSMS. 
¾ As questionnaires were completed and contact sheets returned, validation 
procedures began.  Supervisors ensured that a minimum of 10% of all completed 
questionnaires were validated.  There was also a  5% validation of those contact 
sheets stating that no successful interview could take place because of age of 
inhabitants or that the address was for vacant or commercial properties.  
Validation was conducted by telephone or personal visit. 
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¾ Each week an interim field report was compiled for each Health Board region 
showing addresses issued, successful interviews undertaken, pending interviews, 
refusals etc.   
¾ At the end of each phase of interviewing, a full fieldwork report was compiled 
showing not only full details of the interviews completed but also the results of all 
quality control procedures. 
¾ Interviewers had the support of their local regional supervisors who were always 
available to help them with difficulties in the field or problems of any nature.  All 
supervisors attended the briefings and were kept informed of developments 
across the whole fieldwork period. 
¾ In addition to the support from supervisors, all interviewers had telephone 
numbers of all key Field staff and knew that they could call on any member of 
the Field department for support at any time. 
 
4.5. Enhancing Response Rates 
As with any survey of this nature, eliciting a satisfactory response rate presents a 
variety of challenges.  These can include; difficulties in accessing potential 
respondents at home, due to work etc.; a lack of interest or engagement from 
respondents; a perceived lack of relevance due to the subject matter; queries 
regarding the commissioning body; a lack of trust in surveys generally or a lack of 
credibility in the process; concerns over anonymity and how personal information 
might be used; lack of time for respondents or an unwillingness to participate due to 
survey length; inclement weather. 
 
If the interviewer had visited a household which was occupied, there was a number 
of reasons why an interview may not have been completed at that location.  This 
may have an impact on the accuracy of the sample. During the fieldwork 
considerable effort was taken to avoid such a situation occurring.  Below are some 
approaches used to enhance the response rate for the survey.   
 
Interviewer Calls 
In accordance with EMCDDA guidelines, multiple calls were made to selected 
addresses. Interviewers were instructed to call up to five times – an initial call, plus 
four call-backs – at each address, at different times (including evenings) and on 
different days (including weekends – Saturdays for initial calls and Sundays by prior 
appointment), to try and ensure they would be able to speak to the potential 
respondent.  In practice, many addresses received significantly more calls, as all 
non-contacts and “soft refusals” were re-issued to Regional Field Supervisors for 
further calls.   
 
Trained Interviewers 
The effectiveness of interviewers depends, more than anything, on the training they 
receive – and the encouragement they are offered throughout the fieldwork period.  
This is especially true for random pre-selected surveys.  In this regard, only fully 
trained interviewers worked on the study.  Many of these interviewers had extensive 
experience of pre-selected survey work. 
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Help-line 
A telephone help-line was set up for interviewers and respondents to handle queries, 
refusals, and requests for information or appointments from respondents.  This 
helped reassure respondents that this was a genuine survey.  A thoroughly briefed 
member of the support team at Ipsos MORI's offices in Dublin handled the calls.  
Written procedures outlined the action to be taken in response to different types of 
calls.  
  
Naming the Client  
Research experience indicates that response rates can be significantly enhanced by 
interviewers being able to name the sponsoring client, and this was especially true 
for a survey which some respondents might find sensitive or intrusive, such as this.  
If contacts asked about whom the research was for, the interviewers were able to 
name the relevant government department (Department of Community, Rural & 
Gaeltacht Affairs in Ireland) as sponsoring the study.  This helped provide 
reassurance and establish the credibility of the survey in the respondent’s eyes. 
 
The Promise of Confidentiality 
Response rates were also enhanced by providing a visual reassurance of 
confidentiality to respondents.  As a matter of course, respondents in all Ipsos MORI 
surveys receive a leaflet reassuring them that the research has been conducted 
within the Code of Conduct of the Market Research Society (MRS). This also provides 
a lo-call telephone contact number for Ipsos MORI in Dublin. 
 
For this particular study, potential respondents were provided with a letter from the 
NACD.  Interviewers also had copies of the letter written by an Ipsos MORI Director 
to the Deputy Commissioner, Garda Síochána informing him that the survey was 
taking place.  These letters provided further reassurance that the survey was a bona 
fide research exercise.  This is standard procedure for all face-to-face surveys 
conducted by reputable research agencies and is designed to prevent undue anxiety 
on the part of the respondent.  Copies of the letters that were presented to 
respondents are provided in Appendices H, I, J & K. 
 
With regard to An Garda Síochána, it was also agreed that Ipsos MORI would provide 
the list of interviewing areas to the Gardaí on a regular basis.  These were sent to 
Frances Walsh in An Garda Síochána on approximately a monthly basis, via an Excel 
spreadsheet outlining the areas in which interviews were taking place, with the name 
of the corresponding interviewer and approximate interviewing dates. 
 
Appointment Cards 
Where the selected respondent was not at home, carefully designed appointment 
cards were left with other members of the household.  This card provided brief 
details of the study and a name and telephone number to call to arrange an 
interview at a time most convenient to them.  This was particularly effective in 
converting some interviews with busy young professionals and those who work in 
shift work.   
 
Apartment Complexes 
In any apartment complexes where access had to be gained through a gate or entry 
phone, interviewers were encouraged to make arrangements with caretakers and 
other staff to gain access to the block.  In this way, respondents from these locations 
were also included in the survey. 
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Frequently Asked Questions 
After discussion at the briefing meetings, it was agreed to prepare a series of 
answers to Frequently Asked Questions (FAQs) in order to provide information to 
those who may be unfamiliar with the study.  A copy of this FAQ document is 
provided in Appendix M. 
 
Monitoring and Supervision 
Significant resources were allocated to monitoring progress in the Field, with weekly 
reports being sent to the dedicated Field Study Manager working on the study.  
 
The “Ipsos MORI” Name 
People are more likely to be receptive to an approach from an organisation they are 
familiar with and trust.  As with other studies, interviewers found that the reputation 
and high profile of Ipsos MORI as a trusted and independent research company also 
helped encourage responses. 
 
4.6. Number of Contacts 
The process of re-contacting a selected household a number of times in order to 
achieve an interview with the person chosen is critical to the sampling approach, 
since the random selection of the initial list of addresses is maintained.  Inevitably, 
the number of calls which was necessary to achieve each interview varied.  The 
following table outlines the number of calls required to achieve interviews in each 
health board area. 
 
Number of Calls 
Health Region 
equivalent to RDTFs 
One to 
Three 
Calls (%)
Four to Five 
Calls (%) 
Six or More 
Calls (%) 
Average 
Ireland 87% 10% 3% 2.0 
ERHA 89% 9% 2% 1.9 
Midland RDTF 85% 13% 2% 2.0 
Mid Western RDTF 89% 9% 2% 1.9 
North Eastern RDTF 83% 14% 4% 2.1 
North Western RDTF 89% 11% 1% 2.0 
South Eastern RDTF 77% 17% 6% 2.5 
Southern RDTF 94% 5% 1% 1.5 
Western RDTF 81% 13% 6% 2.3 
 
 
On average, interviewers attempted to contact respondents twice before a successful 
interview was conducted. There was variation across the RDTF areas.  At one end of 
the spectrum, interviewers in the Southern RDTF area had the least difficulty, with 
94% achieving their interviews within three contacts.  In the South East & Western 
RDTF areas meanwhile, 6% of all interviews required more than six calls to be 
completed. 
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4.7. Age & Gender 
The following table compares the profile of the sample for the survey with the profile 
of the target Republic of Ireland adult population as a whole (aged 15 – 64).   
 Population % population Sample % sample
Ireland 2,906,478 100.0% 4,967 100.0% 
Gender     
Male 1,471,032 50.6% 2,027 40.8% 
Female 1,436,441 49.4% 2,940 59.2% 
Age     
15-24 632,732 21.8% 789 15.9% 
25-34 722,439 24.8% 1,200 24.2% 
35-44 623,434 21.4% 1,222 24.6% 
45-54 521,813 17.9% 921 18.5% 
55-64 407,055 14.0% 835 16.8% 
Health Board     
ERHA 1,064,100 36.6% 1,532 30.8% 
Midland RDTF 167,766 5.8% 401 8.1% 
Mid Western RDTF 245,399 8.4% 537 10.8% 
North Eastern RDTF 265,873 9.1% 446 9.0% 
North Western RDTF 155,033 5.3% 386 7.8% 
South Eastern RDTF 307,793 10.6% 440 8.9% 
Southern RDTF 422,749 14.5% 682 13.7% 
Western RDTF 278,760 9.6% 543 10.9% 
 
 
From this comparison it is clear that there are discrepancies between the profile of 
the sample and that of the population generally. In particular, it seems that the 
under-25 year olds, males and those in the former Eastern Regional Health Authority 
(ERHA) appear to be under-represented in the survey.   
 
Given that, as the EMCDDA points out, “no sample frame is perfect and perfect 
probability sampling does not exist”, it is perhaps inevitable that there would be 
some discrepancies.  The weighting procedures followed (as outlined in a subsequent 
section of this report), were aimed at alleviating the impact of any biases arising 
from the differences between sample and population.  The remainder of this section 
of the report looks at other areas which might have given rise to bias in the results. 
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4.8.  Non-Response 
In order to estimate the effects of non-response bias in the achieved sample, the 
contact sheet was used to record the age, gender and ethnicity of the household of 
all those who refused to take part.  Further, interviewers also coded the external 
features of households where contact had not been possible.  This information was 
compared with characteristics among the achieved sample to help assess its 
representativeness.  
Age & Gender 
The table below outlines the gender and age of those who refused to take part in the 
survey. 
 
Area % of Sample % of Refusals 
Male 41% 51% 
Female 59% 49% 
15-24 years 16% 8% 
25-34 years 24% 22% 
35-44 years 25% 25% 
45-54 years 19% 25% 
55-64 years 17% 20% 
 
In terms of gender, it is clear that a higher proportion of males refused to take part 
in the survey, relative to their proportion of the sample.  There was a higher 
proportion of people in the 45-54 age group among those who refused to take part.  
At the same time 15-24 year olds made up a smaller proportion of refusals compared 
to the sample (i.e. 8% vs. 16%).  In terms of the sample, however, these 
discrepancies are greatly reduced after weighting. 
 
Type of House 
It was also of critical interest to compare the social makeup of those who refused 
with the actual sample.  By the definition, it was not possible to gather data on the 
social classification of those who refused to take part, which could be directly 
compared with the survey results.  As a rough measure of the social composition of 
the sample and of those who refused to take part, the contact sheets also included 
details on the external characteristics of the homes of all those which they attempted 
to contact.  The following table compares the property types where completed 
interviews took place and those where potential respondents had refused to take 
part. 
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Type of Property % of Successful 
% of 
Refused 
Ireland 
House/bungalow - detached 49.9% 30.4% 
House/bungalow - semi-detached 27.8% 44.4% 
House/bungalow - mid terrace 12.6% 14.1% 
House/bungalow - end terrace 3.4% 4.7% 
Purpose built flat. etc, - building fewer than 6 floors 5.2% 4.6% 
Purpose built flat. etc, - building 6 or more floors 0.2% 0.2% 
Conversion flat/maisonette(s)/shared house 0.5% 0.3% 
Other 0.0% 0.0% 
TOTAL 100.0 100.0 
 
 
Those who refused to take part were less likely to live in a detached house than the 
sample, with half the sample (49.9%) living in detached houses compared to 30.4% 
of those who refused to participate.  On the other hand, those who refused were 
more likely to live in semi-detached houses in particular, with 27.8% of the sample 
living in semi-detached houses compared to 44.4% of those who refused to 
participate. 
 
 
4.9.  Ineligible Contacts in Sample Frame 
Refusals, of course, were not the only reason that an interviewer might not achieve 
an interview at a selected address.  Frame errors, where contacts were ineligible for 
the defined universe (aged 15-64), or where the property was ineligible, vacant, 
derelict, demolished, not found, or a business, also explained why interviews were 
not conducted at all addresses.  As such, it was important to check that frame errors 
were evenly distributed by region, as an uneven spread of frame errors may point to 
bias in the sample. The following table outlines the extent to which frame errors 
were present in the health board regions.  Besides frame errors, they also show 
breakdowns of the gross sample by:  
¾ Successful interview - persons belonging to the universe who were part of the 
sampling frame and completed the interview fully. 
¾ Non-response - households that refused to take part during the initial screening 
interview and respondent selection process, respondents who refused to take 
part once selected, and properties where wardens etc refused on the contact’s 
behalf, or where no contact could be made after multiple calls.  Reasons for non-
response (refusals) are detailed in a subsequent table. 
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Area Gross Sample 
Successful 
interviews Non-Response Frame Errors
TOTAL n 9643 4967 2710 1966 
% 100% 52%  28% 20%
ERHA n 3448 1532 1075 841 
% 100% 44%  31% 24%
M RDTF n 769 401 230 138 
% 100% 52%  30% 18%
MW RDTF n 841 537 166 138 
% 100% 64%  20% 16%
NE RDTF n 864 446 252 166 
% 100% 52%  29% 19%
NW RDTF n 767 386 220 161 
% 100% 50%  29% 21%
SE RDTF n 930 440 282 208 
% 100% 47%  30% 22%
S RDTF n 1155 682 304 169 
% 100% 59%  26% 15%
W RDTF n 869 543 181 145 
% 100% 62%  21% 17%
 
Frame errors accounted for 20% of the gross sample in Ireland.  There was little 
variation on these figures at health board level, with no more than a five percentage 
point gap between the proportion of frame errors in any given health board area and 
overall figure for Ireland.   
 
4.10.  Response Rates for Population Survey 
For the purpose of this study, it was decided that a target of 5,000 interviews should 
be completed.  A response rate of 65% was anticipated; hence in order to achieve 
the desired sample size, approximately 7,700 contacts needed to be made.   
 
A final response rate of 64.7% was achieved, with 4,967 responses in total.    Details 
of overall response rates for Ireland, along with rates for health boards, are shown 
below. 
 
  Health Board 
Region 
Gross 
Sample 
Valid 
Sample* Response 
% 
Response 
Total Ireland 9,643       7,677  4,967 65% 
ERHA 3,448 2,607 1,532 59% 
M RDTF 769 631 401 64% 
MW RDTF 841 703 537 76% 
NE RDTF 864 698 446 64% 
NW RDTF 767 606 386 64% 
SE RDTF 930 722 440 61% 
SH RDTF 1,155 986 682 69% 
W RDTF 869 724 543 75% 
*Valid sample = Gross sample – (frame errors + non-valid cases)
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OUTCOME Outcome Description ERHA   MHB   MWHB   NEHB   NWHB   SEHB   SHB   WHB   Total   
SUCCESSFUL 
INTERVIEW Successful Interview 1532 59% 401 64% 537 76% 446 64% 386 64% 440 61% 682 69% 543 75% 4967 65% 
Refused before 
Respondent Selection 408 16% 62 10% 51 7% 73 10% 51 8% 61 8% 86 9% 51 7% 843 11% 
Refused after 
Respondent Selection 70 3% 27 4% 26 4% 24 3% 18 3% 46 6% 22 2% 24 3% 257 3% 
Entry to block/scheme 
refused by warden etc. 1 0% 0   0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 1 0% 
REFUSED 
 
Withdrawn by Head 
Office 1 0% 2 0% 1 0% 0 0% 0 0% 1 0% 0 0% 0 0% 5 0% 
Occupied, no contact 
after 5+ calls 379 15% 50 8% 51 7% 69 10% 78 13% 86 12% 127 13% 44 6% 884 12% 
No contact after 4 or 
more calls with selected 
respondent 69 3% 27 4% 8 1% 25 4% 17 3% 24 3% 8 1% 9 1% 187 2% 
Occupier in but not 
answering door after 5+ 
calls 25 1% 9 1% 2 0% 8 1% 7 1% 22 3% 7 1% 6 1% 86 1% 
Unsure if occupied, no 
contact after 5+ calls 20 1% 12 2% 9 1% 15 2% 12 2% 15 2% 4 0% 16 2% 103 1% 
NO CONTACT 
No Contact Other 22 1% 14 2% 4 1% 5 1% 26 4% 0 0% 18 2% 1 0% 90 1% 
Property vacant 98   48   52   50   47   54   43   47   439   
Property derelict 33   2   4   3   0   2   4   3   51   
Property demolished 3   0   1   1   1   0   1   0   7   
Non-residential property 1   1   0   5   7   6   2   4   26   
Property not found 33   18   10   7   9   4   22   20   123   
PROPERTY 
INELIGIBLE 
Unable to access 
block/scheme/gated 
apartments 244   5   2   5   4   1   17   4   282   
Too ill to participate 8 0% 2 0% 1 0% 3 0% 0 0% 1 0% 6 1% 2 0% 23 0% 
Away during fieldwork 7 0% 2 0% 0 0% 3 0% 1 0% 2 0% 5 1% 1 0% 21 0% 
Household not eligible 429   64   69   95   93   141   80   67   1038   
Mother Tongue Required 6 0% 13 2% 1 0% 6 1% 4 1% 5 1% 2 0% 5 1% 42 1% 
OTHER 
Other 59 2% 10 2% 12 2% 21 3% 6 1% 19 3% 19 2% 22 3% 168 2% 
                                       
  3448  769  841  864  767  930  1155  869  9643  
  2607 100% 631 100% 703 100% 698 100% 606 100% 722 100% 986 100% 724 100% 7677 100%
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5. Data Processing & Weighting 
Note that this section has been prepared by Ipsos MORI.  Work conducted by Peter 
Muhlua is presented in Appendix P. 
5.1. Data Processing 
As described earlier in this report, the survey data were captured by the interviewers 
using the Computer Aided Personal Interviewing (CAPI) software package, Quancept.  
The data from all the interviews were collated together into one database with both 
numerical data and text from the open-ended questions.  The numerical data was   
exported into the statistical software package SPSS (Statistical Package for the 
Social Sciences).  Quancept was able to export both the raw data (numbers) and the 
labels associated with both the question itself and the answer responses (e.g. a code 
‘1’ could indicate the response ‘yes’ to a particular question, code ‘2’ could indicate a 
response ‘no’). 
 
Separately, the text from the open-ended questions was exported into comma 
delimited files (csv) for editing and coding.  Coding involved grouping similar 
responses and assigning a code to these responses.  An appropriate label to describe 
the code (e.g. 1 = Ketamine) was then applied.  Once coding was complete, this 
data was exported into SPSS as separate variables and checked against the other 
numeric data.  For some questions, a list of pre-defined codes was presented to the 
interviewer on screen with a code to record any ‘other’ response.   
 
Responses were recorded in text or numeric form as appropriate.  For numeric 
questions, “don’t know” responses were denoted by “8”.  Where a respondent gave 
no answer to a question, this was recorded as “9”.  When questions were not 
relevant to a respondent’s particular circumstances (i.e. they were routed away from 
them) the cells in the SPSS data file were filled with a “.” which is the appropriate 
‘system missing’ value for this data analysis software. 
 
5.2. Weighting 
Surveys are carried out to obtain the values of variables in the target population 
identified for the particular population, in this instance 15-64 year olds who are 
resident in Ireland.  However, it is important to note that the results achieved are 
only estimators of population values.  To take account of sampling and response 
biases, a process of weighting was carried out to ensure that results more accurately 
represent the target population.  
Typically, when the sample of a survey is in some way not fully representative 
(because there are too many respondents from group A and not enough from group 
B), the data can be weighted to more accurately reflect certain characteristics of 
population distributions.  In simple terms, in order to achieve the correct balance, 
responses are multiplied by a coefficient, which ensures that the answers of under-
represented groups (group B) are emphasised and the answers from over-
represented groups (group A) are de-emphasised. 
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For example, the answers of an under-represented group such as males aged 15-24 
living in the South Eastern RDTF are emphasised, and the answers from an over-
represented group such as females aged 55-64 living in the Mid Western RDTF area 
are de-emphasised.  In this way, the raw data were adjusted to achieve data that 
more closely represents the overall population.  
 
Weights were prepared to ensure the sample was fully representative by gender, age 
and health board in Ireland, according to latest census (Ireland 2006).  These 
weighting variables were used as they were reliable, available and they could be 
used in both Northern Ireland and Ireland.  They also facilitated All Ireland weighting 
of the data.  Variables were combined, so within each health board/RDTF persons 
were classified by age group and gender.  The calculation of each individual weight 
was based on the aim to achieve complete correspondence of the distribution of 
these characteristics between response and population.   
 
5.3. Calculation of ROI Weights 
The sample for the survey was subdivided into cells according to the respondent’s 
age group, gender and RDTF area (i.e. 15-24 year old males in the ERHA region).  
Weights for each cell were then calculated by firstly establishing the proportion of 
the overall sample in each cell (the response ratio) and the proportion of the overall 
population represented by the cell (the population ratio).  The weights for each cell 
could then be calculated by dividing the population ratio by the response ratio.  A list 
of the weights used for Ireland is found in the following table. 
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Gender Area Age Response 
Response 
Ration 
(%) {S} Population
Population 
Ratio (%) 
Weight 
{W} 
Squared 
Weights[1] 
{SWW} 
TOTAL TOTAL TOTAL 4967 100% 2907473 100%     
Male ERHA 15-24 106 2.13408% 118406 4.07247% 1.908299 0.077715 
Male ERHA 25-34 177 3.56352% 147909 5.08720% 1.427578 0.072624 
Male ERHA 35-44 143 2.87900% 110293 3.79343% 1.317621 0.049983 
Male ERHA 45-54 108 2.17435% 86820 2.98610% 1.373329 0.041009 
Male ERHA 55-64 93 1.87236% 66018 2.27063% 1.212713 0.027536 
Male M RDTF 15-24 33 0.66438% 18559 0.63832% 0.960769 0.006133 
Male M RDTF 25-34 31 0.62412% 20429 0.70264% 1.125807 0.007910 
Male M RDTF 35-44 45 0.90598% 19162 0.65906% 0.727456 0.004794 
Male M RDTF 45-54 31 0.62412% 16279 0.55990% 0.897108 0.005023 
Male M RDTF 55-64 20 0.40266% 11982 0.41211% 1.023476 0.004218 
Male MWRDTF 15-24 37 0.74492% 27950 0.96132% 1.290502 0.012406 
Male MWRDTF 25-34 59 1.18784% 29074 0.99997% 0.841843 0.008418 
Male MWRDTF 35-44 54 1.08718% 26690 0.91798% 0.844371 0.007751 
Male MWRDTF 45-54 36 0.72478% 23463 0.80699% 1.113421 0.008985 
Male MWRDTF 55-64 28 0.56372% 18649 0.64142% 1.137826 0.007298 
Male NERDTF 15-24 31 0.62412% 28356 0.97528% 1.562650 0.015240 
Male NERDTF 25-34 33 0.66438% 33502 1.15227% 1.734344 0.019984 
Male NERDTF 35-44 49 0.98651% 31336 1.07777% 1.092511 0.011775 
Male NERDTF 45-54 30 0.60399% 24434 0.84039% 1.391399 0.011693 
Male NERDTF 55-64 28 0.56372% 18520 0.63698% 1.129956 0.007198 
Male NWRDTF 15-24 29 0.58385% 17077 0.58735% 1.005986 0.005909 
Male NWRDTF 25-34 26 0.52345% 16461 0.56616% 1.081587 0.006124 
Male NWRDTF 35-44 43 0.86571% 16757 0.57634% 0.665743 0.003837 
Male NWRDTF 45-54 39 0.78518% 15170 0.52176% 0.664507 0.003467 
Male NWRDTF 55-64 33 0.66438% 13046 0.44871% 0.675370 0.003030 
Male SERDTF 15-24 23 0.46306% 33175 1.14103% 2.464118 0.028116 
Male SERDTF 25-34 35 0.70465% 35754 1.22973% 1.745159 0.021461 
Male SERDTF 35-44 40 0.80532% 34549 1.18828% 1.475550 0.017534 
Male SERDTF 45-54 31 0.62412% 29583 1.01748% 1.630268 0.016588 
Male SERDTF 55-64 40 0.80532% 23790 0.81824% 1.016045 0.008314 
Male SRDTF 15-24 46 0.92611% 45756 1.57374% 1.699295 0.026742 
Male SRDTF 25-34 55 1.10731% 51008 1.75438% 1.584361 0.027796 
Male SRDTF 35-44 76 1.53010% 46641 1.60418% 1.048414 0.016818 
Male SRDTF 45-54 60 1.20797% 39914 1.37281% 1.136456 0.015601 
Male SRDTF 55-64 65 1.30864% 31873 1.09624% 0.837699 0.009183 
Male WRDTF 15-24 41 0.82545% 31728 1.09126% 1.322018 0.014427 
Male WRDTF 25-34 35 0.70465% 32602 1.12132% 1.591310 0.017844 
Male WRDTF 35-44 41 0.82545% 29821 1.02567% 1.242558 0.012745 
Male WRDTF 45-54 52 1.04691% 26870 0.92417% 0.882760 0.008158 
Male WRDTF 55-64 45 0.90598% 21626 0.74381% 0.820998 0.006107 
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Gender Area Age Response 
Response 
Ration 
(%) {S} Population
Population 
Ratio (%) 
Weight 
{W} 
Squared 
Weights[1] 
{SWW} 
Female ERHA 15-24 138 2.77834% 119347 4.10484% 1.477444 0.060647 
Female ERHA 25-34 242 4.87216% 146033 5.02268% 1.030894 0.051778 
Female ERHA 35-44 260 5.23455% 110523 3.80134% 0.726203 0.027605 
Female ERHA 45-54 153 3.08033% 90440 3.11060% 1.009828 0.031412 
Female ERHA 55-64 112 2.25488% 68311 2.34950% 1.041960 0.024481 
Female MRDTF 15-24 35 0.70465% 17326 0.59591% 0.845685 0.005040 
Female MRDTF 25-34 65 1.30864% 19261 0.66247% 0.506225 0.003354 
Female MRDTF 35-44 58 1.16771% 18246 0.62756% 0.537425 0.003373 
Female MRDTF 45-54 49 0.98651% 15098 0.51928% 0.526383 0.002733 
Female MRDTF 55-64 34 0.68452% 11424 0.39292% 0.574008 0.002255 
Female MWRDTF 15-24 45 0.90598% 26457 0.90997% 1.004400 0.009140 
Female MWRDTF 25-34 67 1.34890% 27327 0.93989% 0.696780 0.006549 
Female MWRDTF 35-44 77 1.55023% 25484 0.87650% 0.565399 0.004956 
Female MWRDTF 45-54 66 1.32877% 22220 0.76424% 0.575147 0.004395 
Female MWRDTF 55-64 68 1.36904% 18085 0.62202% 0.454347 0.002826 
Female NERDTF 15-24 31 0.62412% 26710 0.91867% 1.471942 0.013522 
Female NERDTF 25-34 75 1.50997% 32659 1.12328% 0.743909 0.008356 
Female NERDTF 35-44 75 1.50997% 29757 1.02347% 0.677807 0.006937 
Female NERDTF 45-54 50 1.00664% 23081 0.79385% 0.788611 0.006260 
Female NERDTF 55-64 44 0.88585% 17518 0.60252% 0.680159 0.004098 
Female NWRDTF 15-24 37 0.74492% 16178 0.55643% 0.746967 0.004156 
Female NWRDTF 25-34 53 1.06704% 16472 0.56654% 0.530944 0.003008 
Female NWRDTF 35-44 42 0.84558% 16637 0.57222% 0.676712 0.003872 
Female NWRDTF 45-54 43 0.86571% 15045 0.51746% 0.597726 0.003093 
Female NWRDTF 55-64 41 0.82545% 12190 0.41926% 0.507924 0.002130 
Female SERDTF 15-24 44 0.88585% 31316 1.07709% 1.215884 0.013096 
Female SERDTF 25-34 82 1.65090% 34294 1.17951% 0.714468 0.008427 
Female SERDTF 35-44 62 1.24824% 33753 1.16091% 0.930035 0.010797 
Female SERDTF 45-54 44 0.88585% 28635 0.98488% 1.111791 0.010950 
Female SERDTF 55-64 39 0.78518% 22944 0.78914% 1.005039 0.007931 
Female SRDTF 15-24 46 0.92611% 44365 1.52590% 1.647635 0.025141 
Female SRDTF 25-34 92 1.85222% 48586 1.67107% 0.902198 0.015076 
Female SRDTF 35-44 89 1.79183% 44896 1.54416% 0.861779 0.013307 
Female SRDTF 45-54 72 1.44957% 38683 1.33047% 0.917838 0.012212 
Female SRDTF 55-64 81 1.63076% 31027 1.06715% 0.654385 0.006983 
Female WRDTF 15-24 67 1.34890% 30026 1.03272% 0.765599 0.007906 
Female WRDTF 25-34 73 1.46970% 31068 1.06856% 0.727058 0.007769 
Female WRDTF 35-44 68 1.36904% 28889 0.99361% 0.725775 0.007211 
Female WRDTF 45-54 57 1.14757% 26078 0.89693% 0.781588 0.007010 
Female WRDTF 55-64 64 1.28850% 20052 0.68967% 0.535249 0.003691 
 
Design Effect 1.130979
Efffective sample size 4392
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5.4. Calculation of All Ireland Weights 
The Northern Ireland survey of Drug Prevalence had been carried out during the 
same fieldwork period by the Central Survey Unit (CSU) of the Northern Ireland 
Statistics and Research Agency.  From the beginning, the goal of both surveys 
(Northern Ireland and Republic of Ireland survey) was not only to report on the 
drugs prevalence in their own respective jurisdictions, but to be merged together to 
provide figures for drug prevalence for the entire island of Ireland.   
 
During the project set-up and at the end of the survey fieldwork period, there were 
joint meetings with CSU, Ipsos MORI and RAG to discuss technical details of the 
databases to ensure that they could be merged easily.  Ipsos MORI was tasked with 
the job of joining the two datasets and then calculating the weights to be applied to 
provide the All Ireland prevalence figures.   
 
The All Ireland Weights were calculated as follows: 
 
The variable ‘Wff’ was created after weighting the ROI and NI data to their 
respective population sizes (in thousands). 
 
NI weight = NI adult population (in thousands)  1133.069 
------------------------------------------ = ----------- = 0.565969 
  Sample size     2002 
 
 
ROI weight =  ROI adult population (in thousands)  2907.473 
  ------------------------------------------- = ----------- = 0.585358 
  Sample size     4967 
 
 
When ‘Wff’ is applied to the data file and a frequency of the variable “sample” is run, 
it gives us 
 
 SURVEY  Northern Ireland or Republic of Ireland data 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
1  Northern Ireland 1133 28.0 28.0 28.0 
2  Republic of Ireland 2907 72.0 72.0 100.0 
Valid 
Total 4041 100.0 100.0   
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To weight the data back up to the sample sizes we would compute a new weight 
(WT_ALL) by multiplying the Wff weight by the factor:    6969 / 4041 = 1.72457 
 
When this new weight (WT_ALL) is applied to the data file, the frequency for the 
variable “sample” is as follows. 
 
 SURVEY  Northern Ireland or Republic of Ireland data 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
1  Northern Ireland 1954 28.0 28.0 28.0 
2  Republic of Ireland 5014 72.0 72.0 100.0 
Valid 
Total* 6968 100.0 100.0   
 
* Due to rounding errors, the final frequency total reads 6968. 
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6. Statistical Reliability 
The respondents to the survey are only a sample of the total “population”, so it is 
not possible to be certain that the figures obtained are exactly those that would have 
been obtained if everybody had been interviewed (the “true” values).  However, the 
variation between the sample results and the “true” values can be predicted from 
knowledge of the size of the samples on which the results are based and on the 
number of times that a particular answer is given.  The confidence with which this 
prediction can be made is usually chosen to be 95% - that is, the chances are 95 in 
100 that the “true” value will fall within a specified range. 
In addition, the data for this survey are weighted (as outlined above).  However, it 
should be noted that a sample which is weighted is less accurate (i.e. has a larger 
standard error) than an unweighted sample of the same size.  The effect of this 
weighting, therefore, needs to be taken into account when considering statistical 
reliability.  The formula for calculating the size of the equivalent unweighted sample 
is pw², where p is the proportion of the sample (unweighted) in the various sectors 
with weighting factors applied, and w is the weight applied to those sectors.  The 
weighting applied to the example data set shown above gives a design factor of 
1.130979 in Ireland, thereby reducing the actual sample size from 4,967 to an 
effective sample size of 4,392 in Ireland.  The same rule applies to sub-groups of the 
total sample, as the table below demonstrates. 
 
Health Board Region Design Effect 
Ireland 1.130979 
ERHA 1.070257 
MRDTF 1.087101 
MWRDTF 1.103689 
NERDTF 1.128179 
NWRDTF 1.055732 
SERDTF 1.132022 
SRDTF 1.096693 
WRDTF 1.104443 
 
The table below illustrates the predicted ranges for different sample sizes and 
percentage results at the “95% confidence interval”, assuming no design effect. 
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 Sampling tolerances applicable to 
results at or near these percentages 
(based on 95% confidence level) 
Health Board 
Region 
Sample 
Size 10/90% 30/70% 50% 
Republic of Ireland 
  +% +% +% 
Total 4,967 0.83 1.27 1.39 
ERHA 1,532 1.50 2.30 2.50 
MRDTF 401 2.93 4.48 4.89 
MWRDTF 537 2.54 3.88 4.23 
NERDTF 446 2.80 4.26 4.64 
NWRDTF 386 3.01 4.58 4.99 
SERDTF 440 2.80 4.28 4.67 
SRDTF 682 2.25 3.44 3.75 
WRDTF 543 2.52 3.86 4.21 
 
For example, with a total sample size of 4,967 completed interviews, where 50% 
give a particular answer, the chances are 19 in 20 that the “true” value (which would 
have been obtained if the whole population had been interviewed) will fall within the 
range of + 1.39 percentage points from the sample result; in fact the actual result is 
proportionately more likely to be closer to the centre (50%), than the extremes of 
the range (51.39 % or 48.61 %). 
When the results are compared between separate sub-groups within a sample, 
different results may be obtained.  The difference may be “real,” or it may occur by 
chance (because not everyone in the population has been interviewed).  To test if 
the difference is a real one - i.e. if it is “statistically significant” - it is again necessary 
to know the total population, the size of the samples, the percentage giving a certain 
answer, and the degree of confidence chosen.   Assuming a “95% confidence 
interval”, the differences between the two sub-sample results must be greater than 
the values given in the table below: 
 
 Sampling tolerances applicable to results at or near 
these percentages (based on 95% confidence level) 
10/90% 20/80% 30/70% 40/60% 50/50% Sample size 
+/- +/- +/- +/- +/- 
4,967 (Ireland) 0.83 1.11 1.27 1.36 1.39 
6,969 (Island of Ireland) 0.70 0.94 1.08 1.15 1.17 
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A.  OJEC Notice re Expression of Interest 
Expressions of Interest sought for 
 Tender Population Drug Prevalence  
Survey 
 
Background 
The National Advisory Committee on Drugs (NACD) was established in July 2000 to advise 
the Government in relation to the prevalence, prevention, treatment/ rehabilitation and 
consequences of problem drug use in Ireland, based on the analysis of research findings and 
information. The Committee oversees the delivery of a work programme on the extent, nature, 
causes and effects of drug use in Ireland. The Committee comprises representatives 
nominated from relevant agencies and sectors, both statutory and non-statutory. The 
Committee operates under the aegis of the Department of Community, Rural and Gaeltacht 
Affairs and reports to the Minister of State responsible for the National Drugs Strategy. 
Further information can be obtained from the NACD website www.nacd.ie. 
 
The Drug and Alcohol Information and Research Unit (DAIRU) was established in May 2001 
to develop and manage a programme of information and research work in support of the joint 
implementation of the Northern Ireland Executive’s Drug and Alcohol Strategies, building on 
previous work to support the Drug Strategy alone.  DAIRU is located within the Department of 
Health, Social Services and Public Safety. Further information can be obtained from the 
DHSSPS website www.dhsspsni.gov.uk/iau. 
 
Commission 
The NACD and DAIRU commissioned a Drug Prevalence Survey to establish population 
prevalence of drug use in Ireland and Northern Ireland in 2002/2003.   (Further information on 
this survey can be obtained from www.nacd.ie. The NACD and DAIRU now wish to 
commission a repeat of the 2002/2003 Drug Prevalence Survey. The new survey may include 
Northern Ireland, as well as Ireland (confirmation of all Ireland approach will be available at 
the request for tender stage.) It is intended that the Drug Prevalence Study fieldwork will be 
carried out from September 2006 to April 2007 and preliminary analysis in the months 
following with a first report of national prevalence figures and trends expected by July 2007.  
The contractor will be required to follow the relevant guidelines published by the European 
Monitoring Centre for Drugs and Drug Addiction (www.emcdda.org) and to achieve a 
minimum population sample of 5,000 in Ireland and possibly also 3,500 in Northern Ireland (to 
be confirmed). Sampling frame will be using the An Post Geo-directory in Ireland and 
Valuation and Lands Agency List in Northern Ireland.  The survey questionnaire will be 
provided to the successful contractor(s). 
 
Contracts awarded will give complete ownership of all data (including electronic and manual 
files) to the NACD and provide for the return of the data by electronic form in SPSS “.sav” 
format to the NACD.  Contractors will be expected to comply with the DATA Protection Act 
1988 (as amended) and with the European Communities (Data Protection) Regulations 2001.  
The contract will be governed by the laws of Ireland. Under the terms of appointment, 
subcontracting of the services will not be permitted. 
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Expressions of Interest 
In accordance with the EU Directive 2004/18/EC, Article 28 and 29 expressions of interest are 
invited for the undertaking of the Drug Prevalence Study fieldwork (September 2006 to April 
2007) and analysis.  Persons wishing to tender for this contract should submit an expression 
of interest to the address below.  
 
Potential contractors should demonstrate in their expression of interest that they have: 
 
• Capacity to carry out Computer-assisted Personal Interviewing (CAPI) only in Ireland / on 
an all-island basis, as appropriate. (For the purpose of demonstrating all island capacity, 
North/South collaborative arrangements are acceptable) 
• Capacity to prepare CAPI interview programme immediately on award of contract 
• Ability to prepare, clean and validate very large SPSS data files 
• Sufficient intellectual capacity with adequate and suitably qualified staff to successfully 
undertake the project 
• Have a track record in this field (large scale social CAPI based research projects).   
• Have high level of quality control and quality assurance to research standards, including 
stringent fieldwork management procedures (please enclose a description), and 
• Have adequate financial standing.  
 
Based on short-listing against the above criteria, the NACD intend to invite five to seven 
contractors to submit a tender at the next stage.  
 
Expressions of interest should be sent to the NACD offices together with  2 copies of recent 
financial accounts, example of previous relevant work (2 copies), track record, and evidence 
of capacity (human and technical) to undertake the work, no later than 15.00 Wednesday 1st  
March 2006. Please mark your envelope Ten/popsurvey0607. 
 
Invitations to tender will be dispatched to selected candidates on Tuesday 21st March 2006.   
 
Note that applicants must provide information regarding the experience, qualifications, 
capacity etc of all those they propose to be involved in the carrying out of the services.  
 
The Secretary 
3rd Floor,  
Shelbourne House 
Shelbourne Road 
Ballsbridge,  
Dublin 4 
Ireland 
 
Tel: 00 353 1 667 0760/765;  
Fax 00 353 1 667 0828; 
 
Email: info@nacd.ie; Web: www.nacd.ie  
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B.  Tender Brief 
Tender NACD Drug Prevalence Survey 2006/2007 
 
Background 
The National Advisory Committee on Drugs (NACD) was established in July 2000 to advise 
the Government in relation to the prevalence, prevention, treatment/ rehabilitation and 
consequences of problem drug use in Ireland, based on the analysis of research findings and 
information. The Committee oversees the delivery of a work programme on the extent, nature, 
causes and effects of drug use in Ireland. The Committee comprises representatives 
nominated from relevant agencies and sectors, both statutory and non-statutory. The 
Committee operates under the aegis of the Department of Community, Rural and Gaeltacht 
Affairs and reports to the Minister of State responsible for the National Drugs Strategy. 
Further information can be obtained from the NACD website www.nacd.ie. 
 
In Ireland, the measurement of the extent and pattern of drug use in the general population is 
one of the priorities set out by the NACD in its current work programme (see business plan on 
http://www.nacd.ie/publications/businessplan.html) and agreed by Government.   As the 
extent and pattern of drug use in the general population is one of the key five indicators 
produced by the EMCDDA5 (www.emcdda.org) and adopted by EU Member States, it is 
imperative that reliable and comparable data is obtained in this regard.   
 
Commission 
The NACD now wishes to commission a repeat of the 2002/2003 Drug Prevalence Survey for 
Ireland (further information on this survey can be obtained from www.nacd.ie).    
The Brief 
It is essential that the Drug Prevalence Study fieldwork be carried out from September 2006 
to April 2007 and preliminary analysis in the months following with a first report of national 
prevalence figures and trends expected by July 2007 and a second report on trends by health 
board area in November 2007.   This will enable the NACD to make comparisons with the 
previous survey, identify trends in drug use nationally, across regions and the EU thus 
meeting commitments to provide the Government and the EMCDDA with the relevant 
population prevalence information.  The proposed survey will be carried out using a pre-
prepared questionnaire (draft attached on a confidential basis) and computer assisted, face-
to-face interviews (preferred method under EMCDDA guidelines) among those aged 15–64 
years.  Information on lifetime use, last year and last month use will be just some of the 
issues explored.   
The survey is based on the guidelines produced by the EMCDDA which state as the main 
aims: 
(1) To report prevalence and continuation rates of the most common illicit drugs in 
the general population by gender and age groups; 
 
(2) To allow cross country assessment of relationships between general patterns of 
use of illicit and licit drugs; 
 
(3) To allow the assessment of relationships between particular population attributes 
and the use of illicit drugs. 
 
                                                          
5 EMCDDA the European Monitoring Centre for Drugs and Drug Addiction 
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Potential bidders should refer to the EMCDDA guidelines (www.emcdda.org) on conducting 
population surveys in relation to drug use and to the Technical Report  
on the 2002/2003 Drug Prevalence Survey published on the web 
(http://www.nacd.ie/publications/prevalence_allireland.html) for further information on how the 
survey should be conducted. 
 
The contractor will be required to achieve a population sample of 5,000 in Ireland. The 
preferred sampling frame will be using the An Post Geo-directory in Ireland.   
 
Copyright will rest with the NACD. The Contract awarded will give complete ownership of all 
data (including electronic and manual files) to the NACD and provide for the return of the data 
by electronic form in SPSS “.sav” format to the NACD.  Contractors will be expected to 
comply with the Data Protection Act 1988 (as amended) and with the European Communities 
(Data Protection) Regulations 2001.  The contract will be governed by the laws of Ireland. 
Under the terms of appointment, subcontracting of the services will not be permitted. 
 
Selection Criteria 
Potential contractors should demonstrate the following in their tender submission: 
 
1. Capacity -  
• Capacity to carry out Computer-assisted Personal Interviewing (CAPI) in Ireland 
• Capacity to prepare CAPI interview programme immediately on award of contract 
• Ability to prepare, clean and validate very large SPSS data files and  demonstrate 
familiarity with SPSS software 
• Sufficient intellectual capacity with adequate and suitably qualified staff to 
successfully undertake the project 
• Have a track record in this field (large scale social CAPI based research projects) 
• Have high level of quality control and quality assurance to research standards, 
including stringent fieldwork management procedures (please enclose a 
description). 
 
2. Survey mode - 
The population survey will be conducted by face-to-face interview and participants will be 
interviewed on use of all drug types to include alcohol, tobacco, prescribed medicines and 
illicit drugs (see Bulletin 2 from the 2003/2003 Drug Prevalence Survey to see full range of 
drugs reported on in tables one and six) . 
 
3. Sampling frame - 
The sample population to be surveyed will be the 15-64 age group and resident in 
households.  Information on lifetime use, last year use and last month use is required.  Non-
contacts and refusals must be dealt with as per EMCDDA guidelines (see technical report 
also).  Tenderers are expected to describe the sampling design appropriate to this survey and 
what mechanisms would be used to include interviews with difficult to reach age groups in the 
tender submission.  The sample profile should reflect the population profile. 
 
4. Fieldwork Management - 
Tenderers are expected to describe how the fieldwork will be managed and supervised.  Any 
variations in how fieldwork is managed, interviewers are recruited and trained should be 
stated in the tender and how this might impact on the study.  In particular, the controls to be 
put in place for data protection; how files will be transferred from CAPI instruments to a 
central database and what procedures are in place to protect the anonymity of the study 
participants so their responses are not known to anyone outside of the study.   
 
5. Data Protection -  
Tenderers must comply with Data Protection legislation.  The successful bidder will be 
expected to demonstrate steps they will take to protect and store the data from corruption, 
infiltration and technical damage. 
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6. Data Analysis- 
Once the data has been collected a comprehensive analysis must be carried out.  The 
substantive report will include an analysis by drug, by age and by gender in the first instance, 
then by age, gender and by region (former health board areas and new HSE regions).  We 
expect comparisons to be made between groups together with a commentary on the results.  
The main findings should be summarised.  Please refer to published Bulletins for further 
information.  Weighting of data by age, gender, former health board areas and the new Health 
Service Executive regions (HSE) in Ireland is required and these weights will be required to 
be detailed in the Technical Report.  The contractor may be required to merge data from a 
comparable dataset from Northern Ireland to provide all island and North South comparable 
figures.  Any issues which could impact on this process of merging data should be identified 
in the tender. 
 
7. Cost 
The tenderer must set out a details and justification for the costs of implementing this study in 
Ireland.    
 
The lowest, or any tender will not necessarily be accepted.  
 
Research Advisory Group - 
A Research Advisory Group comprising representatives from the NACD & DAIRU (Drug and 
Alcohol Information and Research Unit) will be appointed to oversee the project and the 
successful bidder will work closely with the Research Advisory Group.  The Research 
Advisory Group will expect to have some involvement when fieldworkers are briefed on their 
tasks and targets and during the pilot-testing phase.  Progress reports will have to be 
provided to the Research Advisory Group at various stages of the project during the early 
implementation phase pre and post pilot, post interviewer briefings and every four weeks of 
the fieldwork phase confirming that the project is on track.  The successful bidder will be 
expected to flag any potential difficulties or problems early to the Research Advisory Group so 
that a quick resolution can be achieved. 
 
Technical Report-  
The successful bidder will provide a detailed technical report to the Research Advisory Group 
on completion of the fieldwork and before the analysis begins.   Following completion of 
analysis, technical details must be added to the report such as the number and types of 
checks controls and cross validation of the data in cleaning and preparing it for analysis.  
Syntax for check programmes should be provided to the Research Advisory Group.  These 
controls must be applied to the data when it is in SPSS and not in some other software 
database to eliminate the risk of missing errors.  The Research Advisory Group will also carry 
out cross checks on the data when it is provided in SPSS. A separate complete financial 
report for the project on completion will also be required before final payment is made to the 
contractor.   
 
A copy of the NACD contract is attached for your information. 
 
Five copies of the tender together with a signed Freedom of Information Declaration (form 
attached) and an up-to-date Tax Clearance Certificate should be sent to the NACD offices 
together with two copies of an example of previous relevant work and include a short CV of 
those leading and managing this study no later than 15.00 Wednesday 7th June  2006.  
Short listing may take place.  Interviews will be held on Monday 19th June 2006. 
 
Tenders will not be accepted by email. 
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Please mark your envelope Ten-popsurvey06/07.   
 
The Secretary 
3rd Floor,  
Shelbourne House 
Shelbourne Road 
Ballsbridge,  
Dublin 4 
Ireland 
 
Tel: 00 353 1 667 0760/765;  
Fax 00 353 1 667 0828; 
Email: info@nacd.ie; Web: www.nacd.ie  
 
 
44
 
NACD Drug Prevalence Study 2006-2007 
Ipsos MORI – Technical Report – DRAFT 4 – 01/04/08 
 
C.  About Ipsos MORI 
The all-Ireland operation of Ipsos MORI was founded in 1987.  It provides a full 
range of qualitative and quantitative research services, the latter using face-to-face, 
telephone, self-completion and web-based methodologies.   
 
Ipsos MORI embraces both traditional and technologically advanced research 
methods, which means that it can design the research programme that best meets a 
client's research objectives.  
 
As part of the Ipsos MORI group, the company has access to a huge amount of 
specialist expertise and technical support, which ensures it can provide the best 
service possible to our clients. 
 
With offices in Dublin and Belfast, Ipsos MORI adds value to research with 
interpretation, recommendations and advice. Ipsos MORI has an extensive and 
varied client base, incorporating public sector organisations and blue-chip private 
sector companies.   
 
Ipsos MORI offers the highest quality research services throughout Ireland, and the 
only market research agency accredited with ISO 9001 and providing fieldwork to 
IQCS standards throughout Ireland in both telephone and face-to-face interviewing. 
 
In addition to the regular quality surveillance visits carried out by external bodies in 
connection with IQCS, and ISO 9001, Ipsos MORI has its own auditing and quality 
team, including our own Customer Service Monitor which provides feedback from 
our clients on the standard and quality of service we provide.  
Ipsos MORI directors and executive/field staff are members of the Market Research 
Society, and are therefore subject to the requirements of the Market Research 
Society (MRS) Code of Conduct.  This assures all respondents that the information 
gathered during the course of an interview is confidential and that their opinions and 
views would remain anonymous. 
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D.  Quality Standards in Fieldwork 
Quality is at the heart of the Ipsos MORI business model and we believe it is critical 
to the accurate and successful completion of all our research projects. 
 
As the Drug Prevalence Study was dealt with completely in-house by Ipsos MORI 
staff, it ensured quality and accuracy at all stages of the research process – from 
CAPI set-up through the interviewing process to the reporting stage.  As the survey 
results come under external scrutiny and feed into policy decisions, it was essential 
that quality assurances were in place to counteract any questioning of the data or 
the research process and to provide the necessary reassurance in terms of its 
validity.   
 
Detailed below is the Ipsos MORI commitment to quality control and the practical 
implications it has on the work practices in place within the company. 
Commitment to Quality and Quality Control 
 
Ipsos MORI is fully committed to providing services of the highest quality to our 
clients. Outstanding and improving quality has always been one of our guiding 
principles.  All our research operations are governed by the Market Research 
Society’s Code of Conduct.   
 
In addition, all fieldwork is been carried out to IQCS (Interviewer Quality 
Control Scheme) standards since the companies inception in 1987.  The company 
has been accredited to ISO 9001 since 1995, making Ipsos MORI the only 
market research agency working across the island of Ireland to work to these 
standards. 
 
In 1996, Ipsos MORI became one of only two full service agencies to achieve 
accreditation under MRQSA (Market Research Quality Standards 
Association).  This sets out standards for each stage of a market research project 
and is designed to enable accredited companies to provide a superior service to their 
clients.  It is the only assurance that clients can have that key aspects of the project 
are being undertaken to externally imposed and audited standards. 
 
Ipsos MORI regards these various standards as minimum requirements and not as 
goals in their own right.  
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ISO 20252:20252: 2006 Quality Standard 
 
Ipsos MORI is accredited to the ISO 20252: 2006 Quality Standard – the first 
company worldwide to be accredited to the ISO’s new Market Research specific 
quality standard.  Ipsos MORI has previously held the ISO 9001:2000 and ISO 
9001:1994 standards and BS57911 (Market Research Quality Standards Association) 
standard which our new standard supersedes. 
 
Mandatory checks are made of questionnaires, reports and other research materials 
to ensure the high quality of all documents.  Crucial aspects of project specifications 
are agreed in writing to alleviate confusion and project management forms enable 
increased control.  
 
Regular external audits of the system by Management Quality Assurance (MQA) are 
conducted and improvements, where suitable, are made.  As of December 2003 we 
have been accredited with ISO 9001:2000 and our most recent audit was 
successfully completed in January 2006.  
 
Fieldforce and Interviewer Quality Control Scheme (IQCS ) 
 
All interviewing on this project was carried out by members of the Ipsos MORI 
Interviewer Panel who have been trained and work to the standards of the 
Interviewer Quality Control Scheme (IQCS). 
 
IQCS is the only industry scheme which independently audits the fieldwork standards 
of its member companies and it was devised to professionalise the market research 
supply industry.  It is fully endorsed by the Market Research Society. 
 
From its inception in 1987, Ipsos MORI recognised that any research company is 
only as good as its people in the field and therefore decided to work to IQCS 
standards from the beginning and seek membership immediately.  The company 
goes to great lengths to select the right people to become interviewers, give them 
the right training and continually monitor and assess the quality of their work. 
 
Ipsos MORI became members of IQCS after our first inspection and has followed the 
same policy ever since. Its membership of IQCS is renewed annually, following 
independent audits, and Ipsos MORI is currently the only company operating 
throughout Ireland who are members of IQCS.  
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Fieldforce Training and Appraisals 
 
All applicants to the Ipsos MORI Fieldforce have a personal interview with a 
supervisor.  They carry out some trial interviewing designed to assess the 
standard of those who claim interviewing experience and to provide practical insight 
into the difficulties of the job for those who have never interviewed before.  Those 
who wish to continue and are deemed suitable, receive an initial three days' 
training, two in-house and one in the field.  The ratio of instructor to recruit is 
high; a typical training session is one instructor to no more than six trainees in-
house, and one to three in the field. 
 
Only after these three full days of training is an Interviewer Identity Card issued and 
a trainee allowed to work on a 'live' job.  The comprehensive training session covers 
an explanation of: 
 
1. Different types of market research; 
2. Sampling methods; 
3. Respondents/interviewer interface; 
4. Social classification; 
5. Administration and completion of questionnaire; 
6. Code of conduct, respondents' rights etc.; 
7. Assurance of confidentiality and respondent anonymity; 
8. Quality control. 
 
All Ipsos MORI Interviewers and Recruiters carry Identity Cards issued by the Market 
Research Society (MRS), which bear the photograph and signature of the 
interviewer, and are issued only after the signing of a declaration which states that 
the interviewer has read and agrees to abide by the MRS Code of Conduct.  This 
Identity Card is shown to each respondent before an interview takes place, to 
reassure them that the study is genuine.   
 
Furthermore, respondents are given a leaflet at the end of the interview which 
stresses the confidentiality of the process, and provides the telephone number of 
Ipsos MORI’s Field department to call if they have any further queries. 
 
A new interviewer is accompanied by his/her regional supervisor on each new type 
of job worked on.  Regular assessment and further training on an ongoing basis 
means an Ipsos MORI interviewer gains experience in quota sampling, random 
selection, and other forms of market research fieldwork.  This enables us to offer a 
comprehensive service to clients. 
   
The responsibility for all recruitment and training remains with our Field Director who 
has many years fieldwork experience and this ensures absolute uniformity in the 
application of our fieldwork standards. 
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Fieldwork Quality Control 
 
The success of any survey is entirely dependent on the quality of the data collected 
by the interviewers. Ipsos MORI takes pride in our quality control procedures and 
believe that they are second to none.  We firmly believe that this service is unrivalled 
anywhere in terms of quality and commitment. 
 
Fieldwork is carried out by a panel of around 300 fully trained interviewers across 
Ireland.  Ipsos MORI maintains eight regional supervisors who have been personally 
trained by, and answer directly to, our Field Director in all aspects of quality control.  
Ipsos MORI believes that regular accompaniment of interviewers, both 
highly experienced and newly recruited is vital to the continuation of its 
high standard of interviewing, so each interviewer is accompanied at least once 
in a six-month period by his/her regional supervisor.   
 
An accompaniment lasts a minimum of three hours and the interviewer is assessed 
on the initial approach made, administration of the questionnaire, accuracy of 
recording the responses, attitude to the work etc.  Feedback and guidance are given 
as appropriate and documented.   
 
Other appraisals take the form of a discussion between interviewer and field staff 
where information gathered from validation checks, editing and coding together with 
feedback from accompaniments and field/staff executives is presented, and 
supporting documentation is retained.  The contact with the Field Department 
through the local supervisor gives the interviewer a realisation that his/her work is 
valued which, in turn, creates a more professional approach to the job of 
interviewing.  Ipsos MORI is the only company in Ireland, which appraises 
interviewers in an ongoing and carefully controlled fashion. 
 
A minimum of 10% of completed interviews are backchecked on all 
quantitative surveys carried out by Ipsos MORI using a combination of 
telephone recall or postal check card.  This is applied to ensure that the interviewers 
have conducted the interviews professionally and in line with survey specifications.  
 
In general, respondents are asked to comment on, among other things, the duration 
of the interview, their recollection of the being asked specific questions, being shown 
interviewer identification and their reaction to both the interview and the interviewer.   
 
On surveys covering considerable time periods, such as this one, backchecking is a 
continuous process throughout the fieldwork period, whereby each individual 
backcheck is carried out within two weeks of the interview.  Because of this Ipsos 
MORI identifies and corrects particular problems.  All interviewers on our panel have 
their work backchecked and are advised of the results. 
49
 
NACD Drug Prevalence Study 2006-2007 
Ipsos MORI – Technical Report – DRAFT 4 – 01/04/08 
 
 
For the Drug Prevalence survey, there was a need to reassure the respondent that 
responses would remain confidential, therefore, respondent contact details, which 
are necessary for this backchecking process, were recorded separately.  Additionally, 
we were less specific with our backchecking questions by just confirming completion 
of the survey and whether questions about certain topics were asked.  
 
These procedures enabled us to provide detailed information on problems 
encountered during fieldwork, and our methods for correcting these problems, thus 
ensuring that potential survey bias was adequately evaluated. It also ensured that 
any difficulties were identified in good time and swiftly resolved. 
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E.  Questionnaire 
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F.  Showcards 
 
 
 
NACD 
 
POPULATION STUDY 
 
 
 
SHOWCARDS 
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50878 SHOW CARD ‘16’ 
 
       
1 Sedatives 
2 Sleeping pills 
3 Rohypnol ® 
4 Roofies 
5 Row rows 
6 Dalmane ®, Flurazepam 
7 Mogadon ®, (Moggies), Nitrazepam 
8 Phenobarbitone 
9 Tranquillisers 
10 Tranks 
11 Downers 
12 Benzos 
13 Roches 
14 Librium ® 
15 Valium ®, (Diazepam) 
16 Normison ®, (Duck eggs), Temazepam 
17 Ativan ® 
18 Halcion ®, Triazolam 
19 Xanax ® 
20  Stilnoct ®, Zolpidem 
21 Zimovane ®, Zopiclone 
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50878 SHOW CARD ‘23’ 
 
1 Oral (tablets or syrup) 
2 Injection with a needle 
3 Other (please tell me which) 
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50878 SHOW CARD ‘24’ 
 
1 I got them on a prescription 
2 I got them from someone I know 
3 I bought them without a prescription in a chemist 
4 I bought them over the internet 
5 Other (please tell me how) 
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50878 SHOW CARD ‘25’ 
 
1.  
Anti depressants 
2.  
Prozac ® 
3.  
Seroxat ® 
4.  
Prothiaden ® 
5.  
Effexor ® 
6.  
Lustral ® 
7.  
Molipaxin ® 
8.  
Zispin ® 
9.  
Olanzapine (Zyprexa ®)  
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50878 SHOW CARD ‘32’ 
 
1 Oral (tablets or syrup) 
2 Injection with a needle 
3 Other (please tell me which) 
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50878 SHOW CARD ‘33’ 
 
1 I got them on a prescription 
2 I got them from someone I know 
3 I bought them without a prescription in a chemist 
4 I bought them over the internet 
5 Other (please tell me how) 
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50878 SHOW CARD ‘34’ 
 
1 Cannabis 
2 Marijuana 
3 Dope 
4 Grass 
5 Pot 
6 Hash(ish) 
7 Ganja 
8 Shit 
9 Blow 
10 Weed 
11 Draw 
12 Puff 
13 Whacky Backy 
14 Skunk 
15 Resin 
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50878 SHOW CARD ‘38’ 
 
1 None 
2 Once or twice 
3 3 to 5 times 
4 6 to 9 times 
5 10 to 19 times 
6 20 times or more 
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50878 SHOW CARD ‘42’ 
 
1 Grass 
2 Weed 
3 Skunk 
4 Hash Oil 
5 Herb 
6 Hash 
7 Resin 
8 Other (please tell me which) 
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50878 SHOW CARD ‘44’ 
 
1 Joint 
2 Pipe 
3 Bong 
4 Eat 
5 Other (please tell me which) 
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50878 SHOW CARD ‘45’ 
 
1 Ecstasy 
2 Pills 
3 E 
4 XTC 
5 Doves 
6 Mitsubishi 
7 Shamrocks 
8 MDMA 
9 Yokes 
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50878 SHOW CARD ‘49’ 
 
1 None 
2 Once or twice 
3 3 to 5 times 
4 6 to 9 times 
5 10 to 19 times 
6 20 times or more 
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50878 SHOW CARD ‘53’ 
 
1 Amphetamines 
2 Speed 
3 Billy 
4 Whizz 
5 Base 
6 Sulphate 
7 Ice 
8 Crystal 
9 Bennies 
10 Uppers 
11 Dexies 
12 Purple hearts 
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50878 SHOW CARD ‘57’ 
 
1 None 
2 Once or twice 
3 3 to 5 times 
4 6 to 9 times 
5 10 to 19 times 
6 20 times or more 
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50878 SHOW CARD ‘62’ 
 
1 Crack 
2 Rock 
3 Stones 
4 Freebase 
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50878 SHOW CARD ‘66’ 
 
1 None 
2 Once or twice 
3 3 to 5 times 
4 6 to 9 times 
5 10 to 19 times 
6 20 times or more 
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50878 SHOW CARD ‘70’ 
 
1 Cocaine 
2 Charlie 
3 Coke 
4 Snow 
5 Nose candy 
6 Blow 
 
98
 
NACD Drug Prevalence Study 2006-2007 
Ipsos MORI – Technical Report – DRAFT 4 – 01/04/08 
 
50878 SHOW CARD ‘74’ 
 
1 None 
2 Once or twice 
3 3 to 5 times 
4 6 to 9 times 
5 10 to 19 times 
6 20 times or more 
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50878 SHOW CARD ‘78’ 
 
1 Doing a line/Snort 
2 Injection with a needle 
3 Smoke 
4 Other (please tell me which) 
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50878 SHOW CARD ‘79’ 
 
1 Heroin 
2 Smack 
3 Gear 
4 H 
5 Junk 
6 Skag 
7 Brown 
8 Horse 
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50878 SHOW CARD ‘83’ 
 
1 None 
2 Once or twice 
3 3 to 5 times 
4 6 to 9 times 
5 10 to 19 times 
6 20 times or more 
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50878 SHOW CARD ‘87’ 
 
1 Smoke 
2 Injection with a needle 
3 “Chasing the dragon” 
4 Other (please tell me which) 
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50878 SHOW CARD ‘88’ 
 
1 LSD 
2 Acid 
3 Trips 
4 Tabs 
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50878 SHOW CARD ‘92’ 
 
1 None 
2 Once or twice 
3 3 to 5 times 
4 6 to 9 times 
5 10 to 19 times 
6 20 times or more 
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50878 SHOW CARD ‘96’ 
 
1 Solvents 
2 Glues 
3 Dry-cleaning fluids 
4 Aerosols 
5 Paint stripper 
6 Petrol 
7 Nail varnish remover 
8 Correction fluids e.g. Tipp-Ex ® 
9 Gas lighter fuel 
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50878 SHOW CARD ‘100’ 
 
1 None 
2 Once or twice 
3 3 to 5 times 
4 6 to 9 times 
5 10 to 19 times 
6 20 times or more 
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50878 SHOW CARD ‘104’ 
 
1 Poppers 
2 Amyl Nitrite 
3 Rush 
4 Liquid gold 
5 Locker room 
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50878 SHOW CARD ‘108’ 
 
1 None 
2 Once or twice 
3 3 to 5 times 
4 6 to 9 times 
5 10 to 19 times 
6 20 times or more 
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50878 SHOW CARD ‘112’ 
 
1 Magic Mushrooms  
2 Psilocybin 
3 Mushies 
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50878 SHOW CARD ‘116’ 
 
1 None 
2 Once or twice 
3 3 to 5 times 
4 6 to 9 times 
5 10 to 19 times 
6 20 times or more 
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50878 SHOW CARD ‘120’ 
 
1 I picked them myself 
2 I got them from someone I know 
3 I bought them off the internet 
4 I bought them in a shop/market 
5 Other (please tell me how) 
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50878 SHOW CARD ‘121’ 
 
1 Methadone 
2 Physeptone ® 
3 Phy 
4 Brown (phy) 
5 Green (phy) 
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50878 SHOW CARD ‘128’ 
 
1 I got it on a prescription 
2 I got it from someone I know 
3 I bought it without a prescription in a chemist 
4 I bought it over the internet 
5 Other (please tell me how) 
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50878 SHOW CARD ‘138’ 
 
1 Opiates (excluding heroin & methadone) 
2 Temgesic ® 
3 Codeine 
4 Kapake ® 
5 Morphine 
6 Opium 
7 DF118 ® (DF’s) 
8 Diffs 
9 Dikes 
10 Peach 
11 
Fentanyl 
(Durogesic ® & Sublimaze ® & Actiq ®) 
12 
Oxycodone 
(Oxycontin ® & Oxynorm ®) 
13 MST ® (MST’s) 
14  Buprenorphine (Subutex ®) 
15 Diconal ® 
16 Pethidine 
17 Napps 
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50878 SHOW CARD ‘145’ 
 
1 I got them on a prescription 
2 I got them from someone I know 
3 I bought them without a prescription in a chemist 
4 I bought them over the internet 
5 Other (please tell me how) 
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50878 SHOW CARD ‘146’ 
  
1 
 
Anabolic Steroids 
 
(There are more than 100 kinds of anabolic steroids which are used in body 
building as well as in gender reassignment and the treatment of certain sexual 
dysfunctions.  This does not include steroids taken for the treatment of 
respiratory ailments e.g. Asthma, Arthritis and other inflammatory conditions) 
2 Dianabol 
3 Deca-Durabolin ®, Durabolin ®, Nandrolone 
4 Stanozolol 
5 DHEA 
6 Winstrol ® 
7 British Dragon, Primobol ® (Primo) 
8 Clenbuterol 
9 Methandranone 
10 Stanolone 
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50878 SHOW CARD ‘153’ 
 
1 I got them on a prescription 
2 I got them from someone I know 
3 I bought them without a prescription in a chemist 
4 I bought them over the internet 
5 Other (please tell me how) 
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50878 SHOW CARD ‘154’ 
 
1 More as a criminal 
2 More as a patient 
3 Neither a criminal nor a patient 
4 Both a criminal and a patient 
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50878 SHOW CARD ‘155’ 
 
1 Fully agree 
2 Largely agree 
3 Neither 
4 Largely disagree 
5 Fully disagree 
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50878 SHOW CARD ‘156’ 
 
1 Do not disapprove 
2 Disapprove 
3 Strongly disapprove 
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50878 SHOW CARD ‘157’ 
 
1 No risk 
2 Slight risk 
3 Moderate risk 
4 Great risk 
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50878 SHOW CARD ‘162’ 
 
1 Yes – tried to and stopped 
2 Yes -  tried to but not stopped 
3 No 
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50878 SHOW CARD ‘163’ 
 
1 Cost/could no longer afford it 
2 Persuaded by friends/family 
3 Impact on job/friends/family 
4 No longer part of social life 
5 Concern about health/health reasons 
6 Pregnancy 
7 Less available supply 
8 Put on rehabilitation programme 
9 Did not want to take anymore 
10 Did not enjoy after effects 
11 The pros of taking did not outweigh the cons 
12 Other (please tell me) 
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50878 SHOW CARD ‘166’ 
 
1 Yes – tried to and stopped 
2 Yes -  tried to but not stopped 
3 No 
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50878 SHOW CARD ‘167’ 
 
1 Cost/could no longer afford it 
2 Persuaded by friends/family 
3 Impact on job/friends/family 
4 No longer part of social life 
5 Concern about health/health reasons 
6 Pregnancy 
7 Less available supply 
8 Put on rehabilitation programme 
9 Did not want to take anymore 
10 Did not enjoy after effects 
11 The pros of taking did not outweigh the cons 
12 Other (please tell me) 
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50878 SHOW CARD ‘170’ 
 
1 Yes – tried to and stopped 
2 Yes -  tried to but not stopped 
3 No 
127
 
NACD Drug Prevalence Study 2006-2007 
Ipsos MORI – Technical Report – DRAFT 4 – 01/04/08 
 
50878 SHOW CARD ‘171’ 
 
1 Cost/could no longer afford it 
2 Persuaded by friends/family 
3 Impact on job/friends/family 
4 No longer part of social life 
5 Concern about health/health reasons 
6 Pregnancy 
7 Less available supply 
8 Put on rehabilitation programme 
9 Did not want to take anymore 
10 Did not enjoy after effects 
11 The pros of taking did not outweigh the cons 
12 Other (please tell me) 
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50878 SHOW CARD ‘172’ 
 
1 Given by family/friend 
2 Given by a contact I did not know personally 
3 Given by a stranger 
4 Shared amongst group of friends 
5 Bought from a friend 
6 Bought from a contact I did not know personally 
7 Bought from a stranger 
8 Other (please tell me) 
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50878 SHOW CARD ‘173’ 
 
1 Street/park 
2 Disco/bar/club 
3 Office/workplace 
4 School/college 
5 House of a dealer 
6 House of a friend 
7 Ordered by phone for collection/delivery 
8 Internet 
9 Other (please tell me) 
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50878 SHOW CARD ‘174’ 
 
1 Very easy 
2 Fairly easy 
3 Neither easy nor difficult 
4 Fairly difficult 
5 Very difficult 
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50878 SHOW CARD ‘175’ 
 
1 Given by family/friend 
2 Given by a contact I did not know personally 
3 Given by a stranger 
4 Shared amongst group of friends 
5 Bought from a friend 
6 Bought from a contact I did not know personally 
7 Bought from a stranger 
8 Other (please tell me how) 
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50878 SHOW CARD ‘176’ 
 
1 Street/park 
2 Disco/bar/club 
3 Office/workplace 
4 School/college 
5 House of a dealer 
6 House of a friend 
7 Ordered by phone for collection/delivery 
8 Internet 
9 Other (please tell me) 
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50878 SHOW CARD ‘177’ 
 
1 Very easy 
2 Fairly easy 
3 Neither easy nor difficult 
4 Fairly difficult 
5 Very difficult 
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50878 SHOW CARD ‘178’ 
 
1 Given by family/friend 
2 Given by a contact I did not know personally 
3 Given by a stranger 
4 Shared amongst group of friends 
5 Bought from a friend 
6 Bought from a contact I did not know personally 
7 Bought from a stranger 
8 Other (please tell me) 
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50878 SHOW CARD ‘179’ 
 
1 Street/park 
2 Disco/bar/club 
3 Office/workplace 
4 School/college 
5 House of a dealer 
6 House of a friend 
7 Ordered by phone for collection/delivery 
8 Internet 
9 Other (please tell me which) 
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50878 SHOW CARD ‘180’ 
 
1 Very easy 
2 Fairly easy 
3 Neither easy nor difficult 
4 Fairly difficult 
5 Very difficult 
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50878 SHOW CARD ‘C2’ 
 
1 Single (never married) 
2 Married 
3 Co-habiting 
4 Separated 
5 Divorced 
6 Widowed 
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50878 SHOW CARD ‘C4’ 
 
 White 
1 Irish 
2 Irish Traveller 
3 British 
4 Roma 
5 Other white background (please tell me which) 
 Black or Black Irish 
6 African 
7 Any other black background (please tell me which) 
 Asian or Asian Irish 
8 Chinese 
9 Any other Asian background (please tell me which) 
 Other 
10 Other including mixed background (please tell me which) 
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50878 SHOW CARD ‘C6’ 
 
 In Paid Job 
1 Self employed 
2 Working full-time 30hrs+/week 
3 Working part time 
 No Paid Job 
4 Seeking work for the first time 
5 Unemployed (having lost or given up job) 
6 Home (domestic) duties 
7 Unable to work due to permanent illness/disability 
8 Not working (seeking work) 
9 Not working (not seeking work) 
10 On Government training/education scheme 
11 On Government employment scheme (CE, job options etc) 
12 Retired 
13 Student 
14 Other (please tell me which) 
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50878 SHOW CARD ‘C6c’ 
1 Unemployment benefit 
2 Unemployment assistance 
3 One parent payment 
4 Disability benefit 
5 Disability allowance 
6 Invalidity pension 
7 Carer’s allowance 
8 Family income supplement 
9 Widow/widowers pension 
10 Other (please tell me which) 
11 None of these 
141
 
NACD Drug Prevalence Study 2006-2007 
Ipsos MORI – Technical Report – DRAFT 4 – 01/04/08 
 
50878 SHOW CARD ‘C10’ 
A Retired, gets pension from previous job 
B Unemployed, less than 2 months 
C Sick, still receiving pay or statutory pay from job 
D Widowed, receiving pension from spouse’s previous job 
E Divorced/separated, receiving maintenance 
F Full-time student 
G Not working, private means 
H Unemployed longer than 2 months 
I Sick – only receiving Income Support or Invalidity Benefit 
J Receiving State Pension only 
K Paid job – Full time or Part time 
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50878 SHOW CARD ‘C13’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A person has a disability if he/she has a physical or mental impairment which 
has a substantial and long-term adverse effect on his/her ability to carry out 
normal day to day activities.   
 
On the basis of this definition, do you regard yourself as being disabled? 
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50878 SHOW CARD ‘C14’ 
 
1 No formal education 
2 Primary education 
3 Second level 
4 Lower secondary 
(Junior/Intermediate/Group Certificate, ‘O’ levels/GCSEs, NCVA 
Foundation Certificate, basic Skills Training Certificate or 
equivalent) 
5 Upper secondary 
Leaving certificate, (including Applied and Vocational 
Programmes), ‘A’ Levels NCVA Level 1 Certificate or equivalent) 
6 Third level 
Non degree qualification (National Certificate, Diploma 
NCEA/Institute of Technology or equivalent) 
7 Primary degree (Third level bachelor degree) 
8 Professional qualification (of degree status at least) 
9 Both a degree and a professional qualification 
10 Postgraduate certificate or diplomas 
11 Postgraduate degree or masters 
12 Doctorate (PhD) 
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G.  Contact Sheet 
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H.  NACD letter to survey respondents 
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I.  Letter to Households 
 
Population Survey on behalf of 
Department of the Community, Rural and Gaeltacht Affairs and  
the National Advisory Committee on Drugs (NACD) in the Republic of Ireland 
 
Ipsos MORI is a market research company which has been commissioned by the above 
organisations to conduct a study on lifestyles.  
 
The survey will investigate people’s views on a wide range of issues including their attitudes 
and behaviour in relation to alcohol, drugs and tobacco.  The information will help the 
Department and the National Advisory Committee on Drugs (NACD) make important decisions 
in relation to policy and service provision in these areas. 
  
We are interviewing 5,000 people between the ages of 15 and 64 across Ireland.  All of the 
addresses chosen to take part in the survey have been selected at random from all 
residential addresses in Ireland to which An Post delivers mail.  Within each household there 
is a further random procedure to select who in the household should be interviewed.  The 
selection of the individual household member would take place when the interviewer calls.  
As your address was one of those selected, we would be very grateful if the selected 
household member would agree to be interviewed on this important study. 
 
There is no need to respond to this letter, as one of our interviewers will call at your 
home during the next month and, if it is convenient, we hope you will be able to spare 
approximately 20 minutes to answer some questions.  The interviewer will carry an 
identification card which should be presented to you. The interview will be conducted using a 
laptop computer so the interviewer will need to carry out the interview inside your home.  All 
of the information collected will be treated in strict confidence and will be processed solely for 
the purposes of this research. 
 
Ipsos MORI conforms with the principles of the Data Protection Act.  The information you 
provide will not be disclosed to anyone outside the Research Team.  The results of the 
research will be published in 2007.  However, please be completely reassured that the 
research data will remain confidential at all times and it will not be possible to 
identify you or any other member of your household from the published 
information. 
 
As it is important to have the views of the widest possible range of people, I hope you will 
agree to take part in the survey.  
 
Thank you, in anticipation, for your help. 
 
Yours faithfully 
 
 
 
 
Lesley McClure 
Managing Director -Ireland 
Ipsos MORI 
24 Windsor Place  Dublin 2   Tel: +353 (0) 1 6326000   Fax: +353 (0) 1 6326061  
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J.  Letter to Households (Polish Translation) 
 
 
 
 
Date jak na znaczku pocztowym 
Drogi respondencie, 
Badanie populacji dla departamentu Ministerstwa Zdrowia: 
 
Population Survey on behalf of Departament of the Community, Rura land 
Gaeltacht Affairs and the National Advisory Committ on Drugs(NACD) in the 
Republic of Ireland. 
 
Ipsos MORI jest agencja zajmująca się marketing research, która otrzymała 
pozwolenie od powyższej organizacji na przeprowadzenie badania na temat stylu 
zycia. Badanie ma na celu prześledzenie ogólnego podejścia ludzi mieszkających w 
Irlandii do używek takich jak: alkohol, papierosy i narkotyki. 
Nasi pracownicy przeprowadzają badania z 5,000 osob pomiędzy 16-tym a 
64-tym rokiem zycia. Wszystkie listy za pomocą których się z Tobą skontaktowaliśmy 
zostały wyslane pod adresy które wytypowaliśmy przypadkowo z rejestru jakim 
dysponuje Poczta Irlandzka. Jako ze Twój adres został wylosowany, bylibyśmy 
bardzo wdzięczni, gdyby wybrany przez naszego pracownika, mieszkaniec tego domu 
udzielił nam wywiadu będącego częścią przeprowadzanego badania. 
Pracownik Ipsos MORI będzie miał przy sobie identyfikator, który na samym 
początku zostanie Ci okazany. Wywiad będzie przeprowadzany przy użyciu laptopa, 
wiec istnieje potrzeba zaproszenia (wprowadzenia) pracownika Ipsos MORI do 
mieszkania. 
Posługujemy się specjalna procedura, która pozwala losowo wyłonić osobę z 
danego mieszkania, z która przeprowadzimy wywiad. Losowo( przypadkowo) 
wybrana osoba musi być ta, która, która jako ostatnia miała urodziny. Prosze jednak 
mieć na uwadze fakt, ze nie oznacza to wcale ze musi to być najmłodsza osoba tylko 
ta, która jako ostatnia obchodziła urodziny. 
Nie ma potrzeby żebyś odpowiadał na ten list. Nasz pracownik w przeciągu 
kilku tygodni pojawi się u Ciebie w domu w celu przeprowadzenia badania. Będziemy 
bardzo zobowiązani, gdy będziesz mógł poświęcić 20 minut na przeprowadzenie tego 
badania. Wszelkie udzielone przez Ciebie odpowiedzi w czasie trwania wywiadu będą 
użyte tylko i wyłącznie przez pracowników naszej firmy do przeprowadzenia badan 
statystycznych.  
W celu jakichkolwiek pytań proszę się skontaktować z naszym biurem w 
Dublinie 01 6326000 i prosić Anne Andruszkiewicz. 
  
Z wyrazami szacunku 
 
 
                                     
Lesley McClure 
Lesley McClure 
Managing Director -Ireland 
Ipsos MORI 
24 Windsor Place  Dublin 2   Tel: +353 (0) 1 6326000   Fax: +353 (0) 1 6326061  
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K.  Letter to An Garda Síochána  
 
 
The Deputy Commissioner 
An Garda Síochána  
Garda House 
Phoenix Park 
Dublin 8 
 
23 October 2006 
 
Re: Population Survey on behalf of 
Department of the Community, Rural and Gaeltacht Affairs and the  
National Advisory Committee on Drugs (NACD) in the Republic of Ireland 
 
Dear Sir,  
 
The Department of Community, Rural and Gaeltacht Affairs and the National 
Advisory Committee on Drugs has commissioned Ipsos MORI, the independent 
research agency, to carry out a household survey, asking people about their use of 
tobacco, alcohol and drugs.  This is a repeat of a previous survey conducted in 
2002/2003. 
 
Ipsos MORI interviewers will be conducting a total of 5,000 randomly selected face-
to-face interviews, in respondents’ homes, across Ireland (the Republic of), between 
late October and mid December, and again between mid January and April 2007.  
Interviews will be conducted at a range of times between 9am and 9pm, Monday to 
Saturday, and on Sundays (by prior appointment).   
 
Interviewers will be informing Garda stations when they are interviewing in local 
areas.   
 
As with the previous study, Ipsos MORI thought it would be helpful to let you know 
about this study in advance.  Please find attached a copy of a letter from the NACD 
to survey respondents, for your reference.   
 
I trust that everything is in order, but please call me on 01 6326000 if you wish to 
discuss this study further.   
 
Yours sincerely, 
 
Tarik Laher 
Director 
24 Windsor Place  Dublin 2   Tel: +353 (0) 1 6326000   Fax: +353 (0) 1 6326061  
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L.  Parental Permission Form 
  
 
Population Survey on behalf of 
Department of the Community, Rural and Gaeltacht Affairs and 
the National Advisory Committee on Drugs in the Republic of Ireland 
 
 
Your child __________  aged _____________ has been selected randomly from the 
people aged 15-64 in your household to participate in a study about lifestyles 
including topics on alcohol, tobacco and drugs. Your household’s address was earlier 
selected randomly from all residential addresses to which An Post delivers mail. 
 
We are interviewing 5,000 people between the ages of 15 and 64 and their answers 
to the study will all be grouped together so that no individual’s responses will be 
identified. 
 
We need to interview people as young as 15 years old because it is important to 
understand changes to lifestyles over time. Under the rules of the Market Research 
Society we are not allowed to ask children under 16 any questions without an adult’s 
permission. He/she will not have to answer any questions he/she doesn’t want to.   
 
Your child’s name, address and telephone number will not be passed to anyone 
outside our company so neither you nor your child will be contacted by anyone 
outside the company as a result of participation in the study. All the details collected 
are purely for the purpose of market research and the information is used purely for 
statistical purposes. The only contact that may be made would be if a supervisor or 
member of staff wrote to, telephoned or called you or your child to check only that 
the interview was carried out to instructions. 
 
You may if you wish be present at your child’s interview, although he/she may be 
more comfortable if you are out of hearing. 
 
If you give consent to your child taking part in this important study please sign both 
copies.  One is for you to keep and one will be sent into the office for our records. 
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Permission to interview: 
 
I hereby give my consent for my child to be interviewed in this study. 
 
 
Child’s Name (Please print):  
 
Parent/Guardian (Please print):  
 
Signature of parent/guardian:  
 
Interviewer Name:  
 
Interviewer Number:     
 
Unique Address Code:    
 
Date:     0 6 
   
 
 
154
 
NACD Drug Prevalence Study 2006-2007 
Ipsos MORI – Technical Report – DRAFT 4 – 01/04/08 
 
M.  Frequently Asked Questions 
Frequently Asked Questions 
 
What is this survey about? 
The survey is designed to get people’s views on a wide range of issues, including 
their attitudes and behaviour in relation to alcohol, drugs and tobacco. This is a 
repeat of a similar survey which was conducted in 2002/2003, and will help make 
important decisions in relation to policy and service provision in these areas.   
  
Who is conducting the research? 
Ipsos MORI is an independent market research company, which has been 
commissioned by the Department of the Community, Rural and Gaeltacht Affairs and 
the National Advisory Committee on Drugs to conduct this study.  
 
Who is being surveyed? 
We are interviewing a total of 5,000 members of the public aged 15-64 across 
Ireland.  
 
Why am I being invited to participate? 
You have been selected completely at random.  All of the addresses chosen to take 
part in the survey have been selected at random from all residential addresses in 
Ireland to which An Post delivers mail, and there is a further random procedure to 
select who in the household should be interviewed.   
 
What does the interview involve? 
One of our interviewers will call at your home to conduct the interview, which takes 
approximately 20 minutes.  The interviewer will carry an identification card which 
should be presented to you.  The interview will be conducted using a laptop 
computer, an efficient and modern way to conduct the survey, and follows the same 
procedures as a traditional ‘clipboard-style’ interview – the only difference being that 
answers are automatically coded onto the computer rather than written down. 
 
Is what I say during the interview confidential? 
Absolutely.  All of the information collected is completely anonymous and will be 
treated in strict confidence – it will not be possible to identify you or any other 
member of your household in the analysis of results (although you may be re-
contacted as part of our quality control checking process).  Ipsos MORI conforms 
with the principles of the Data Protection Act and the information you provide cannot 
be made available to anybody, including An Garda Síochána. 
 
Will the results be published? 
The results of the research will be published and will be made available on to the 
public.  They are also likely to be covered in the media.   
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N.  Interviewer Instructions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interviewer Instructions 
 
POPULATION STUDY 
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50878 
1. Background to the Study 
 
 
The European Union has an ongoing Action Plan on drugs to establish and monitor the 
prevalence of drug use in the general population of the EU member states. 
 
To enable the EU to take this forward all member countries carry out population 
studies using a common methodology and basic questionnaire. 
 
This, the second study of its type in Ireland will provide data about the frequency of 
drug use (both legal and illegal) among the general population of Ireland.   
  
A virtually identical study was carried out by us in 2002/2003 for the National 
Advisory Committee on Drugs (NACD) and the Drug and Alcohol Information and 
Research (DAIRU).  These bodies represent an all-Ireland front in providing data and 
advice to various government departments about the prevalence of drug use and 
other related aspects. 
 
Now in 2006, NACD has commissioned Ipsos MORI in the Republic of Ireland to 
interview 5,000 adults aged between 15 and 64, using a CAPI methodology.   
 
We will, as far as possible, carry out the interviewing across the same time period as 
the previous study, October to April with a break for Christmas and the New Year. 
 
 
NACD was established in 2000 to provide advice to the Government on problem drug 
use in Ireland in relation to prevalence, prevention, consequences and treatment 
based on its analysis of reliable and relevant information.  The research we will 
undertake will provide robust trend information on drug use on Ireland.  Information 
on the use of substances such as tobacco, alcohol and drugs for lifetime use, last 
year and last month will be examined together with opinions on drug matters. 
 
NACD has published four bulletins from the previous survey which can be 
downloaded form the website www.nacd.ie 
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2. Sampling 
 
 
In this study the people to be interviewed are to be adults aged 15-64 whose 
normal place of residence is Republic of Ireland.  The people can be of any 
nationality, so long as they are living in the Republic of Ireland at the time the study 
is being worked.  There are no exclusions; in other words anyone in the population 
could be selected for interview. 
 
We will interview a minimum of 5,000 people across the Republic of Ireland by 
means of a random selection method.  
 
To arrive at the addresses where interviewers will call we have ranked sampling 
points in order of the social deprivation index so that all types of areas will be 
represented.  We then select sampling points using a random selection procedure to 
ensure that the points chosen will give a full representation of the different types of 
areas in the country.    In each of the sampling points or areas we have then 
selected main and reserve addresses, again randomly.  
 
 Addresses have been chosen from each of the Health Boards in the Republic of 
Ireland. The number of addresses chosen is proportionate to the populations in each 
Health Board, so for example, as there are more people living in the EHRA than in 
any of the other boards, it follows that we have more addresses here to obtain more 
interviews.   
 
The numbers of interviews to be achieved in each of the Health Boards is as follows: 
 
ERHA 1,750
SHB 640
SEHB 460
WHB 450
MWHB 450
NEHB 450
MHB 400
NWHB 400
 
When using random sampling to select individuals for interview the results obtained 
are very accurate so long as very precise instructions are followed 
accurately, in order that the correct person is chosen for interview. 
 
Interviewing will be conducted over the next few months.  It is important that we 
spread the interviews across the time period so that any changes in the behaviour of 
our respondents during holiday periods, for example, is not over represented. 
 
Our nationally representative sample of addresses has been selected from the An 
Post/Ordnance Survey Geo-Directory.  The Geo Directory is comprised of all 
addresses to which An Post delivers mail.  The files are updated regularly from 
information collected from each postal round, so provide the most comprehensive 
and up to date sample frame available in the Republic of Ireland. 
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The sample we have selected excludes large users and organisations so the vast 
majority of addresses issued to each interviewer will be private residential addresses. 
 
Each assignment will contain a specific number of addresses which should all be 
approached and an attempt made to interview the selected individual at each 
address, providing there is someone aged 15-64 living there. 
 
Overall we need to achieve a high response rate although we appreciate that some 
areas will prove more fruitful than others. 
 
All selected addresses will be written to in advance of fieldwork to advise the 
occupiers that an interviewer will be calling with the view to take an interview with a 
person aged between 15 and 64 from the household.  Interviewers will have copies 
of the letter to hand out in case the contact at the door does not recall seeing the 
letter.    It may be that in some instances the letter may not have been delivered or 
the contact has not seen it so be prepared to give a copy to the contact you make 
and allow them time to peruse it. 
 
The reason that we decided to send letters in advance of interviewers calling was to 
prepare the way for interviewers gaining access to the home and being able to sit 
down with their laptop computer.  The response rate should be improved by writing 
in advance.   Although there is more chance of a letter not being delivered in a rural 
area because of more than one household having the same address it will be easier 
to gain access to homes in rural areas. 
 
We will be working across 385 different sampling points over the fieldwork period.  
Each sample point will have 24 main addresses with six or seven held in reserve to 
cover ineligibles.  Working across this number of sample points will give us a wide 
coverage of the country. 
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3. When to Interview 
 
 
Each address has to be visited a minimum of five times before it can be deemed to 
be non effective.  Where a 15 -24 year old is the selected person then a further two 
calls must be made.   
 
The reason for this approach is to ensure that each address has the best possible 
chance of providing an interview.   
 
It is essential therefore to space out your calls across different days and times of day 
so as to allow people living at an address the best chance of being contacted. 
 
Ideally you should not begin work before mid-afternoon (c. 3.30pm) which will 
maximise your chances of finding someone at home. 
 
Once you have made contact with a responsible adult in the household you will 
follow a strict procedure to select the correct individual in the household to 
interview. 
 
You will keep a record of the number of calls and times of these calls on the Contact 
Record Sheet, explained in Chapter 4 and will update us after each day’s work by 
means of “eprogress”.  We will then be able to monitor and inform NACD on 
achievement, not only on completed interviews but also on number of calls made, 
and eventual outcomes.  
 
Until you have established contact you should make your calls before 9.00pm and 
from Monday to Sunday.  Calls later than 9:00 pm can only be made by prior 
appointment and a first call on a Sunday should be made after mid-day. 
 
You must not make subsequent calls at the same time of day, as it is likely that if the 
household is empty at 5.00pm on a Tuesday it will be on a Wednesday and Thursday 
too! 
 
If you establish that a young person (that is aged between 15 and 24) is the selected 
respondent you must make an additional two evening and/or weekend calls before 
you can send back the contact sheet as non effective. 
 
Although it will be necessary to keep trying to make contact at some addresses at 
different times of day and on different days it is worth knowing that on the last 
survey 70% of all the successful interviews were carried out on the first or 
second call! 
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4. The Contact Record Sheet/Address List 
 
 
In this study you will be given particular addresses in a relatively small geographical 
area.  These are printed on to “Contact Sheets” and how you record the information 
you will collect when making your calls   is crucial to the overall success and 
reporting on this study. 
 
It is sensible to plan your route before going out on the first day so that you can 
make your initial calls as quickly and easily as possible.  You may wish to consult a 
street map or ordnance survey map showing town-lands to help you plan your route. 
If you don’t know the area you have been given you may wish to drive round in 
daylight on your first day. 
 
When you receive each assignment, please check the addresses in case you know 
anyone living at any of them.  We do not want you to attempt to interview anyone 
you know.  If you find such an address, please code “19” as the final outcome on the 
contact sheet and state “Known to me”.  Return the contact sheet to the office at 
once; don’t wait until you have completed the assignment.  
This also applies if, when you make contact at any given address, you discover that 
you know the person/people living there.  We will organise that another interviewer 
contacts this household. 
 
Make sure that you inform us/ update eprogress at the same time. 
 
As far as we can know, the addresses you will have been given are those of private 
households.  (There may be the occasional commercial property such as a small 
shop but this should be the exception.) 
 
A private household is where a group of people (not always related) live together 
and whose food and household expenses are managed as one unit. 
 
However, sometimes more than one household is found at a single address. 
 
This could be: 
 
(1) A house has been converted into two or more flats; 
(2) Two families sharing a dwelling such as a young married 
couple living with parents but with separate catering and 
housekeeping arrangements – each is a separate household. 
(3) A group of students or other non-related individuals living 
together at one address.   Those sharing occupancy can be 
siblings but it is likely in this situation that each is his or her 
own household unit.  These individuals form separate  
households, if they don’t cater as one unit. 
(4) Several households in town-lands with the same address 
 
If you come across a multi-household dwelling or multi household addresses you 
must first randomly select the household before randomly selecting an individual 
within that household.  You do this by using a random table selection grid. This is 
known as a KISH Grid. 
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There are different kinds on multi households,   The KISH grid provided will enable 
you to recordt the number of households (in the case of a flat conversion or two 
or more households at the one address) or enable you to record  the number of 
people who share the one address but are each their own heads of household, i.e. a 
group of students living together who don’t have communal budgeting/catering.   
Once you have recorded the households/individual heads of household you follow 
the instruction on the Kish Grid as to which household/ head of household to select.  
 
The same principle applies if you are selecting one property out of several properties 
sharing the same address,  but use Kish Grid 2  (Property selection) which allows for 
a greater number than Kish Grid 1.   
 
Each contact sheet has a unique address code which you transfer to the 
questionnaire when you begin to interview the selected individual.  You must take 
the greatest care to transfer this number accurately as the computer is set up to take 
all the numbers in the range (that is all the individual addresses that have been 
selected). 
 
The numbers in this unique address code represent the Health Board, the 
sample point and the addresses within that sample point.  
 
Because you will need to introduce yourself and the study to the person you initially 
make contact with; the full introduction is written on the contact sheet, as well as on 
the actual CAPI script. 
 
When you do make contact with a responsible adult in the (private) household, you 
will explain who you are and what you are doing.  Practise and learn your 
introduction at home, show your ID card and look at the person, rather than reading 
out the introduction.  You may be asked why you are at the particular address and 
you can explain it was chosen at random, from the An Post/Ordnance Survey Geo-
Directory.   
 
This is important to do if the person is concerned about how their address was 
obtained. 
 
If the person who answered the door to you seems reluctant to talk, back off before 
you get an outright refusal.  Offer a copy of the letter from the client and The 
Frequently Asked Questions Leaflet and say you’ll call at another time when you’re 
next in the area.  You can catch people at a bad time for them and if you don’t try to 
pressure them you may be successful next time you call.  Try as far as possible to 
avoid getting a refusal at this stage.   
Better to postpone carrying out the selection procedure than to never have the 
chance of doing so. 
 
The next call may find them more receptive. 
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How to proceed with the selection of correct individual within the household using 
the last birthday rule. 
 
If your respondent is amenable then ask: 
 
 “How many people aged between 15-64 live here?” 
 
(a) If the answer is none then no interview can be taken here. 
 
(b) If the answer is one, me! – take the interview there and then if you 
can.  In 2002, 22% of households were single person 
households so the total may well be higher in 2006. 
 
(c) If the answer is one but he/she isn’t in then you should try to 
ascertain the best time to call and interview that person. 
 
(d) If the answer is two or more then you need to record their details on 
the contact sheet and select the one who has celebrated their 
birthday most recently.   
 
This is the “last birthday rule” and is used to select individuals within a 
household in a random manner.  You must select and interview the “chosen” 
person.  To do otherwise introduces bias into the sample and affects the 
reliability of the data. 
 
It doesn’t matter in which order your contact gives you the names of 
all those aged between 15-64.  Ask what was the day and month of 
(all) their birthdays.  Choose the individual who had the most recent 
birthday.  This has nothing to do with the age of respondents, only 
when they had their birthdays.  We don’t need dates of birth, only 
the birthdays, i.e. not 10th June 1962 only 10th June. 
  
You only need to determine only the age of the selected 
individual which you write on to the contact sheet as this will 
be transferred to the questionnaire. 
 
If there are twins in the household and their birthday is the most 
recent one then interview the twin born second. 
 
If two (or more) people in any household share the same birthday, 
select the younger person as your respondent. 
If a member of the household has their birthday on the day that you 
make contact and carry out the selection procedure, select this person 
as the respondent who will complete the interview. 
 
If your selected respondent isn’t at home then you try to establish a 
good time to call back. 
 
If the last birthday has changed since you first made contact at the 
address you still proceed with the person who was selected at the time of 
the first contact. 
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Each time you make a call you record the result using abbreviations you understand 
like NAH for not at home or NR for no reply as well as the day and time the call was 
made by using the codes provided for time of day and day of the week.  Also write 
on the comments line any information which will be useful to you when planning 
future calls in the area.  
 
 For example, your initial contact has told you that her teenage son (your selected 
respondent) comes in to eat his dinner at 7.00pm and usually is out of the house for 
the evening by 8.00pm.  You’ll need to catch him about 7.30!  Write this to remind 
you when you’re planning your route for your next round of calls. 
You may wish to leave a calling card if you have not succeeded in making contact 
after two visits or an appointment card to remind selected respondents of when they 
have agreed to carry out the interview.  If you have made an appointment then you 
must keep it. 
 
Record codes at C5 and C6 after your final call.  If you are refused please record the 
refusal information, not forgetting to estimate the age and ethnicity of the person 
who refused you. 
 
Rules for interviewing those aged 15  
 
If your selected individual in the household is aged 15 you need to obtain written 
parental permission before you can conduct an interview.  As the interview is 
conducted using CAPI there is a special letter for the parent/guardian of such a child 
to sign.   
 
It would be best to give this letter to the parent to peruse before trying to set up the 
interview with the child. If the parent agrees to the interview with their child then 
please ensure that the parent signs both copies of the letter and keeps one for 
his/her own records and that you send one copy back to the office, fully completed 
with unique address code, parent and child’s name and parent’s signature. 
 
Obviously with this study it would not be ideal to have the parent present during the 
interview so try to explain the subject matter in general terms. Explain that we do 
want to interview 15 year olds if they have been selected.  
 
If you appear very matter-of-fact about everything, the odds are that the parent will 
allow you to conduct the interview alone (or at least out of their hearing) with the 15 
year old.  If the parent wants to sit in you must accede.   It is a parent’s right not 
only to know the type of questions that you are going to ask but to actually sit in on 
the interview if they wish.  
 
Proceed with the interview as instructed and record on the questionnaire whether or 
not the parent of the 15 year old was present during the interview. 
 
If permission is not granted you cannot take an interview with a child aged 
15 and you will record this in the final outcome box on the contact sheet.  No 
substitute can be taken if the parent refuses permission.  Please note that if 
the parent gives permission for you to approach the child to interview you still need 
to get the child’s consent.  If he or she doesn’t wish to do the interview then you 
must accept that. 
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If after five calls to the address on different days/different times of day you have not 
got an interview you may record the final outcome as a non-contact on the contact 
sheet and return to the office.  It may be that you could not make any contact with 
anyone in the household or it may be that you could never get to see the selected 
respondent.  If the selected respondent is aged 15-24 we would like you to keep 
trying at least twice more to get the interview.  This age group is always hard to 
get at home.  
 
However, you may feel that you still have a chance of getting the interview.   In that 
case keep the contact sheet and try again when you are close by the area, perhaps 
working on another point of this study.  So long as you have updated us using 
eprogress and your supervisor knows that you are holding on to that 
contact sheet this is fine. 
 
Sometimes you may not be able to carry out an interview with the selected 
respondent because they don’t speak adequate English.  If this happens we will try 
to find an interpreter to conduct the interview.  Try to establish the language spoken 
and tell the Field Office.  We will write to the household in their own language and 
ask them to contact us to arrange an interview if they wish. 
 
In the case of a blind respondent or one who has difficulty in reading the show cards 
you must read out the cards to such a person.  People cannot be excluded because 
they can’t read.  Equally if a person is deaf then you will have a list of questions to 
show to them so that they will have the opportunity to participate in the survey. 
 
You must complete the contact sheets accurately and conscientiously with 
full details.  We may need to reallocate the work to another interviewer or 
supervisor if response rate in the area is too low and a complete history of previous 
calls will be useful.  In any event you will need a record of calls and time of call for 
the eprogress questionnaire. 
 
From the contact sheets we will calculate the study response rate and construct a 
profile of non-productive or invalid addresses and refusals for the report to our client. 
 
Included in this will be information about the type of property lived in and in the case 
of refusals the type of person who refused.  Please fill this section in accurately. 
 
If any address is non-residential, eg, a small shop or office, make no attempt to take 
an interview.   Do check however that there isn’t living accommodation above or 
attached to the business premises with the same address.  If completely non-
residential, code this in the Final Outcome Box. 
 
Should you have an area with a high number of ineligible addresses (over 65s only 
or commercial addresses like small shops, vacant or demolished properties) we can 
issue you with reserve addresses to supplement the addresses which cannot yield 
interviews.  If there are too many such “ineligible” addresses then we may issue a 
reserve point. 
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If you feel that you need to have reserve addresses you must request to 
have these in writing to the office or by telephone to Marianne who will 
put your request in writing. 
 
In the majority of cases you will be able to complete a successful interview so don’t 
forget to record the name and telephone number of the selected respondent 
on your contact sheet this will help you to set up an appointment. 
 
 
 
 
 
 
166
 
NACD Drug Prevalence Study 2006-2007 
Ipsos MORI – Technical Report – DRAFT 4 – 01/04/08 
 
5. Questionnaire Downloading and Using Eprogress 
 
 
As we are working on CAPI this time not only will you download your completed 
interviews after each day’s work you will inform us of progress by completing an 
eprogress questionnaire for each call made to an address.  Your supervisor will also 
contact you at regular intervals to see how your work is going.  Please keep your 
paperwork organised so that you can always give her an up-to-date report.  Note the 
column on your contact sheet for you to record that you have completed the 
eprogress report. 
 
The basic information that we will get from the General Survey Management System 
will cover: 
 
• Total number of successful interviews conducted to date; 
• Total number of definite non-productives to date; 
• Total number of invalid addresses to date; 
• Number of addresses still being worked on. 
 
 
We will only get meaningful information if you use eprogress regularly and download 
all questionnaires after each day’s work. 
 
Complete all your eprogress questionnaires before downloading and everything will 
be sent at the one time. 
 
Dial in at a sensible time so that you are less likely to get the engaged tone.  
Remember that early evening is the time that most of Ipsos’s interviewers will be 
trying to do the same thing.  
 
Remember to clear any messages waiting on your answer service before 
beginning to download.  If you do not do or a call tries to come in as you are 
attempting the download, it will not be successful. 
 
Check that you have indeed downloaded your work and eprogress before switching 
off your machine.    If you get an error message then you will need to try again. 
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6. The Interview 
 
 
We will have written to Garda Headquarters to advise them that this study is taking 
place before fieldwork begins.  You should contact the local Garda station in the area 
you are to work in to tell them when you will be working, car registration (if asked 
for) etc.  This can be in person but is acceptable by phone.   
 
You should conduct the interview in a one-to-one setting.  This is desirable for most 
surveys: in this study it is essential. 
 
The purpose of the interview is to determine the respondent’s use of tobacco, 
alcohol, drugs sometimes used as medicines and illegal drugs.  While the use of 
illegal drugs these days is not necessarily seen as something to be embarrassed 
about or kept quiet by those who use them, nevertheless, many people would not 
freely talk about their use of these types of drugs in front of members of their family. 
 
For the majority of respondents the interview will take less than 20 minutes.  
However try where possible to be invited into the home so that you can sit down 
with your laptop.  The letter that will be sent in advance explains that you will be 
using a laptop computer to carry out the interview.   If invited into a living room with 
other members of the household present, decline and say something like – “I don’t 
want to disturb them, can we do the interview in the hall or the kitchen or 
somewhere we can be private?”  If you have access to an electrical socket, please 
plug your machine in. If you haven’t access to a socket, don’t worry as you will have 
plenty of battery power.  However if you use battery to interview then be sure to 
charge it up again before going out the next day. 
 
Reassure respondents at the beginning of the interview about confidentiality.  Their 
names and individual address will not be linked to their answers.  Indeed the only 
reason for taking their names and telephone numbers (remember you are at the 
address) is to check that you, the interviewer, have carried out your work accurately.  
Explain as you usually do about backchecking and give whatever reassurance is 
needed as to their complete anonymity. 
 
Point out if you need to that their name doesn’t go on the questionnaire and that the 
answers of all the people interviewed on this study (5,000 in total) are input to 
computers like yours using numbers and that the results of all the 5,000 are 
produced as statistics, tables of figures etc. 
 
You must ask all the questions using the exact wording, and show the cards which 
are designed not only to speed up the answering process but to ensure that all 
respondents are presented with the same choices. You must not (as in all surveys) 
betray any emotion or reaction to any of the answers given to your questions. 
  
You must appear interested in what your respondent says in order to encourage 
him/her to keep answering but please do not engage in discussion or pass any 
opinion about the topic of the study or answers you have been given. 
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If it helps secure an interview or in response to the enquiry “What’s it for?” you may 
tell your respondent (or contact) that although everyone has an opinion about the 
prevalence of drug use in Ireland, this study is to provide real information.  You may 
advise them of the earlier study and direct them to the NACD website.   
 
You will have photocopies of the front page of a bulletin that NACD released after 
the last study which you can show them as well as copies of the client letter.   You 
have copies of FAQ sheet which may answer respondents’ queries.  
 
You can explain if you need to that the results of this study will be published in the 
late summer of 2007.   The information gathered from this study will be used by 
various government departments to plan resources needed for education, 
rehabilitation etc.  You also have an actual published bulletin which you can show to 
respondents so that they can understand how the results are collated and used.  Do 
not leave this with anyone as you will have only one copy of the actual 
bulletin. 
 
Any contact or respondent can contact NACD at any time for reassurances about 
their participation or indeed any worries they may have.   If you sense someone has 
concerns either about drug use or the interview they have given you leave them a 
copy of the client letter and point out that they can ring the director or any of her 
colleagues at any time. 
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7. The Questionnaire (and Show Cards) 
 
 
This is straightforward and clearly set out and flows well. 
 
Remember to read out the entire preamble on the information screens.   Information 
screens are marked “pause.” 
 
One of the joys of carrying out an interview using CAPI is that you don’t have to 
think about routing or what to ask next.  Ask the questions as written and use the 
show cards where instructed.  Their use will minimize the risk of embarrassment at 
potentially sensitive questions and answers, as respondents can call you out a 
number rather than have to tell you something that may be embarrassing. 
 
Each section is laid out in similar fashion, as is the type of question.  The exact 
words must be used. Do not abbreviate questions or leave any out.  Do not assume 
that you know the answer to a particular question because of a previous answer.  
You will find that the questions will begin to flow rhythmically after the first couple of 
sections.  
 
Where exact ages or number of days is required to be recorded and a respondent 
may not be sure, get them to give you their best estimate. 
 
For example, if you are talking to a smoker in his mid forties and he cannot 
remember whether he was 14 or 15 when he first smoked tobacco products ask him 
just to give you the one he thinks.  He needs to make the decision, not you! Try hard 
to get a figure. 
 
Don’t knows are not very useful to anyone so we really don’t want too many of 
them.  Don’t offer the “Don’t know” or “Refused” options to your respondents and 
only use them if they really cannot or will not give you an answer to the question.  
These options are present at every question but must only be used in exceptional 
circumstances. 
 
You will introduce the show cards at Q 15.  This is a picture card which explains the 
approximate number of “standard alcoholic drinks” for each common type of drink.  
Allow your respondent time to understand this card before asking question 15.   
 
When using the subsequent cards, where applicable, ask the respondent just to call 
you out the number that applies to the answer.  Be certain that they are giving 
you the code against the answer by checking the answer you are given a 
couple of times.  For example say “Is that code 2 or two times?” 
 
Control the use of the show-cards and allow the respondent to look only at the card 
relevant to the question.  The card numbers match the question numbers. 
 
Show Card 16:  Ask Q 16 – “Have you ever heard of any of these?” – showing the 
relevant card at the same time.  If ‘yes’ you will ask the questions in this section.  If 
none are heard of then code ‘no’ and you will be routed to the next section. 
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Using the appropriate show cards and reading out the questions as they appear , 
continue in this way for all sections. 
 
Be careful to enter the number which relates to the answer the respondent 
has given you.  It is an easy thing to enter the number 2 (for no) instead of 
the number 1 (for yes) and so miss asking the correct questions in that 
section. 
 
Encourage the respondent to look at the show card that introduces each section as 
you ask the subsequent questions in each section.   
 
Use the link between the sections, enabling you to progress from legal drugs, 
tobacco, alcohol and drugs sometimes used as medicines to illegal drugs. 
 
Read out the preamble before Q 154 as the questionnaire moves away from 
collecting facts to collecting opinions.  Please do not get drawn into a discussion with 
a respondent at these questions or indeed at any others.   
 
Note the wording of Q155; Not disapproving is not the same as approving and it 
may be helpful to emphasise the not disapprove slightly when reading out the 
question. 
 
Q.157, Note that this question is about risk, not whether or not they disapprove.  
You may remind them of this by reading out the question again and emphasise the 
words “risk harming themselves”. 
 if your respondent asks what is meant by  ”Have five or more drinks at the 
weekend”, you may clarify that this means having five or more drinks, on any one 
occasion at the weekend.    It does not mean 5 drinks in total across all three days.                            
  
Q.158 will be asked of those who drink or have ever drunk alcohol.  If the age your 
respondent gives you is an age earlier than the age at which he/she first drank 
alcohol the answer will not be accepted and you will have to get your respondent to 
think again. 
The word “regularly” means different things to different people so it is whatever your 
respondent means by regularly. 
 
This applies to all the questions relating to the age at which a respondent first took a 
substance regularly. Should the respondent not have “ever” taken the substance 
these questions will not be asked. 
 
Should a respondent give you two or more answers to a question which has been set 
up as a single code it will not be possible to enter two codes.  You will need to ask 
your respondent to choose the most appropriate answer from those answers he or 
she has already given you. 
 
Q181 asks if the respondent has taken any other illegal or illicit drug not already 
mentioned. If the answer is yes then you ask and record the name of this drug. 
 
At any point in the questionnaire, if you sense that your respondent is uneasy about 
any of the questions or answers that you are recording, please take the time to 
reassure him/her about confidentiality.   This reassurance should always be offered 
before you begin collecting the classification data. 
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8. Classification Section 
 
 
Having completed the interview you do not want respondents to feel concerned or 
nervous about giving you personal information about themselves or the household so 
please ask the classification questions in as relaxed a fashion as you have asked the 
rest of the questionnaire. 
Some of the questions on this classification section you are well used to, others may 
be new to you.  Use show cards throughout the classification section where directed. 
 
C1a asks for the respondent’s date of birth.  This should match the age that the 
respondent has already given you and if it does not the script will ask you which is 
correct. 
C4. This question regarding the ethnicity of the respondent is worded as the last 
census so you should not have any problems with it.  Ask the respondent to call you 
out the number from the card. 
 
Please collect as much information as you can about the occupation of the Chief 
Income Earner in order to be able to arrive at the correct social grading. 
 
Please note that there is a slight change in how we determine the occupation of the 
Chief Income Earner.  Q C10 is now an ASK ALL question and the description which 
BEST describes the CIE includes “working full time or part time”.     
 
Please familiarise yourself with the other questions, and be sure to code up answers 
accurately.  
 
If you have any comments about the interview record these in the comments box at 
the end and don’t forget, you need to move on until you reach the “New” screen 
before an interview is complete and saved on your laptop.  If you don’t want to 
record comments in front of the respondent then stop and save your interview so 
that you can complete when you leave.    Please remember that your interview isn’t 
“saved”, i.e. safe until you have reached the ”new” screen again. 
 
Do remember to leave a completed thank you letter with each respondent. It is 
useful for respondents to have a contact number if they have any queries or 
concerns after you leave. 
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9. The Interviewer’s Role 
 
 
This is all important.  Please always remember that this important work could not be 
undertaken without skills such as yours. 
 
The quality of the information collected (and reported on) depends on your 
interviewing ability, people skills, accuracy and powers of persuasion. 
 
Follow the procedures of selection correctly.  If you don’t, the validity of the sample 
and the accuracy of the results could be affected.  The sample is only representative 
if: 
 
1. You select the correct person; 
2. You never interview a substitute, no matter how difficult it is to make 
contact with the selected person. 
3. You make every effort to contact and take an interview at every 
address; 
4. You use all your skill to persuade a reluctant respondent to take part. 
 
You can tell people how important this study is and that the results will be published 
next year.  Assure them that there are no right or wrong answers and that 
their answers are of value to the final outcome of the study.  Again if you 
feel it will help, stress the fact that all information given is treated in the strictest 
confidence.  
 
Show them your copy of the bulletin so they understand how their 
answers will be used. 
 
If you are told by your contact or your selected respondent that he/she is too busy 
assure them that you will come back at a more convenient time.  Do your best to 
make them feel that their participation is important and that it isn’t any trouble for 
you to call back.  Sometimes this sort of courtesy will swing the balance in your 
favour and you will get the interview there and then. 
 
In other words, do your utmost to make contact and secure an interview with the 
correct respondent. 
 
Unlike quota studies you cannot just keep moving on until you find someone who 
meets your quota requirements. 
 
Pre-selected or random studies like this one give much more accurate results, which 
is why this methodology is being used. 
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10.       Materials Check List 
 
 
• These Instructions 
• * Set of questions to show to deaf respondents  
• 24 Contact Sheets Main Sample 
• Tally sheet for all addresses 
• * Show Cards in plastic pockets containing Illustration of Standard Alcoholic 
Drinks, show card 15 to Show card 120 plus classification cards C2 to C14. 
• * Kish Grid 1- Household Selection Table( PINK) 
• * Kish Grid 2- Property in Rural Areas Selection Table(YELLOW) 
• * 6 copies of letter to Households  
• * 3 Parental Permission Letters ( 2 copies of each) (GREEN) 
• * Note to request music voucher after at least two attempts to contact 15-24 
year olds (i.e. original contact call plus two attempts) 
• * 6 Appointment Cards  (YELLOW) 
• * 6 Calling Cards           (WHITE) 
• * Copy of Director’s letter to Garda Headquarters( BLUE) 
• Form for local Garda Station (you do not need to call in person but do advise 
that you will be working in the area.) 
• * 6 copies of Client letter explaining survey 
• * 6 copies of Bulletin  3 – Cannabis Results released by NACD on last survey 
• * 6 copies of  FAQ sheets ( MINI BOOKLETS) 
• 24 Thank You letters 
• Pay Claims (You may submit a pay claim when you have finished a point or 
claim    fortnightly.) 
• Return Envelopes for pay claim and the return of contact sheets. 
• 1 complete Bulletin 3 or 4  (for showing to respondents only) 
 
 
 
Please do not discard any of the * items above, nor return them to the 
office with pay claims.   
 
On subsequent points you may not be sent as many copies of these.  If at any time 
you require additional materials please request these in writing from Dublin office 
or by telephone to Marianne, who will put your request in writing. 
 
If you have any queries about the survey or the interviewing software please get in 
touch with us immediately. 
 
Everyone should have a copy of the CAPI training manual and the manual for the 
laptop.  If you haven’t got these please let us know. 
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O.  Sampling Points   
 
Sample 
Point Area Detail County 
Former Health 
Board 
68 ASHTOWN A DUBLIN ERHA 
70 AYRFIELD DUBLIN ERHA 
72 BALLYBOUGH B DUBLIN ERHA 
73 BALLYGALL A DUBLIN ERHA 
77 BALLYMUN A DUBLIN ERHA 
78 BALLYMUN B DUBLIN ERHA 
79 BALLYMUN C DUBLIN ERHA 
81 BALLYMUN E DUBLIN ERHA 
83 BEAUMONT A DUBLIN ERHA 
84 BEAUMONT B DUBLIN ERHA 
85 BEAUMONT C DUBLIN ERHA 
86 BEAUMONT D DUBLIN ERHA 
88 BEAUMONT F DUBLIN ERHA 
91 BOTANIC C DUBLIN ERHA 
97 CABRA WEST C DUBLIN ERHA 
99 CLONTARF EAST A DUBLIN ERHA 
100 CLONTARF EAST B DUBLIN ERHA 
109 DRUMCONDRA SOUTH A DUBLIN ERHA 
112 EDENMORE DUBLIN ERHA 
113 FINGLAS NORTH A DUBLIN ERHA 
114 FINGLAS NORTH B DUBLIN ERHA 
115 FINGLAS NORTH C DUBLIN ERHA 
120 GRACE PARK DUBLIN ERHA 
136 MOUNTJOY B DUBLIN ERHA 
140 NORTH DOCK C DUBLIN ERHA 
142 PRIORSWOOD A DUBLIN ERHA 
149 RAHENY-ST.ASSAM DUBLIN ERHA 
162 CRUMLIN B DUBLIN ERHA 
166 CRUMLIN F DUBLIN ERHA 
168 DRUMFINN DUBLIN ERHA 
173 KILMAINHAM C DUBLIN ERHA 
177 KIMMAGE D DUBLIN ERHA 
179 KYLEMORE DUBLIN ERHA 
183 MERCHANTS QUAY B DUBLIN ERHA 
184 MERCHANTS QUAY C DUBLIN ERHA 
188 PEMBROKE EAST A DUBLIN ERHA 
190 PEMBROKE EAST C DUBLIN ERHA 
192 PEMBROKE EAST E DUBLIN ERHA 
194 PEMBROKE WEST B DUBLIN ERHA 
195 PEMBROKE WEST C DUBLIN ERHA 
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Sample 
Point Area Detail County 
Former Health 
Board 
201 RATHMINES WEST A DUBLIN ERHA 
205 RATHMINES WEST E DUBLIN ERHA 
206 RATHMINES WEST F DUBLIN ERHA 
207 ROYAL EXCHANGE A DUBLIN ERHA 
209 SAINT KEVIN'S DUBLIN ERHA 
210 SOUTH DOCK DUBLIN ERHA 
213 TERENURE C DUBLIN ERHA 
215 USHERS A DUBLIN ERHA 
216 USHERS B DUBLIN ERHA 
219 USHERS E DUBLIN ERHA 
220 USHERS F DUBLIN ERHA 
225 WOOD QUAY B DUBLIN ERHA 
228 BALLINTEER-LUDFORD DUBLIN ERHA 
229 BALLINTEER-MARLEY DUBLIN ERHA 
230 BALLINTEER-MEADOWBROADS DUBLIN ERHA 
232 BALLINTEER-WOODPARK DUBLIN ERHA 
236 BLACKROCK-CENTRAL DUBLIN ERHA 
237 BLACKROCK-GLENOMENA DUBLIN ERHA 
238 BLACKROCK-MONKSTOWN DUBLIN ERHA 
242 BLACKROCK-TEMPLEHILL DUBLIN ERHA 
247 CABINTEELY-POTTERY DUBLIN ERHA 
259 DALKEY-BULLOCK DUBLIN ERHA 
261 DALKEY HILL DUBLIN ERHA 
262 DALKEY UPPER DUBLIN ERHA 
265 DUNDRUM-SANDYFORD DUBLIN ERHA 
266 DUNDRUM-SWEETMOUNT DUBLIN ERHA 
271 DUN LAOGHAIRE-MONKSTOWN FARM DUBLIN ERHA 
273 DUN LAOGHAIRE-SALLYNOGGIN EAST DUBLIN ERHA 
274 DUN LAOGHAIRE-SALLYNOGGIN 
SOUTH 
DUBLIN ERHA 
276 DUN LAOGHAIRE-SANDYCOVE DUBLIN ERHA 
283 GLENCULLEN DUBLIN ERHA 
285 KILLINEY SOUTH DUBLIN ERHA 
286 SHANKILL-RATHMICHAEL DUBLIN ERHA 
299 BALBRIGGAN URBAN DUBLIN ERHA 
300 BALDOYLE DUBLIN ERHA 
301 BALGRIFFIN DUBLIN ERHA 
305 BLANCHARDSTOWN-BLAKESTOWN DUBLIN ERHA 
307 BLANCHARDSTOWN-CORDUFF DUBLIN ERHA 
312 CASTLEKNOCK-KNOCKMAROON DUBLIN ERHA 
313 CASTLEKNOCK-PARK DUBLIN ERHA 
315 DONABATE DUBLIN ERHA 
320 HOWTH DUBLIN ERHA 
327 PORTMARNOCK NORTH DUBLIN ERHA 
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Sample 
Point Area Detail County 
Former Health 
Board 
330 SKERRIES KILDARE ERHA 
331 SUTTON DUBLIN ERHA 
332 SWORDS-FORREST DUBLIN ERHA 
333 SWORDS-GLASMORE DUBLIN ERHA 
334 SWORDS-LISSENHALL DUBLIN ERHA 
335 SWORDS-SEATOWN DUBLIN ERHA 
392 ATHY URBAN WEST KILDARE ERHA 
395 NAAS URBAN KILDARE ERHA 
397 ATHY RURAL KILDARE ERHA 
428 CELBRIDGE KILDARE ERHA 
433 LEIXLIP KILDARE ERHA 
434 MAYNOOTH KILDARE ERHA 
441 CLONCURRY KILDARE ERHA 
455 BODENSTOWN KILDARE ERHA 
458 CLANE KILDARE ERHA 
461 DROICHEAD NUA RURAL KILDARE ERHA 
468 KILL KILDARE ERHA 
474 MORRISTOWNBILLER KILDARE ERHA 
480 RATHERNAN KILDARE ERHA 
482 ROBERTSTOWN KILDARE ERHA 
341 BALLYBODEN DUBLIN ERHA 
345 CLONDALKIN-DUNAWLEY DUBLIN ERHA 
346 CLONDALKIN-MONASTERY DUBLIN ERHA 
348 CLONDALKIN-ROWLAGH DUBLIN ERHA 
349 CLONDALKIN VILLAGE DUBLIN ERHA 
351 FIRHOUSE-BALLYCULLEN DUBLIN ERHA 
353 FIRHOUSE VILLAGE DUBLIN ERHA 
354 LUCAN-ESKER DUBLIN ERHA 
356 LUCAN- ST.HELENS DUBLIN ERHA 
358 PALMERSTON VILLAGE DUBLIN ERHA 
359 PALMERSTON WEST DUBLIN ERHA 
364 RATHFARNHAM- ST. ENDA'S DUBLIN ERHA 
366 SAGGART DUBLIN ERHA 
369 TALLAGHT-FETTERCAIRN DUBLIN ERHA 
371 TALLAGHT-JOBSTOWN DUBLIN ERHA 
374 TALLAGHT-KILTIPPER DUBLIN ERHA 
377 TALLAGHT-OLDBAWN DUBLIN ERHA 
378 TALLAGHT-SPRINGFIELD DUBLIN ERHA 
381 TEMPLEOGUE-KIMMAGE MANOR DUBLIN ERHA 
386 TERENURE-CHERRYFIELD DUBLIN ERHA 
1276 ARKLOW NO.1 URBAN WICKLOW ERHA 
1281 BRAY URBAN NO.3 WICKLOW ERHA 
1285 WICKLOW URBAN WICKLOW ERHA 
1295 HARTSTOWN WICKLOW ERHA 
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Sample 
Point Area Detail County 
Former Health 
Board 
1312 DELGANY WICKLOW ERHA 
1314 GREYSTONES WICKLOW ERHA 
1283 KILMACANOGE WICKLOW ERHA 
1341 NEWCASTLE LOWER WICKLOW ERHA 
1342 NEWCASTLE UPPER WICKLOW ERHA 
1343 OLDTOWN WICKLOW ERHA 
1353 CARNEW WICKLOW ERHA 
1364 TINAHELY WICKLOW ERHA 
620 COLT LAOIS MHB 
653 BALLYBRITTAS LAOIS MHB 
656 BORRIS LAOIS MHB 
672 KILMULLEN LAOIS MHB 
678 MOUNTMELLICK URBAN LAOIS MHB 
683 PORTLAOIGHISE RURAL LAOIS MHB 
684 PORTLAOIGHISE URBAN LAOIS MHB 
708 GRAIGUE RURAL LAOIS MHB 
715 LONGFORD NO.1 URBAN LONGFORD MHB 
719 AGHARRA LONGFORD MHB 
720 BALLYMAHON LONGFORD MHB 
761 CALDRAGH LONGFORD MHB 
935 BIRR URBAN OFFALY MHB 
937 TULLAMORE URBAN OFFALY MHB 
943 CLOGHAN OFFALY MHB 
948 DROMOYLE OFFALY MHB 
969 SRAH OFFALY MHB 
1004 DAINGEAN OFFALY MHB 
1005 DERRYCOOLY OFFALY MHB 
1018 RAHAN OFFALY MHB 
1026 TULLAMORE RURAL OFFALY MHB 
1041 MOATE WESTMEATH MHB 
1043 MOYDRUM WESTMEATH MHB 
1060 FINNEA WESTMEATH MHB 
1073 DELVIN WESTMEATH MHB 
1103 ENNISCOFFEY WESTMEATH MHB 
1115 KILLUCAN WESTMEATH MHB 
1116 KINNEGAD WESTMEATH MHB 
1122 MULLINGAR RURAL WESTMEATH MHB 
1123 MULLINGAR NORTH URBAN WESTMEATH MHB 
1124 MULLINGAR SOUTH URBAN WESTMEATH MHB 
1367 ENNIS URBAN NO.1 CLARE MWHB 
1375 KILRUSH URBAN CLARE MWHB 
1400 CLENAGH CLARE MWHB 
1372 ENNIS RURAL CLARE MWHB 
1432 KILLILAGH CLARE MWHB 
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Sample 
Point Area Detail County 
Former Health 
Board 
1462 KILBALLYOWEN CLARE MWHB 
1467 KILMIHIL CLARE MWHB 
1482 BALLYCANNAN CLARE MWHB 
1489 FAHYMORE CLARE MWHB 
2143 ABBEY B LIMERICK MWHB 
2150 CASTLE B LIMERICK MWHB 
2160 GALVONE A LIMERICK MWHB 
2178 SINGLAND B LIMERICK MWHB 
2199 KILPEACON LIMERICK MWHB 
2202 FLEANMORE LIMERICK MWHB 
2204 KILFERGUS LIMERICK MWHB 
2213 CAHERCORNEY LIMERICK MWHB 
2225 KNOCKAINY LIMERICK MWHB 
2232 ABINGTON TIPPERARY MWHB 
2234 BALLYCUMMIN LIMERICK MWHB 
2235 BALLYSIMON LIMERICK MWHB 
2236 BALLYVARRA LIMERICK MWHB 
2240 CAPPAMORE LIMERICK MWHB 
2248 LIMERICK NORTH RURAL LIMERICK MWHB 
3669 CARRICKATEE MONAGHAN NEHB 
3673 CREMARTIN MONAGHAN NEHB 
3474 BUNCRANA URBAN DONEGAL NWHB 
3478 LETTERKENNY URBAN DONEGAL NWHB 
3496 EANYMORE DONEGAL NWHB 
3503 TANTALLON DONEGAL NWHB 
3516 MAGHERACLOGHER DONEGAL NWHB 
3537 KILLYBEGS DONEGAL NWHB 
3541 MAGHERY DONEGAL NWHB 
3542 MALINBEG DONEGAL NWHB 
3551 BURT DONEGAL NWHB 
3557 DESERTEGNY DONEGAL NWHB 
3564 ILLIES DONEGAL NWHB 
3566 KILDERRY DONEGAL NWHB 
3579 CASTLEWRAY DONEGAL NWHB 
3588 MAGHERABOY DONEGAL NWHB 
3594 CARRICKART DONEGAL NWHB 
3606 MILLFORD DONEGAL NWHB 
3611 TERMON DONEGAL NWHB 
3622 FIGART DONEGAL NWHB 
3623 GLENEELY DONEGAL NWHB 
2923 NEWTOWNGORE LEITRIM NWHB 
2930 CARRICK-on-SHANNON LEITRIM NWHB 
2953 BELHAVEL LEITRIM NWHB 
2992 MOHILL LEITRIM NWHB 
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Sample 
Point Area Detail County 
Former Health 
Board 
3285 SLIGO EAST URBAN SLIGO NWHB 
3286 SLIGO NORTH URBAN SLIGO NWHB 
3287 SLIGO WEST URBAN SLIGO NWHB 
3306 CASTLECONOR WEST SLIGO NWHB 
3308 DROMARD WEST SLIGO NWHB 
3323 BALLYMOTE SLIGO NWHB 
3332 CLIFFONY SOUTH SLIGO NWHB 
3354 BANADA SLIGO NWHB 
8 HACKETSTOWN CARLOW SEHB 
5 CARLOW RURAL CARLOW SEHB 
488 KILKENNY NO.1 URBAN KILKENNY SEHB 
489 KILKENNY NO.2 URBAN KILKENNY SEHB 
500 KILMANAGH KILKENNY SEHB 
510 TUBBRID TIPPERARY SEHB 
542 KILKENNY RURAL KILKENNY SEHB 
594 AGLISH KILKENNY SEHB 
605 PORTNASCULLY KILKENNY SEHB 
2421 CLONMEL WEST URBAN TIPPERARY SEHB 
2435 BALLYSHEEHAN TIPPERARY SEHB 
2462 CAHER TIPPERARY SEHB 
2472 TULLAGHORTON TIPPERARY SEHB 
2422 CLONMEL RURAL TIPPERARY SEHB 
2507 DRUMWOOD TIPPERARY SEHB 
2523 BALLYBEG NORTH WATERFORD SEHB 
2524 BALLYBEG SOUTH WATERFORD SEHB 
2533 CLEABOY WATERFORD SEHB 
2540 GRANGE SOUTH WATERFORD SEHB 
2568 CLONEA WATERFORD SEHB 
2600 SESKINAN WATERFORD SEHB 
2633 LISMORE URBAN WATERFORD SEHB 
2651 TRAMORE WATERFORD SEHB 
1142 ENNISCORTHY URBAN WEXFORD SEHB 
1145 NEW ROSS URBAN WEXFORD SEHB 
1156 BALLYHUSKARD WEXFORD SEHB 
1189 BALLYCANEW WEXFORD SEHB 
1195 COOLGREANY WEXFORD SEHB 
1198 GOREY RURAL WEXFORD SEHB 
1219 CARRICKBYRNE WEXFORD SEHB 
1236 TEMPLETOWN WEXFORD SEHB 
1245 BALLYMITTY WEXFORD SEHB 
1251 FORTH WEXFORD SEHB 
1268 ST. HELEN'S WEXFORD SEHB 
1272 WEXFORD RURAL WEXFORD SEHB 
1539 BALLYPHEHANE A CORK SHB 
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Sample 
Point Area Detail County 
Former Health 
Board 
1542 BISHOPSTOWN B CORK SHB 
1543 BISHOPSTOWN C CORK SHB 
1550 CENTRE B WATERFORD SHB 
1567 GLASHEEN C CORK SHB 
1574 KNOCKNAHEENY CORK SHB 
1576 KNOCKREA B CORK SHB 
1578 MAHON B CORK SHB 
1579 MAHON C CORK SHB 
1581 MAYFIELD CORK SHB 
1583 MONTENOTTE B CORK SHB 
1587 ST. PATRICK'S LEITRIM SHB 
1597 THE GLEN B CORK SHB 
1620 MACROOM URBAN CORK SHB 
1629 YOUGHAL URBAN CORK SHB 
1633 BALLYMODAN CORK SHB 
1663 MEALAGH CORK SHB 
1692 KNOCKS CORK SHB 
1700 BALLYGARVAN CORK SHB 
1704 BLARNEY CORK SHB 
1706 CARRIGALINE CORK SHB 
1709 COBH RURAL CORK SHB 
1710 DOUGLAS CORK SHB 
1716 INISHKENNY CORK SHB 
1720 LEHENAGH CORK SHB 
1725 RATHCOONEY CORK SHB 
1726 RIVERSTOWN CORK SHB 
1727 ST. MARY'S CORK SHB 
1739 DUNMANWAY NORTH CORK SHB 
1742 KINNEIGH CORK SHB 
1774 BANTEER CORK SHB 
1810 BALLYMARTLE CORK SHB 
1847 SLIEVEREAGH CORK SHB 
1849 WARRENSCOURT CORK SHB 
1851 ARDSKEAGH CORK SHB 
1865 MALLOW RURAL CORK SHB 
1869 RATHLUIRC CORK SHB 
1874 TEMPLEMARY CORK SHB 
1898 COOMLOGANE CORK SHB 
1903 DRISHANE CORK SHB 
2036 BALLYHAR KERRY SHB 
2076 CLOONTUBBRID KERRY SHB 
2082 KILFEIGHNY KERRY SHB 
2091 LISTOWEL RURAL KERRY SHB 
2107 BALLYNAHAGLISH KERRY SHB 
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Sample 
Point Area Detail County 
Former Health 
Board 
2109 BALLYSEEDY KERRY SHB 
2119 CRINNY KERRY SHB 
2131 KNOCKNAGASHEL KERRY SHB 
1971 TRALEE RURAL KERRY SHB 
2663 BALLYBAAN GALWAY WHB 
2665 BARNA GALWAY WHB 
2667 CLADDAGH GALWAY WHB 
2668 DANGAN GALWAY WHB 
2672 MENLOUGH GALWAY WHB 
2673 MERVUE GALWAY WHB 
2683 TAYLORS HILL GALWAY WHB 
2687 BALLINASLOE URBAN GALWAY WHB 
2700 KILLORAN GALWAY WHB 
2727 SKANNIVE GALWAY WHB 
2729 ANNAGHDOWN GALWAY WHB 
2730 AUGHRIM GALWAY WHB 
2735 CARNMORE GALWAY WHB 
2760 CREGGS GALWAY WHB 
2778 CASTLETAYLOR GALWAY WHB 
2811 KILLOGILLEEN GALWAY WHB 
2820 LOUGHREA URBAN GALWAY WHB 
2853 OUGHTERARD GALWAY WHB 
2855 TURLOUGH MAYO WHB 
2870 PORTUMNA GALWAY WHB 
2895 HILLSBROOK GALWAY WHB 
2911 TUAM RURAL GALWAY WHB 
3005 CASTLEBAR URBAN MAYO WHB 
3008 WESTPORT URBAN MAYO WHB 
3035 RATHOMA MAYO WHB 
3037 SRAHEEN MAYO WHB 
3040 BALLINROBE MAYO WHB 
3006 CASTLEBAR RURAL MAYO WHB 
3100 COURSE MAYO WHB 
3129 SWINEFORD MAYO WHB 
3147 DOOEGA MAYO WHB 
3151 GLENHEST MAYO WHB 
3227 BALLINLOUGH ROSCOMMON WHB 
3234 CASTLEREAGH ROSCOMMON WHB 
3247 BALLYGARDEN ROSCOMMON WHB 
2286 NEWCASTLE RURAL LIMERICK MWHB 
2293 ASKEATON EAST LIMERICK MWHB 
2312 PALLASKENRY LIMERICK MWHB 
2329 TEMPLEMORE TIPPERARY MWHB 
2331 THURLES URBAN TIPPERARY MWHB 
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Sample 
Point Area Detail County 
Former Health 
Board 
2336 BORRISOKANE TIPPERARY MWHB 
2371 KILNANEAVE TIPPERARY MWHB 
2375 LATTERAGH TIPPERARY MWHB 
2402 LITTLETON TIPPERARY MWHB 
2410 THURLES RURAL TIPPERARY MWHB 
3404 BALLYJAMESDUFF CAVAN NEHB 
3406 KILBRIDE CAVAN NEHB 
3417 BELLANANAGH CAVAN NEHB 
3434 DERRIN CAVAN NEHB 
3448 MILLTOWN CAVAN NEHB 
3449 MOYNEHALL CAVAN NEHB 
3456 WATERLOO CAVAN NEHB 
776 FAIR GATE LOUTH NEHB 
777 ST. LAURENCE GATE LOUTH NEHB 
778 WEST GATE LOUTH NEHB 
783 DUNDALK URBAN NO.2 LOUTH NEHB 
785 DUNDALK URBAN NO.4 LOUTH NEHB 
790 ARDEE RURAL LOUTH NEHB 
798 DUNLEER LOUTH NEHB 
800 TALLANSTOWN LOUTH NEHB 
808 DARVER LOUTH NEHB 
787 DUNDALK RURAL LOUTH NEHB 
813 HAGGARDSTOWN LOUTH NEHB 
780 ST. MARY'S MEATH NEHB 
832 NAVAN URBAN MEATH NEHB 
843 DONAGHMORE MEATH NEHB 
844 DUNBOYNE MEATH NEHB 
852 RODANSTOWN MEATH NEHB 
871 MOYNALTY MEATH NEHB 
881 DULEEK MEATH NEHB 
892 KENTSTOWN MEATH NEHB 
893 NAVAN RURAL MEATH NEHB 
906 OLDCASTLE MEATH NEHB 
932 TRIM RURAL MEATH NEHB 
3636 CARRICKMACROSS URBAN MONAGHAN NEHB 
3644 MONAGHAN URBAN MONAGHAN NEHB 
3647 BALLYMACKNEY MONAGHAN NEHB 
3652 DONAGHMOYNE MONAGHAN NEHB 
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1  CONFIDENCE INTERVALS FOR PROPORTIONS 
 
Sampling 
 
For the NACD population surveys, not all persons in the sampling frame were interviewed, but only a 
relative small selection of about 5,000 persons, the sample. Hence, the prevalence rates calculated from 
the sample are only estimates of the prevalence rate in the frame population. The same sample design, 
i.e. the same procedure to derive the sample, could have resulted in an almost infinite number of 
different samples. If prevalence rates would be calculated for these potential samples, the estimated 
prevalence rates would vary somewhat. This variation is called the sampling variance. The higher the 
sampling variance the lower the precision of an estimate derived from a particular sample.  
 
Confidence intervals 
 
For the evaluation of the findings of the NACD population surveys it is therefore useful to provide not 
only the sample prevalence rate as estimate of the population prevalence rate, the point estimate, but 
also an indication of how reliable or precise this estimate is.  Such an indication is provided by 
confidence intervals. A confidence interval is an interval estimate for a population parameter with an 
associated probability, the confidence level. For studies like the NACD drug prevalence studies, the 
confidence level is typically 95%. A 95%-confidence interval means that if the sampling was repeated 
numerous times and a confidence interval calculated for each sample, 95 percent of the confidence 
intervals should contain the population prevalence rate. 
 
Quality of methods to estimate confidence intervals  
 
There are many different methods to estimate confidence intervals. Given the variety of methods, 
researchers should select methods to determine confidence intervals that are best suited for the purpose 
of their study. The main criterion to evaluate the quality of a confidence interval method is how likely 
confidence intervals estimated by a specific method cover the population value. The confidence level 
of a confidence interval is also called the nominal coverage. The question of how the actual coverage 
of a confidence interval compares with the nominal coverage is typically examined in simulation 
studies where samples are repeatedly drawn from a population with known characteristics. The 
percentage of confidence intervals containing the population rate is established and this coverage 
probability is compared with the nominal coverage. Under-coverage is considered to be undesirable, 
i.e. the percentage of confidence intervals covering the population rate should not be systematically 
smaller than the confidence level. Given satisfactory coverage, the width of the confidence intervals is 
a second criterion, where more narrow confidence intervals are preferred to wider ones. Finally, 
consideration should be given to computational requirements. 
 
The ‘conservatism’ issue 
 
While there is general agreement that under-coverage should be avoided, there is some disagreement of 
what characterises a confidence interval with good coverage properties. Confidence interval methods 
do not perform uniformly across all possible combinations of prevalence rates in the population, π, and 
samples of different sizes n. The first position is that a good method to determine confidence intervals 
should guarantee at least a coverage probability that is equal to the nominal coverage. This means that a 
95% percent confidence interval should in all possible circumstances cover the population parameter in 
not less than 95 percent of the samples. This position has been criticised as ‘too conservative’ (e.g., 
Agresti and Coul, 1998; Brown et al., 2001). The alternative position is that a good method is 
characterised by confidence intervals where – across all possible combinations of population 
proportions and sample sizes – the actual coverage on average equals the nominal coverage. 
 
We adopt in the evaluation of the methods a differentiated approach: With regard to confidence 
intervals for prevalence rates we choose a more conservative or cautious position, arguing for methods 
that guarantee actual coverage of at least the nominal value for the combinations of population 
proportions and sample sizes that are relevant in the drug surveys. With regard to confidence for 
differences between proportions, i.e. comparisons between the 2002 and 2006 surveys, we prefer a less 
strict position. With regard to comparisons, the construction of the confidence intervals is directly 
related to hypotheses testing. In this context the avoidance of ‘false negatives’ is important: We wish to 
know whether the data provide enough evidence to reject the null-hypothesis that the prevalence rate 
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has not changed between 2002 and 2006 (and that observed differences in the prevalence rates are due 
to sampling error). In a hypothesis testing framework, two potential sources of error have to be 
considered: The likelihood that the null-hypothesis is rejected although the null-hypothesis is true (false 
positives) and the likelihood that the null-hypothesis is not rejected although the alternative hypothesis 
is true (false negatives). A more conservative approach to testing has as a consequence that the 
likelihood of false negatives increases, i.e. that the null hypothesis that drug use did not change 
between 2002 and 2006 is not rejected in spite of ‘sufficient evidence’ to the contrary. With regard to 
the prevalence rates, we adopt a more conservative position as there are no meaningful null or 
alternative hypotheses regarding the prevalence rates. 
 
Sampling distribution of proportions 
 
In order to calculate confidence intervals, an idea about the sampling distribution of the statistic in 
question is needed. The sampling distribution of a rate (i.e. a proportion) is binomially distributed. The 
shape of the sampling distribution depends on the ‘true’ prevalence rate in the population, π, and – in 
the case of simple random sampling -- the sample size n. The mean of the sampling distribution is π 
and the variance σ2 = π(1- π)/n. Further, the sampling distribution of a proportion is not symmetric (if π 
is not exactly .5). The measure for the degree of asymmetry is called skewness. The skewness of the 
sampling distribution of a rate is a function of the population proportion and the sampling variance:  γ 
= (1-2 π)/σ, i.e. the smaller π (for π < .5), the more the mass of the distribution is concentrated on the 
left of the mean and the longer the right tail (positively skewed), and the larger π (for π < .5), the more 
the mass of the distribution is concentrated on the right of the mean and the longer the left tail 
(negatively skewed).  
 
Confidence Intervals for single proportions: Wald 
 
The standard method to calculate confidence intervals for rates is not based on the (binomial) sampling 
distribution, but on the approximation of the sampling distribution by the normal distribution. The 
normal approximation method of determining confidence intervals is based on the inverted Wald test 
(Wald procedure). The limits of the confidence is given by:  
 
⎥⎦
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⎡ −+−−
n
ppzp
n
ppzp )
ˆ1(ˆˆ;)
ˆ1(ˆˆ 2/2/ αα   
 
where  
pˆ  is the sample proportion  
n is the sample size 
2/αz  is the value of the standard normal distribution such that the area to its right is equal to alpha/2. 
 
Quality of Wald intervals 
 
The Wald method has various deficiencies which are mainly related to the fact that the normal 
approximation does not reflect the skewness of the sampling distribution of proportions and that the 
width of the confidence interval converges towards zero when sample probability approaches zero. 
Various studies showed that the Wald method generates confidence intervals that grossly undercover 
the population parameter. The under-coverage is more severe when samples are small and when the 
population parameter is close to 0 percent (or close to 100 percent). While the former poses no problem 
for surveys with substantial sample size, the latter is a problem in drug prevalence studies. Prevalence 
rates for drug use are close to zero for many drugs and subpopulations in the population surveys. 
Therefore, Wald confidence intervals should not be used for population surveys on drug use. Wald 
confidence intervals have the additional problem that they provide no meaningful confidence intervals 
for rates that are zero and can generate lower 
confidence limits that are smaller than zero (over-shooting).  
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Confidence Intervals for single proportions: Clopper-Pearson 
 
The Clopper-Pearson procedure to compute two-sided confidence intervals is based on the binomial 
procedure (Clopper and Pearson, 1937). The interval estimator is obtained by inverting the test 
procedure for two one-sided hypotheses, one for the lower limit and the other for the upper bound.  
Due to the relationship of the cumulative binomial and beta distributions, the following formula for the 
confidence interval can be derived as a function of the observed number of drug users k and the sample 
size n (e.g., Krishnamoorthy, 2006: 38): 
 [ ]);1;2/1();1;;2/( 11 knkknk −+−ℑ+−ℑ −− αα  for 0 < k < n; [ ]);1;2/1(;0 1 knk −+−ℑ− α  for k=0; [ ]1);1;;2/(1 +−ℑ− knkα  for k=n. 
 
where  is the inverse function of the beta distribution with quantile p and shape 
parameters a and b.  
);;(1 bap−ℑ
 
Quality of Clopper-Pearson intervals 
 
Clopper-Pearson confidence intervals guarantee an actual coverage that is at least as high as nominal 
coverage, i.e. a 95%-confidence intervals covers the population rate with a probability larger than 95 
percent. Clopper-Pearson intervals can show substantially higher coverage than the nominal coverage. 
However, the problem of over-coverage is less severe for large samples as the actual coverage 
approximates the nominal coverage with increasing n (Agresti, 2003). The results of one simulation 
study are particularly relevant for drug prevalence surveys because the study examines combinations of 
k and n how they are typically found in the drug prevalence surveys (Tobi et al., 2005). This study 
recommended the Clopper-Pearson procedure and showed that they generate confidence intervals that 
have higher coverage but are not wider than the highly regarded Wilson score method (see below; Tobi 
et al., 2005). 
 
Confidence Intervals for difference between independent proportions: Wald 
 
For the difference between rates, the standard method is again a Wald procedure (Wald confidence 
intervals for differences between proportions of independent samples). The limits of the Wald 
confidence intervals are given by::  
 
 
⎥⎥⎦
⎤
⎢⎢⎣
⎡ −+−+−−+−−−
2
22
2
11
2/21
2
22
2
11
2/21
)ˆ1(ˆ)ˆ1(ˆ
)ˆˆ(;
)ˆ1(ˆ)ˆ1(ˆ
)ˆˆ(
n
pp
n
ppzpp
n
pp
n
ppzpp αα   
 
where p1 hat and p2 hat are the proportions observed in the first and the second sample and n1 and n2 the 
respective sample sizes.  
 
Quality of Wald intervals for difference between proportions 
 
For differences between rates, the Wald procedure shows similar coverage and overshoot problems as 
the Wald procedure for single proportions (Newcombe, 1998; Agresti and Coull, 2001). The 
performance of Wald is particularly problematic if either p1 or p2 approaches 0, conditions frequently 
met in the drug surveys. 
 
Confidence Intervals for difference between independent proportions: Newcombe’s hybrid score 
method 
 
However, exact confidence intervals for the difference between proportions of independent samples 
(analogous to the Clopper-Pearson procedure for single proportions) are very difficult to compute. 
Newcombe (1998) has developed a ‘hybrid score method’ that is easier to compute than exact methods 
but avoids the pitfalls of the Wald method.  
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Exact confidence intervals for the difference between proportions of independent samples (analogous 
to the Clopper-Pearson procedure for single proportions) are very difficult to compute. Newcombe 
(1998) has developed a ‘hybrid score method’ that is easier to compute than exact methods but avoids 
the pitfalls of the Wald method.  Newcombe hybrid score method is based on Wilson’s score method 
(Wilson, 1927) for single proportion. Wilson score method derives a midpoint for the confidence 
intervals as a weighted average of the sample proportion and .5 (with the sample proportion gaining 
greater weight as the sample size rise). Further, the weighted average of the variance of the observed 
sample proportion and the variance of a proportion of .5 is used instead of the variance of the sample 
proportion as estimate of the sampling variation. 
 
The Wilson score method derives the following confidence interval for the proportion estimate of 
sample i:  
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For two samples 1 and 2 with p1 hat > p2 hat, the Newcombe hybrid score confidence interval for the 
difference between the proportion is derived from the lower and upper limits of the Wilson score 
intervals for single proportions: 
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Quality of Newcombe hybrid score intervals 
 
In several studies of the coverage qualities of confidence intervals for the difference between 
proportions, Newcombe hybrid score method belonged to the best-performing methods (while Wald 
was always the poorest performing method). 
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2  DESIGN EFFECTS 
 
Complex surveys and sampling 
variance  
 
The NACD population survey is a complex survey that differs in various aspects from single random 
sampling. As most population surveys that collect data by personal interviews, the survey uses a multi-
stage design. In the first stage, electoral districts are selected as primary sampling units. Within the 
electoral districts, residential addresses (households) are randomly selected as secondary sampling 
units. The number of secondary sampling units is roughly proportional to the population size of the 
primary sampling units. One member of each household is selected as final sampling unit following a 
quasi-random procedure. In the first stage, stratified random sampling is employed for the selection of 
the primary sampling units. The strata are formed by health board areas and - in order to secure 
sufficient sub-sample sizes for the smaller health board areas – the number of sampled primary units is 
disproportional to the size of the health board population resulting in different inclusion probabilities of 
the secondary sampling units. Finally, the resulting sample has been weighted in order to calibrate the 
age-gender distribution in the health boards with the population distribution according to the CSO 
census.  
 
The complexity of the sample design influences the point estimates of the prevalence rates only by the 
fact that unequal inclusion probabilities – due to unequal selection probabilities ex ante or differences 
in response rates – have to been taken into account. Aiming to reduce sampling bias, point estimates 
derived from the NACD population surveys are based on the samples weighted by calibration (or post-
stratification) weights. However, interval estimates of the prevalence rates (confidence intervals) 
directly depend on the variance of the relevant statistics.  
 
Design Effect 
 
In complex surveys such as the NACD population surveys, the variance of the estimates is usually 
larger than in simple random sample. A measure for this variance inflation is the design effect (DEFF). 
The design effect is the ratio of the true variance of a statistic of a complex sample design to the 
variance of the statistics for a simple random sample with the same number of cases (Kish, 1995). 
Three aspects of complex designs affect the variance inflation: (1) stratification, (2) clustering, (3) 
weighting. 
 
(1) Stratification: Stratification tends to reduce the sampling variance; the variance deflation is stronger 
the lower the variation on the relevant variables within the strata and the higher the variation between 
the strata. Disproportional allocation in contrast tends to result in higher sampling variance compared 
with proportional allocation to strata.  
 
(2) Clustering: The NACD population survey uses a multi-stage design with Electoral districts as 
primary sampling units. These electoral districts are ‘clusters’. Clustering almost always leads to 
inflated sampling variance. The magnitude of the design effect due to clustering is dependent on two 
aspects, the size of the clusters and the homogeneity within the clusters. Large cluster size and low 
variation within the clusters increase the sampling variance.  
 
(3) Weighting: Weighting inflates more often than not the sampling variance. If weights are 
uncorrelated with the variation of the relevant variables, the design effect is larger the more the weights 
vary (this is the MORI ‘design effect’). It is however crucial whether groups with higher selection 
probabilities (smaller weights) exhibit larger variation on the survey variables. If the weights are 
negatively correlated with the variation on the relevant variables, sampling variance is deflated. Else, 
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weighting increases sampling variance, the more so the larger the variance of the weights and the 
stronger the correlation between weights and the variation on the survey variables.  
 
Effective sample size 
 
The effective sample size is the sample size under a simple random sample design that is equivalent to 
the actual sample under the complex sample design. The effective sample size can be determined by 
dividing the actual sample size by the design effect. For example, an actual sample of 5000 units and a 
design effect of 2 result in an effective sample size of 2500 units. The  same precision of the estimates 
could have been achieved by a simple random sample of half the size.  
 
Design effect estimation 
 
For a particular sample with a given design and post-survey adjustment procedure, design effects differ 
for different statistics, survey variables and subgroups. For the NACD population surveys, the design 
effects have been estimated by SPSS 14.0 Complex Samples. In order to derive an estimate of the 
sampling variance, SPSS uses the Taylor series linearization method. This method is the most widely 
used method. 
 
For the estimation of the design effects, the following design parameter have been used: 
 
Weights 
Probability weights are calculated by multiplying the frequency weights provided by Ipsos MORI with 
the ratio of the population size (according to the CSO 2002 census and CSO 2006 census, respectively) 
and the actual sample size. The frequency weights are post-stratification weights. The weights are 
based on ratio of the population and sample frequencies of age X gender X health board area cells. The 
resulting probability weights corresponds with  
 
S
ijk
Census
ijk
ijk h
h
wgt =  
 
where hCensus is the stratum size according to the CSO census Estimate and hS is the stratum size in the 
NACD surveys; 
and i (= 1 to 8) refers to the health board area, j (=1 to 2) to gender and k (=1 to 5) to age group. 
 
Strata 
Health board areas were specified as strata with inclusion probabilities equal to reciprocal of the 
stratum mean of the probability weight.  
 
Cluster 
Electoral districts were used as clusters 
Sampling 
Random sampling without replacement 
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Relative weight of stratification, 
clustering and weighting 
 
Table 1 illustrates the relative influence of stratification, clustering and weighting on the total design 
effect for prevalence rates of selected drugs. DEFFStrat is the estimated design effect if the sample 
would have been stratified, but neither clustered or weighted. DEFFClus is the isolated design effect of 
clustering and DEFFWeigh represents the design effect due to weighting. DEFFTotal is the combined 
design effect of stratification, clustering and weighting. Due to interactions between the three 
components, DEFFTotal is not exactly the product of the three isolated design effects. The design effects 
associated with stratification smaller than one indicating that stratification tends to increase the 
sampling efficiency. However, health board strata are internally not particularly homogenous as 
reflected in the fact that the values are close to one. The design effects associated with weighting are 
more substantial and reflect the fact that groups with lower response probabilities (larger weights) such 
as young peoples and males tend to use the drugs more likely. Clustering accounts for the largest share 
of the design effect and its variation. That reflects the fact that area of residence (or neighbourhood) 
affects drug consumption habits to a strong degree and that this ‘neighbourhood effect’ differs largely 
for different drugs. 
 
Table1:  
Decomposition of total design effect – selected drugs, lifetime, ROI 2006 
 
Drug  DEFFTotal DEFFStrat DEFFClus DEFFWeigh 
Cannabis 2.324 0.984 2.058 1.223 
Heroin   1.047 1.000 0.949 1.121 
Cocaine  1.571 0.994 1.283 1.319 
Ecstasy  1.827 0.996 1.536 1.304 
Any illegal drug  2.404 0.983 2.153 1.219 
 
Design effects: Descriptives 
 
Table 2 summarises the calculated design effects for the NACD 2002 and 2006 population surveys. 
The column DEFF presents the mean design effect and its standard deviation for all estimated design 
effects, the column DEFF(LIM) refers to the sample of design effects larger than one, i.e. the design 
effects that have been used in adjusting the confidence intervals. Design effects for the 2006 survey are 
slightly larger than for 2002 and for lifetime prevalence larger than for last year and last month 
prevalence. For males, they are larger than for females, and for young adults, in particular for the age 
bracket between 15-24 years, larger than for older adults. Design effects for cannabis, cocaine and 
ecstasy as well as for any illegal drug are relatively large. Relatively small design effects have been 
estimated for methadone, solvents and STAs, 
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Table 2: 
Design effect by sample, prevalence type, sub-sample and drug type 
 
 2002 2006 
 DEFF DEFF(LIM) DEFF DEFF(LIM) 
 Mean SD Mean SD Mean SD Mean SD 
Total 1.26 .25 1.27 .22 1.32 .35 1.34 .31 
Prevalence         
Lifetime 1.28 .26 1.29 .23 1.38 .34 1.39 .32 
Last Year 1.24 .23 1.26 .21 1.30 .34 1.33 .31 
Last Month 1.24 .25 1.26 .22 1.26 .35 1.29 .31 
Subsample         
All 1.40 .20 1.40 .20 1.49 .40 1.51 .38 
Males 1.39 .20 1.39 .20 1.63 .32 1.63 .32 
Females 1.20 .17 1.20 .16 1.03 .19 1.09 .12 
15-34 1.42 .18 1.42 .18 1.50 .31 1.50 .30 
35-64 1.06 .14 1.09 .12 1.20 .23 1.23 .18 
15-24 1.50 .15 1.50 .15 1.57 .26 1.57 .25 
25-34 1.23 .15 1.23 .14 1.35 .24 1.36 .21 
35-44 0.96 .10 1.02 .04 1.06 .19 1.11 .13 
45-54 1.22 .18 1.23 .18 1.20 .22 1.21 .20 
55-64 0.92 .15 1.01 .02 0.99 .17 1.05 .07 
Drug type         
Alcohol 1.11 .19 1.14 .15 1.26 .29 1.27 .27 
Tobacco 1.25 .22 1.25 .21 1.39 .23 1.39 .23 
Cannabis 1.40 .30 1.41 .28 1.64 .46 1.64 .46 
Opiates (Tot) 1.27 .28 1.29 .25 1.41 .34 1.42 .33 
Heroin 1.32 .18 1.32 .17 1.01 .26 1.11 .16 
Methadone 1.18 .17 1.18 .17 1.04 .23 1.11 .18 
Other opiates 1.20 .34 1.25 .25 1.45 .36 1.46 .35 
Cocaine (Tot) 1.34 .21 1.35 .21 1.40 .23 1.40 .23 
Crack 1.22 .21 1.23 .20 1.22 .24 1.25 .19 
Cocaine 1.35 .20 1.35 .20 1.41 .24 1.41 .24 
Amphetamines 1.29 .19 1.29 .19 1.26 .26 1.30 .20 
Ecstasy 1.32 .17 1.32 .17 1.48 .34 1.48 .34 
Hallucinogens 1.23 .25 1.25 .22 1.36 .38 1.38 .34 
LSD 1.23 .15 1.23 .15 1.27 .34 1.31 .29 
Magic mushr. 1.22 .26 1.25 .25 1.40 .28 1.40 .28 
STA 1.12 .13 1.14 .10 1.18 .19 1.18 .15 
Sed, Tranqu     1.14 .17 1.16 .15 
Anti-Depress     1.11 .13 1.12 .12 
Solvents 1.22 .22 1.23 .20 1.09 .32 1.19 .21 
Poppers 1.25 .23 1.26 .22 1.35 .29 1.37 .25 
Anabolic Stero     1.21 .39 1.29 .28 
Other illegal dr 1.10 .25 1.16 .18     
Any illegal dr 1.41 .32 1.42 .30 1.66 .48 1.66 .46 
 
192
 
NACD Drug Prevalence Study 2006-2007 
Ipsos MORI – Technical Report – DRAFT 4 – 01/04/08 
 
3 DESIGN-EFFECT ADJUSTED CONFIDENCE INTERVALS  
 
Confidence Intervals for single proportions with over-dispersion:  
deff-adjusted Clopper-Pearson  
 
Let and  be the estimates of the proportion and of the sampling variance of the proportion 
computed through proper estimation method for complex survey data:  
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Following Korn and Graubard (1998), the Clopper-Pearson procedure can be adjusted for complex 
designs (design-effect adjustment, deff-adjustment) by substituting n by n’ and k by k’: 
 [ ])'';1';2/1();1'';';2/( 11 knkknk −+−ℑ+−ℑ −− αα  for 0 < k < n; [ ])'';1';2/1(;0 1 knk −+−ℑ− α  for k=0; [ ]1);1'';';2/(1 +−ℑ− knkα  for k=n. 
 
Simulation studies show that the deff-adjusted Clopper_Pearson method has coverage probabilities 
closer to the nominal level than deff-adjusted logit transformation intervals, deff-adjusted normal based 
confidence intervals and the confidence intervals based on the classical Clopper-Pearson procedure 
(Korn and Graubard, 1998; Chen and Tipping, 2002).  
 
 
Confidence Intervals for difference between independent proportions with over-dispersion: deff-
adjusted Newcombe’s hybrid score method 
 
Wilson score method can be deff-adjusted by substituting the model based sampling variance estimate 
   by , the sampling variance properly calculated for complex design data, and 
the sample size n by the effective sample size n’ (cp., e.g., Sukasih and Jang, 2005): 
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For two samples 1 and 2 with p1 hat > p2 hat, the deff-adjusted Newcombe hybrid score confidence 
interval for the difference between the proportion is derived from the lower and upper limits of the 
deff-adjusted Wilson score intervals for single proportions: 
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To my knowledge, the coverage probabilities of confidence intervals computed by the deff-adjusted 
Newcombe hybrid score method have both been subject of a study. 
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Design effects smaller than one 
 
Confidence intervals and significance levels have been only adjusted for design effects if the estimated 
design effect is larger than one. In the case of design effect that are smaller than one the statistics has 
been calculated using the unadjusted procedures. This decision follows the practice of the US National 
Survey on Drug Use and Health (see Gordek and Folom, 2006). In cases, where the sampled number of 
positives (drug users) is zero, design effects cannot be calculated and the unadjusted procedures were 
used.  
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Q. Ballymun Survey – Summary    
1.  Introduction 
A smaller, booster survey was conducted in parallel with the nationwide study in the 
area of Ballymun, Dublin 10.  This survey, commissioned by Ballymun Local Drugs 
Task Force, which was designed to test the merit of conducting a local prevalence 
study.   
The same questionnaire as that used in the main survey was used, with the survey 
also conducted on CAPI.  Fieldwork was conducted in Ballymun from 8th January-12th 
May 2007, and an approximate sample size of 300 was agreed in order that the 
survey would provide robust and reliable data at a total sample level only.  A total of 
302 interviews were achieved. 
2.  Survey Design – Ballymun Survey 
It was agreed that 4 DEDs would be covered for the purposes of the Ballymun 
survey, i.e. Ballymun A,B,C and D.  However, it was agreed to interview at 20 
sampling points in order to provide a broad coverage of the defined area.  The target 
number of interviews was agreed at 300 and a 55% response rate was estimated.  
As such, a total of 650 addresses were sampled from the GeoDirectory to achieve 
this.  All other aspects of sampling was as per the main survey. All addresses drawn 
were compared with those from the main survey and any duplicates removed.  As 
with the main survey, letters were sent out in advance and incentives provided 
where necessary to boost the response rate amongst 15-24s. 
 
 Number of Sampling Points 
Ballymun Total 20 
BALLYMUN A 3 
BALLYMUN B 5 
BALLYMUN C 8 
BALLYMUN D 4 
 
All other aspects of the Ballymun survey remained identical to the national 
population study, from project design to interviewing approach via CAPI, using the 
same survey questionnaire and script.  Interviewers working on the Ballymun study 
were also working on the main study, and the same training, rigorous data checks 
and quality control procedures were adhered to. 
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3.  Fieldwork Observations – Ballymun Survey 
When the survey in Ballymun was commissioned, it was envisaged that Ipsos MORI 
interviewers living or working close to Ballymun itself would work on the study.  At 
the outset, twelve interviewers expressed an interest in carrying out fieldwork in 
Ballymun.  The majority of these had worked in the area before on other surveys, 
(albeit mostly on quota sampling work), although a few had also worked in Ballymun 
on the previous drug prevalence study.  At the briefing stage, interviewers generally 
expressed positive opinions about their previous experiences of interviewing in 
Ballymun, citing respondents who were generally easy to contact, friendly and co-
operative to interviewers. 
 
At the time of commissioning, the Ballymun area consisted of a range of dwellings, 
including large tower blocks of flats on fifteen levels, other blocks of flats on seven 
levels and other smaller housing areas.  Twenty sample points were selected across 
Ballymun A, B, C and D, to yield an average of 15 addresses per sample point.  
Random sampling of all of the addresses in these wards resulted in a sample 
encompassing all housing types.  Allocations to interviewers were made and at the 
beginning of fieldwork and it was anticipated that all the interviewing would be 
completed within 10 weeks.   
 
Making Contact at Selected Addresses 
 
Soon after fieldwork began, it became apparent that interviewing in Ballymun was 
likely to be more challenging than in the main population study.  Few interviews 
were conducted in the first few weeks, as interviewers struggled to get accustomed 
to working in areas where there was so much vacant and derelict property, which 
added to the difficulty of finding addresses. 
 
Certain interviewers requested to work in pairs, as they felt some of the areas they 
had been given to work in were unsafe.  (This suggestion had also been put forward  
with regard to other parts of the country in the main study). 
 
In Ballymun EDs ‘B’, ‘C’ and ‘D’ many of the addresses were from the tower blocks 
and these proved the most challenging for some interviewers.  Six of the sample 
points selected contained addresses from these tower blocks.  Some of the blocks 
were composed of flats on fifteen levels, with six flats per floor.  Under Dublin City 
Corporation’s clearance policy these blocks will in time all be demolished and modern 
apartment complexes built in their stead. During the fieldwork period of the study, 
the process of clearing the flats of tenants was well underway.  As each flat became 
vacant, the door was sealed off with a metal sheet.  As each floor was cleared of 
people the door to the level was blocked off similarly. 
 
If interviewers had an address or addresses from the tower blocks in their 
assignment, it had to be determined if the address was still occupied.  This was 
usually not apparent on entering the block.  Furthermore, some interviewers found 
the partially empty tower blocks of flats somewhat intimidating, with groups of 
young men sometimes congregated in and around these areas.  In many cases, the 
address proved to be unoccupied, or for other flats that appeared occupied, (i.e. not 
sheeted off), contact was not able to be made.  Further detail is provided in the 
response rate analysis.    
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One of the added difficulties encountered when trying to make contact at selected 
addresses in the tower blocks was the fact that the numbering of flats was often not 
present or had been defaced.  In some cases, the lifts in some of the tower blocks 
were also observed not to be functional or deemed unsafe. 
 
Another challenge encountered was in finding addresses in the “courts”.  Originally, 
houses had been built around small courtyards and later more housing was built to 
the sides of these.  These extensions were connected by walkways and paths, but 
due to security reasons (according to those dwelling there) many of these were 
sealed off.  The numbering of the houses was not sequential due to the building 
extensions and only those with local knowledge were able to direct interviewers to 
the selected address.   
 
Another problem with gaining access to the houses in the courts was that access for 
cars was typically at the rear of the house.  Residents usually expected only those 
familiar to them (e.g. family or friends) to use the rear entrances, so that anyone 
coming to the front door was perceived to be a stranger.  As with the main study, 
during the dark evenings many people did not answer their doors if they were not 
expecting a caller. 
 
Some interviewers had security concerns around carrying their CAPI laptop about in 
advance of securing an interview; to counter this, it was often left in the car until 
they had established whom in the household the selected respondent was, while 
others carried their laptop in a shopping bag. 
 
After some weeks in the field, the number of interviewers working in Ballymun 
dropped to seven or eight only at any one time and progress was much slower than 
had been anticipated. 
 
Securing the Interview 
 
Despite some of the difficulties outlined above, most interviewers who persevered 
with the study found interviewing in Ballymun to be a positive experience.   
 
They became adept in dealing with respondent queries, using the ‘Frequently Asked 
Questions’ sheet to help alleviate respondent concerns. 
 
There were refusals both at the initial contact stage and at the respondent selection 
procedure, which were observed to be somewhat higher than in the main study.  
However, the majority of people interviewed were described as warm and friendly, 
who made interviewers feel welcome in their homes and enjoyed participating in the 
research, providing what were deemed to be honest responses. 
 
While interviewers had some reservations about their personal safety at the outset, 
they found over time that these fears were unfounded.  Locals offered advice about 
when to be in the area, places to avoid, where to park and so on.  In summary, 
interviewers experienced no harassment or interference to their work. 
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4.  Number of Contacts – Ballymun Survey 
The following table outlines the number of calls that were required to achieve 
interviews in each DED area in Ballymun. 
 
Number of Calls 
ED One to Three 
Calls (%) 
Four to Five 
Calls (%) 
Six or More 
Calls (%) 
Average 
Ballymun Total 89% 10% 1% 1.83 
BALLYMUN A 85% 13% 2% 2.13 
BALLYMUN B 88% 13% 0% 2.05 
BALLYMUN C 95% 5% 0% 1.57 
BALLYMUN D 78% 19% 3% 2.14 
 
Overall, interviews were achieved after 1.83 contacts on average, which was slightly 
lower than the main study average of 2.0. There was variation across the DED areas.  
At one end of the spectrum, interviewers in the Ballymun ‘C’ DED area had the least 
difficulty, with 95% achieving their interviews within three contacts.  In the Ballymun 
‘D’ DED area meanwhile, 3% of all interviews required more than six calls to be 
completed. 
 
5.  Contact Sheet Details – Ballymun Survey 
As with the main study, in order to estimate the effects of non-response bias in the 
achieved sample, the contact sheet was used to ask interviewers to record, or 
estimate where necessary, the age, gender and ethnicity of the household of all 
those who refuse to take part.  Further, interviewers also coded the external features 
of households where contact had not been possible.  This information was compared 
with characteristics among the achieved sample to help assess its 
representativeness.  
Age & Gender 
The table below outlines the gender and age of those who refused to take part in the 
Ballymun survey. 
 
Area % of Sample % of Refusals 
Male 38% 59% 
Female 62% 41% 
15-24 years 17% 14% 
25-34 years 29% 22% 
35-44 years 25% 22% 
45-54 years 14% 33% 
55-64 years 15% 8% 
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Type of House 
It was also of critical interest to compare the social makeup of those who refused 
with the actual sample.  By the definition, it was not possible to gather data on the 
social classification of those who refused to take part, which could be directly 
compared with the survey results.  As a rough measure of the social composition of 
the sample and of those who refused to take part, the contact sheets also included 
details on the external characteristics of the homes of all those, which they 
attempted to contact.  The following table compares the property types where 
completed interviews took place in Ballymun and those where potential respondents 
had refused to take part. 
 
Type of Property % of Successful 
% of 
Refused 
House/bungalow - detached 0.7% 7.3% 
House/bungalow - semi-detached 30.1% 11.0% 
House/bungalow - mid terrace 39.7% 51.2% 
House/bungalow - end terrace 5.6% 2.4% 
Purpose built flat. etc, - building fewer than 6 floors 7.9% 3.7% 
Purpose built flat. etc, - building 6 or more floors 13.9% 23.2% 
Conversion flat/maisonette(s)/shared house 0.3% 0.0% 
Other 1.7% 1.2% 
TOTAL 100.0% 100.0% 
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6.  Frame Errors 
Refusals, of course, were not the only way that an interviewer may not achieve an 
interview at a selected address.  Frame errors, where contacts were ineligible for the 
defined universe (aged 15-64), or where the property was ineligible, vacant, derelict, 
demolished, not found, or a business, were also explained how interviews were not 
conducted at all addresses.  As such, it was important to check that frame errors 
were evenly distributed by area, as an uneven spread of frame errors may point to 
bias in the sample. The following table outlines the extent to which frame errors 
present in the Ballymun DED areas.  Besides frame errors, they also show 
breakdowns of the gross sample by:  
¾ Successful interview - persons belonging to the universe who were part of the 
sampling frame and completed the interview fully 
¾ Non-response - households who refused to take part during the initial screening 
interview and respondent selection process, respondents who refused to take 
part once selected, and properties where wardens etc refused on the contact’s 
behalf, or where no contact could be made after multiple calls.  Reasons for non-
response (refusals) are detailed in a subsequent table. 
 
 
Area Gross Sample Successful interviews Non-Response Frame Errors
Total n 743 302 188 253 
 % 100% 41% 25% 34% 
BALLYMUN A n 99 52 31 16 
 % 100% 53% 31% 16% 
BALLYMUN B n 215 64 40 111 
 % 100% 30% 19% 52% 
BALLYMUN C n 277 150 55 72 
 % 100% 54% 20% 26% 
BALLYMUN D n 152 36 62 54 
 % 100% 24% 41% 36% 
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7.  Response Rates for Ballymun Survey 
At the outset of the Ballymun survey, both Ipsos MORI and the RAG anticipated that 
the response rate would be similar to the anticipated 65% for the main study.   It 
was on this basis that it was anticipated that a total of around 300 interviews would 
be completed.   
 
This estimate proved highly accurate, as a final response rate of 62% was achieved, 
with 302 responses in total.   
 
Details of overall response rates for Ballymun, along with rates for the four DED 
areas, are shown below. 
 
 
   Gross Sample 
Valid 
Sample* Response 
% 
Response 
Ballymun Total 743 490 302 62% 
BALLYMUN A 99 83 52 63% 
BALLYMUN B 215 104 64 62% 
BALLYMUN C 277 205 150 73% 
BALLYMUN D 152 98 36 37% 
 
*Valid sample = Gross sample – (frame errors + non-valid cases)
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Outcome  Outcome Description BALLYMUN A % 
BALLYMU
N B % 
BALLYMUN 
C % 
BALLYMUN 
D % Total % 
SUCCESSFUL 
INTERVIEW Successful Interview 52 63% 64 62% 150 73% 36 37% 302 62% 
Entry to block/scheme refused 
by warden etc. 0 0% 1 1% 0 0% 0 0% 1 0% 
Refused after Respondent 
Selection 4 5% 5 5% 6 3% 6 6% 21 4% 
REFUSED 
Refused before Respondent 
Selection 12 14% 5 5% 31 15% 12 12% 60 12% 
No contact after 4 or more calls 
with selected respondent 8 10% 9 9% 1 0% 20 20% 38 8% 
Occupied, no contact after 5+ 
calls 2 2% 15 14% 9 4% 10 10% 36 7% 
Occupier in but not answering 
door after 5+ calls 2 2% 4 4% 1 0% 1 1% 8 2% 
NO CONTACT 
Unsure if occupied, no contact 
after 5+ calls 3 4% 1 1% 7 3% 12 12% 23 5% 
Household not eligible 3  17  25  7  52  
Non-residential property 1  0  0  1  2  
Property demolished 4  0  2  5  11  
Property derelict 0  76  24  37  137  
Property not found 3  6  16  1  26  
Property vacant 0  1  5  2  8  
PROPERTY 
INELIGIBLE 
Unable to access 
block/scheme/gated apartments 5  11  0  1  17  
OTHER Away during fieldwork 0 0% 0 0% 0 0% 1 1% 1 0% 
 Total Eligible Sample 83 100% 104 100% 205 100% 98 100% 490 100% 
 Total Sample 99  215  277  152  743  
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8. Calculation of Ballymun Weights 
The Ballymun survey was carried out on 4 Electoral Divisions (ED), however, due to 
the small sample size it was felt that the calculation of weights within ED level would 
not be appropriate.  Instead, the database was weighted to the overall age and 
gender profile across the 4 EDs.   
 
The table below gives a breakdown of how the weights were calculated.  Under the 
column title ‘Response’, the figures were recorded for the number of respondents 
who matched the ‘gender’ and ‘age’ profile.  These figures were then displayed as 
percentages of the total number of responses (302) in the ‘Response Ratio’ column.  
 
The population figures for the 4 combined EDs (from the 2006 ROI census) were 
completed in the ‘population’ column with percentage breakdown in column 
‘Population Ratio’.  The ‘weight’ is then based on the figure needed to correct the 
‘Response Ratio’ column to reflect the ‘Population Ratio’ column (Population Ratio / 
Response Ratio).   
 
The final column ‘Squared Weights’ is used to calculate the design effect this 
weighting has on the data.  It is calculated by multiplying the ‘Response Ratio’ by the 
square of the ‘weight’ column.  The design effect is the total of these ‘squared 
weights’. 
 
 
Gender Age Response 
Response 
Ratio (%) 
{S} Population
Population 
Ratio (%) Weight {W} 
Squared 
Weights[1] 
{SWW} 
TOTAL TOTAL 302 100.0% 10,190 100.0%   
Male 15-24 26 8.6% 1521 14.9% 1.73376 0.2588 
Male 25-34 31 10.3% 1282 12.6% 1.22563 0.1542 
Male 35-44 27 8.9% 903 8.9% 0.99119 0.0878 
Male 45-54 15 5.0% 558 5.5% 1.10249 0.0604 
Male 55-64 17 5.6% 559 5.5% 0.97453 0.0535 
Female 15-24 26 8.6% 1,339 13.1% 1.52630 0.2006 
Female 25-34 56 18.5% 1,479 14.5% 0.78273 0.1136 
Female 35-44 49 16.2% 1,175 11.5% 0.71068 0.0819 
Female 45-54 28 9.3% 677 6.6% 0.71658 0.0476 
Female 55-64 27 8.9% 697 6.8% 0.76507 0.0523 
 
Design Effect =  1.1107 
Effective n = 272 
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9.  Sampling Points for Ballymun Survey 
Points Worked 
POINT_NUMBER ED 
1 BALLYMUN A 
2 BALLYMUN A 
3 BALLYMUN A 
4 BALLYMUN B 
5 BALLYMUN B 
6 BALLYMUN B 
7 BALLYMUN B 
8 BALLYMUN B 
9 BALLYMUN C 
10 BALLYMUN C 
11 BALLYMUN C 
12 BALLYMUN C 
13 BALLYMUN C 
14 BALLYMUN C 
15 BALLYMUN C 
16 BALLYMUN C 
17 BALLYMUN D 
18 BALLYMUN D 
19 BALLYMUN D 
20 BALLYMUN D 
 
 
 
